ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4

ISTH 2012 11.6.2012 14:46 Page 1

Table of Contents

3 Welcome Message from the Meeting President

3 Welcome Message from ISTH Council Chairman

4 Welcome Message from SSC Chairman

5 Committees

7 ISTH Future Meetings Calendar

8 Meeting Sponsors

9 Awards and Grants 2012

12 General Information

20 Programme at a Glance

21 Day by Day Scientific Schedule & Programme

22 Detailed Programme Tuesday, 26 June 2012

25 Detailed Programme Wednesday, 27 June 2012

33 Detailed Programme Thursday, 28 June 2012

44 Detailed Programme Friday, 29 June 2012

56 Detailed Programme Saturday, 30 June 2012 68 Hot Topics Schedule 71 ePoster Sessions 97 Sponsor & Exhibitor Profiles

110 Exhibition Floor Plan

111 Congress Centre Floor Plan

www.isth.org ISTH 2012 11.6.2012 14:46 Page 2 ISTH 2012 11.6.2012 14:46 Page 3

WelcomeCommittees Messages

Message from the ISTH SSC 2012 Message from the ISTH Meeting President Chairman of Council

Dear Colleagues and Friends, Dear Colleagues and Friends,

We warmly welcome you to the elcome Messages It is my distinct privilege to welcome W Scientific and Standardization Com- you to Liverpool for our 2012 SSC mittee (SSC) meeting of the Inter- meeting. national Society on and Dr. Cheng-Hock Toh and his col- Haemostasis (ISTH) at Liverpool’s leagues have set up a great Pro- UNESCO World Heritage Centre waterfront! gramme aiming at making our off-congress year As setting standards is fundamental to all quality meeting especially attractive for our participants. outcomes, our objective for this meeting in Liverpool Since 2008, beside the usual in-depth work of the will be to convey how the SSC is well-positioned to Subcommittees, our SSC meetings include a large translate new knowledge into better patient care. educational programme that targets young basic and Promoting cross-information exchange and engaging clinical scientists. Because of the smaller format of with external partners are key to deliver solutions for these meetings, compared to our biennial congresses, patients with haemostatic and thrombotic problems. it also allows to experiment with innovations. With a Developing future leaders is also key to the vitality of very encouraging number of abstracts submitted, we ISTH and this meeting will be rooted in the themes will have stimulating “hot topic abstracts” reporting of Education, Engagement and Translation.I am late-breaking results in basic and clinical science, and therefore delighted that SSC 2012 offers a coherent also regular abstracts featured as “e-posters”. These programme with a Trainees’ Day on Consultative Coagu- innovations will further foster the exchange of know- lation, an Education Day on Setting Standards of Care, ledge and the educational experience for our parti- a Presidential Plenary on Translational Thrombosis & cipants. Haemostasis and enhanced opportunities to Meet-the- I look forward to meeting you in the course of the week Experts. and attending and actively participating in what looks I look forward to greeting you personally and wish you like an outstanding program. the best of experiences in Liverpool ! Thank you for attending our 58th SSC meeting to With best wishes. experience the “science, culture, and friendship!”. Welcome to Liverpool ! CHENG-HOCK TOH HENRI BOUNAMEAUX M.D. M.D., FRCP, FRCPath

3 ISTH 2012 11.6.2012 14:46 Page 4

Welcome Messages

Message from the SSC Chairman

Dear Colleagues and Friends, Following the success of the SSC Professor Cheng-Hock Toh and his colleagues on the meeting in Kyoto, we are back in Local Organizing Committee have assembled a very Europe and I warmly welcome you to a high-level programme, which will also include for the new and very innovative meeting in first time “Hot topic abstracts” and regular abstracts Liverpool. that will be presented as e-posters. This novelty will As is the tradition of the SSC, the format of the 2012 help to highlight the most recent achievements in basic meeting is designed to favor an active exchange of new and clinical research and will be a great challenge for important information and topics of research, and to young investigators. stimulate cross-disciplinary collaborations. The confe- To maintain the high level reached by the SSC it is rence will start with a strong educational programme, important that those who are not currently a member, providing an opportunity of intensive training for our not only participate in the meeting, but make an active younger colleagues. Then the meetings of all sub- contribution, participating in the working projects and committees of the SSC will follow and the results of the registries, and become a member of one of the sub- new and on-going projects of each subcommittee will committees. be extensively discussed. This will provide the new The dynamic and energizing atmosphere of Liverpool insights into the most challenging practical issues in will provide the perfect setting for the offspring of new thrombosis and hemostasis, and also will grant an projects and collaborations, and will guarantee a great expert view on the standardization of basic and clinical success of the 2012 ISTH/SSC conference. research methods, nomenclature, preparation of Welcome to Liverpool ! reference reagents, and evaluation of new tests and new drugs. ANNA FALANGA M.D.

4 ISTH 201211.6.201214:46Page5 J Hideo W E Walter Ageno(Italy) E ihe .King(USA) Michael R. ua .Smyth (USA) Susan S. D D C C B B Standardization Committee Subcommittees oftheScientificand Secretary/Chair David Lillicrap (Canada) (2010-2012) Chairman Anna Falanga (Italy) Committee Officers oftheScientific andStandardization Colin Downey (UnitedKingdom) Ian Greer(UnitedKingdom) Tina Dutt(UnitedKingdom) Simon Abrams (UnitedKingdom) Jecko Thachil (UnitedKingdom) Cheng-Hock Toh, President(UnitedKingdom) Organizing Committee o o A A Committees Committees an Rosing(TheNether f f x x i i n n i i o o

o o s s T T o o i i n n s s m m r r h h g g t t h h e e r r r r e e a a e e o o m m o o n n l l o o l l , , m m

i i o o ada (J n n l l o o C C o o u u b b a a f f e e g g

s s o o t t A A l l e e y y

s s l l H H u u n n d d i i s s l l e e t t

apan) a a i i I I m m man-Elect (2010-2012/2012-2014) c c n n r r , , o o t t o o r r a a a a a a s s n n g g v v t t d d a a u u a a

t t l l s s M M i i a a c c c c lands) t t

o o u u i i F F o o l l l l e e a a a a n n c c r r c c

u u t t C C o o l l a a o o r r s s r r a a

, , M M g g R R u u o o e e l l d d a a g g e e t t i i i i s s l o l o s s t t n n

r r

y y ( (

D D o o I I f f C C ) ) Flora Peyvandi (Italy) F F F F Agnes J Stev Ann Gils() Paul Monagle(Australia) Hans PKohler () Thomas L Ortel (USA) Thomas LOrtel Paul (UnitedKingdom) Harrison Thomas Renne(Sweden) P P H Yv C H C P F Y Lee(Canada) P F P P P A F P A F P P L L ames Douketis (Canada) a a a a a a u u e e i i l l l l l l r r n n a a e e a a a a b b a a e e c c c c es Gruel (Fres Gruel c c p r p r r r t t m m s s t t t t r r i i d d t t d i d i t t t t e u e u e e n n i en Kitchen(UnitedKingdom) i b b o o o o o o m m n n o o i i i i l l l l a a s s c c o o r r o o r r r r e e e e s s o o a a

t t Y t t v v d d V V X t X t t t a a X X A t A t i i l l

v v y y a a a a i i C C P P I I l l I I I I I I e e n n / / e e I I m m s s s s s s I I

P P I I o o h h I I s s t t a a

i c i c i i

i i s & s & s s m m H H a a e e y y c n c n a a u u

g s g s d d

o o d d e e n n l l & & u u F F a a i i u u i i a a

m m d d ance) n n o o a a

a a r r t t l l M M g g

h h

o o l l t t a a c c o o F F D D o o r r u u e e l l t t t t a a i i s s o i o i o o g g i i c c l i l i

b b o o l l s s a a t t C C g g r r

y y i i a a r r g g e e n n H H

n n i y i y I I o o t t n n n n a a

X X t t i i e e

I I n n c c / / o o a a s s n n P P

m m

t t g e g e n V n V a a h h h h o o e e c c a a c c i i o o b b s y s y n n r r t t s s

i i i i t t

a a S S t t a a p p o o b b y s y s h h r r l l s i s i s s o o e e s s t t s l s l e e i i p

p m m a a i i d d n n - - d d d d

e e p p e e n n d d e e n n t t 5

Committees ISTH 2012 11.6.2012 14:46 Page 6

CommitteesCommittees

Vascular Biology Class of 2014 Françoise Dignat-George () Nuala Booth (United Kingdom) Françoise Dignat-George (France) Jeroen CJ Eikenboom (The ) Nigel Key (USA) Robert Montgomery (USA) Women’s Health Issues in Thrombosis and Haemostasis Hugo ten Cate (The Netherlands) Sabine Eichinger (Austria) Class of 2016 SSC Working Group on Standards Marco Cattaneo (Italy) Anthony Hubbard (United Kingdom) Björn Dahlbäck (Sweden) Andreas Greinacher (Germany) Council of the International Society on Paula Tracy (USA) Thrombosis and Haemostasis (ISTH) Yukio Ozaki (Japan) Chairman of Council (2010-2012) Henri Bounameaux (Switzerland) Ex-Officio Council Members Secretary/Chairman-Elect of Council Bruce Furie (USA) (2010-2012 / 2012-2014) Secretary General (2010-2014) Michael Berndt (Ireland) Frits R. Rosendaal (The Netherlands) Treasurer (2011-2015) President of the XXIV Congress (Amsterdam, 2013) & Immediate Past Chairman of Council Nuala Booth (United Kingdom)

Class of 2012 Pieter Reitsma (The Netherlands) Vice-President of the XXIV (Amsterdam, 2013) Michael Berndt (Ireland) Congress Henri Bounameaux (Switzerland) Alan Nurden (France) Yasuo Ikeda (Japan) Bjarne Østerud (Norway) President of the XXIII Congress (Kyoto, 2011) Pieter Reitsma (The Netherlands) Mike Greaves and David Lane (United Kingdom) Editors-in-Chief, Journal of Thrombosis and Haemostasis

Anna Falanga (Italy) Chairman, Scientific and Standardization Committee

6 ISTH 201211.6.201214:46Page7 Steve Watson (UnitedKingdom) Theodore Wark Cheng-Hock Toh (UnitedKingdom) Jecko Thachil (UnitedKingdom) Hugo tenCate(TheNetherlands) Ev (Norway) Østerud Bjarne Andrew Mumford (UnitedKingdom) Nigel Mackman (USA) Paul Kyrle (Austria) Bendt Jilma(Austria) Keith Hoots(USA) Hajjar(USA) Katherine Tilman Hackeng (TheNetherlands) Alison Goodall(UnitedKingdom) Françoise Dignat-George(France) James Crawley (UnitedKingdom) Nuala Booth(UnitedKingdom) Ken Bauer(USA) SSC 2012AbstractReviewers Committees an Sadler(USA) entin (Canada) 2019 President AustraliaMelbourne, Medcalf, Robert 2017 President Germany Berlin, Oldenburg, Johannes 2015 President Toronto, Canada Schulman, Sam 2014 President Milwaukee,USA WI, Montgomery, R. Robert 29 June -4July, 2013 President Netherlands Amsterdam, The Rosendaal, R. Frits 6 6 X X X X w I X X X X w I S S 0 0 X X X X X X X X w w T T t t h h I V V V I V V V w w V V H H A A I I I I . . I

I I I i i n n

I I I I S S s s I I S S S S F F S n S n T T t t T T T T h h u u u u T T H H 2 H H 2 H H t t a a H H u u

0 0 l l

C C

C C C C r r 1 1 S S C C e e o o 3 3 o o o o S S n o n o

. . n n n n M M c c C C g g n n g g g g o o g g r r

e e r r r r e e M M m m r r e e e e e e s s e e s s s s e e s s t t s s s s s s i i e e

s s n n

a a t t

a a a a g g i i a a n n n n n n n n s s n n d d g g d d d d

d d

6 6 C C

5 6 5 6 6 6 1 1 a a 9 3 9 3 5 5 s s r t r t t t l l d h d h t t e e h h A A A A S S n n S S n n S S n n d d S S n n n n C C a a u u C C u u r r

a a

M M a a M M l l

l l e e

S S e e S S e e S S e e S S t t t t C C i i n n i i C C n n

g g

M M g g M M e e e e e e e e t t i t i t n n i i n n 7 g g g g

Committees ISTH 2012 11.6.2012 14:46 Page 8

Meeting Sponsors

The ISTH and the SSC 2012 Local Organizing Sponsors, Exhibitors and Partners Committee would like to thank the following companies List correct as at 22 May 2012 for their generous support of the 58th Annual Meeting 4S DAWN Clinical Software of the Scientific and Standardization Committee of the ACC Liverpool ISTH. Affinity Biologicals Inc. Alexion Amgen Baxter Healthcare Inc. Platinum Level Bayer Biogen Idec & Swedish Orphan Biovitrum Boehringer Ingelheim Limited CSL Behring Daiichi Sankyo Europe GmbH Gold Level Enzyme Research / r2 Diagnostics GlasxoSmithKline Haematologic Technologies, Inc. Haemonetics Corporation Helena Biosciences Europe HPS Network UK Silver Level HemaCore LLC Inspiration Biopharmaceuticals, Inc. Instrumentation Laboratory Microvisk Technologies Mitsubishi Pharma Multiplate - Verum Diagnostica GmbH Bronze Level Novo Nordisk Octapharma AG Pathway Diagnostics Ltd. Pentapharm / DSM Pfizer Precision BioLogic Sanofi Schattauer GmbH Siemens / Healthcare Diagnostics Products GmbH Stago Sysmex UK Ltd. Technoclone

8 ISTH 201211.6.201214:46Page9 Er Ming-Y Jun Deng Katarzyna Cz Roza Chaireti Annemieke Bouman Marc Blondon Jonathan Douxfils Susanne de Hugoline deHaan Jelonkiewicz mittee meeting of the International Society on Throm- on Society International the of meeting mittee bosis and Haemostasis. and bosis Saar Giselle Begue Cecilia Becattini Anna Balandina Sandra Baker Seam Yasir Alhamdi Simon Abrams to thanks possible made been have awards These ISTH Young Investigator Awards ISTH and the 58 the and ISTH Awardees Country Awardees Committees Awards andGrants2012 ika Diani tje Bloemen us Allen ang Deng Witt 2012) whosubmithighlyrated abstracts. (under 35years ofageas27June, medical trainees andyoung scientists provided intheform oftravel grants to The Young Investigator Awards were ri’k-Poland erwin’ska- th Scientific and Standardization Com- Standardization and Scientific China USA Italy China The Nether The Nether Argentina Ireland Sweden The Netherlands Belgium The Netherlands Italy Russian Federation USA United Kingdom United Kingdom lands lands lxnr ahra UnitedKingdom MoxonChristopher Micah Mooberry Kate Monagle Alexandra Mazharian Olesya Matvienko Maura Marucci Mancini Ilaria Stephen Macdonald Yeling Lu Gillian Lowe Mar Ana Lopez TheNetherlands Rinske Loeffen Gerhardus Kuiper Kleinegris Marie-Claire Alev Karasu Yosuke Kanno Miao Jiang SouthAfrica Jiang Walter Janse van Rensburg Iv India Wenjuan He Jayandharan Rao Giridhara Geenen Irma Lena Furmark Giovanni Favuzzi FaioniElena Maria Petra Erkens Lisa Duff Lizaveta Drozd Natalia Dovlatova ana Horvat ie Lordkipanidze ett A United Kingdom United Kingdom Ireland China China Canada China Japan China USA Russian Federation Italy United Kingdom The Netherlands The Netherlands USA Italy The Netherlands Belarus United Kingdom United Kingdom Italy The Netherlands The Netherlands Italy ustralia 9

Awards & Grants ISTH 2012 11.6.2012 14:46 Page 10

CommitteesAwards and Grants 2012

Omonivie Okaisabor United Kingdom ISTH Reach the World Travel Awards Abimbola Onasoga USA In recognition of the expanding educa- Maria Teresa Pagliari Italy tional format of ISTH’s SSC Annual Leonid Parunov Russian Federation Meetings, the ISTH is extending its Leonie Pelkmans The Netherlands “Reach the World” initiative to enable Rachel Roach The Netherlands participation by scientists from all areas of the world in the educational and working sessions of the SSC. Nathan Schloemer USA Henrike Schouten The Netherlands Bayer HealthCare has partnered with Anish Sharda USA ISTH to make possible these 2012 Awards through a generous unrestricted Wie Shi China educational grant. Welcome to All! We Jane Skov Denmark hope that you will find attendance at SSC 2012 fruitful Francesca Stufano Italy in your continued research and educational activities. Carmen Tartari Italy Claudia Tersteeg The Netherlands Awardees Country Thea Tilley Ireland Magy Abdelwahab Egypt Jasmijn Timp The Netherlands Xia Bai China Julien Toh United Kingdom Venina Barros Brazil Giacomo Tuana Italy Munira Borhany Pakistan Thomas Vanassche Belgium Qiulan Ding China Anyou Wang China Irina Gribkova Russian Federation Yan Xia China Tarandovskiy Ivan Russian Federation Guoling You China Gwo-Ping Jong Taiwan, China Jingyi Zhou China Arshi Naz Pakistan Xuemei Zhu China Ira Puspitawati Indonesia Xiaoyu Zhu China Analía Sánchez-Luceros Argentina Stéphane Zuily France Jianbo Wu China

10 ISTH 2012 11.6.2012 14:46 Page 11 ISTH 2012 11.6.2012 14:46 Page 12

CommitteesGeneral Information

International Society on Thrombosis • The right to nominate, elect and serve on ISTH and Haemostasis committees. For more information, please visit The International Society on Thrombosis & Haemo- www.isth.org stasis (ISTH) is the leading worldwide organization Contact Information dedicated to the advancement of the understanding, prevention, diagnosis and treatment of thrombotic and For general information about the Society, please disorders. contact ISTH at: ISTH is a global professional individual membership ISTH Headquarters organization with over 3,000 members in more than 80 610 Jones Ferry Road Suite 205 countries around the world. Among its highly regarded Carrboro, NC 27510 activities and initiatives are education and standard- USA ization programmes, research activities, meetings and Phone: +1 919 929-3807 conferences, peer-reviewed publications and expert Fax: +1 919 929-3935 committees. Email: [email protected] ISTH offers 3 categories of membership: For membership related questions, please contact • Regular: for active researchers, educators and ISTH at Email: [email protected] clinicians in the field For educational enquiries, please contact ISTH at: • Associate: for students, trainees, research staff, [email protected] post-doctoral fellows as well as allied health profes- sionals Meeting Secretariat • Reach-the-World: for researchers, educators and SSC 2012 clinicians in non-industrialized countries c/o MCI Suisse SA - Rue de Lyon 75 1211 Geneva 13 - Switzerland Membership benefits include: Phone: +41 22 33 99 588 • A network of over 3,000 members in more than 80 Fax: +41 22 33 99 631 countries Email: [email protected] • Priority registration and discounted fees for ISTH meetings and congresses Accommodation • Complimentary print and online subscription to The Mersey Partnership Conference Bureau ISTH’s Journal of Thrombosis and Haemostasis Phone: +44 (0) 151 237 3938 • Access to the ISTH members-only online resour- Fax: +44 (0) 151 227 2621 ces, including educational materials, e-learning and Email: [email protected] membership directory A help desk for participants who have booked their • Exclusive access and/or reduced fees for other accommodation in advance via The Mersey Partner- educational activities, Programmes and publications ship Conference Bureau is located in the registration • The quarterly ISTH Newsletter and regular e- area. The staff at this counter will also help you to find updates and book rooms, if required.

12 ISTH 201211.6.201214:46Page13 par This business meetingisopentoallinterested occasional rain. on Level 1attheConference Centre. atRoom11B information, contacttheISTHSecretariat r A Barclays cashmachineissituatedon site, onthe Banks &Automatic Teller Machines (ATM) activities of Subcommittees,Working reports Parties, liaison andrecommendationsresultingfromthe reports sessions, actionon the ScientificSubcommittees’ Annual BusinessMeetingoftheSSC on the30June. only 16:30) from27-29June 2012andin themorning breaks arescheduleddaily(10:00-10:30 and16:00- Coffee Exhibition Areaonthelower ground floor. coffee inthe Complimentary andtea willbeserved Coffee Breaks of£1.00(GBP)peritem. at aprice Itemscanbeleftinthecloakroom Conference Centre. A cloakroomfacility willbeprovided by theACC Cloakroom - 73degrees F betw In lateJ Climate 'W The Liverpool Waterfront CarPark issign-posted Car Parking charge for usingit. thereisno the exit andthemachineisonleft; C C S S iv Committees a a o o General Information rieo h ulig Walk down thestepsbefore erside ofthebuilding. aterfront' onthecitywide'available spaces'signage. t t n n ticipants. The agenda includes brief oral reports of oral reports Theagendaincludesbrief ticipants. u u f f een 18and23degrees Celsius(approximately 64 r r e e d d r r a a e e y y une n n n olbrtv ok For further , andcollaborative work. , , c c 3 3 e e 0 0 , av

C C

J J e e arenheit). u u er n n n n t t e e age temperatures vary in Liverpool r r

e e 2 2 0 0 1 1 2 2 , , There isalways achancefor R R o o o o m m

1 1 2 2

o o n n

L L e e v v e e l l

1 1

a a t t

t t h h e e The 58 The 58 for medicalspecialists. cation (EACCME) toprovide thefollowing CMEactivity Accreditation Councilfor Continuing MedicalEdu- 30 June 2012)hasbeenaccreditedby theEuropean UnitedKingdom(27- Haemostasis (ISTH)Liverpool, national Societyon Thrombosis and Committee (SSC)meetingoftheInter- be found at process toconvert EACCME credittoAMAcan Information onthe 1Credits™. AMA PRACategory convert EACCME creditstoanequivalent number of MedicalAssociation,physiciansAmerican may European UnionofMedicalSpecialistsandthe Through anagreement between the www.uems.net. the EuropeanUnionofMedicalSpecialists(UEMS), TheEACCME isaninstitutionof educational activity. those creditsthathe/sheactuallyspentinthe Eachmedicalspecialist shouldclaimonly (ECMEC). maximum of, orupto20EuropeanCMEcredits bosis andHaemostasis(ISTH)isdesignatedfor a Societyon (SSC) meetingoftheInternational Throm- Conference Venue Continuing MedicalEducation www.btconventioncentre.com Website: [email protected] Email: +441514758888 Phone: Liverpool Waterfront, L34FPUK Kings Dock BT Convention Centre(ACC) cians andSurgeonsofCanada. Program of Certification The Royal CollegeofPhysi- Activities (Section1)asdefined by the Maintenance of are deemedtobeAccredited GroupLear recogniz LiveCanada, educationalactivities, outsideof occurring E E A A C C C C M M th th E E ed by theUEMS-EACCME for ECMECcredits Scientific andStandardization Scientific andStandardizationCommittee www.ama-assn.org/go/internationalcme ning 13 .

General Information ISTH 2012 11.6.2012 14:46 Page 14

CommitteesGeneral Information

EHA Certificate of Attendance The European Association has accredited Certificates of attendance will be available from 14:00 the 58th Scientific and Standardization Committee on Friday, 29 June 2012 in the registration area. (SSC) meeting of the International Society on Participants will need to scan the bar-code on their Thrombosis and Haemostasis (ISTH) Liverpool, badge in order to print out their certificate. United Kingdom (27- 30 June 2012) with 16 credit points. All participants may print a European Hema- Cyber Café tology Association CME System approved CME A wired internet zone is located certificate indicating the number of EHA-CME Credit within the exhibition and is Points awarded, directly from the system on the CME generously sponsored by Inspi- section of the EHA website at www.ehaweb.org. An ration Biopharmaceuticals, Inc. EHA-CME Credit Point account will be used by all interested participants. Participants will receive a login Delegate Bags after the meeting which will allow them to complete the You will receive your delegate bag at the registration online evaluation in order to obtain the EHA credits. area. No replacements for lost bags are available. BSHT Electricity The British Society for Haemostasis & Thrombosis The UK, Scotland and Republic of Ireland use a 13 (BSHT) has accredited the 58th Scientific and amp plug with 3 rectangular pins which is different to Standardization Committee (SSC) meeting of the the rest of Europe. As such, an adaptor may be needed International Society on Thrombosis and Haemostasis depending on the country you are coming from. (ISTH) Liverpool, United Kingdom (27-30 June 2012) with 16 credit hours as follows: ePosters • Wednesday, 27 June: Educational Programme: ePosters are an electronic version of the traditional 08:30-12.00 [3.5 hours] and scientific Posters. The objective of the ePosters is to 13:15-15:00: [1.75 hours] followed by reach an audience beyond that of a traditional poster Special Symposia: 15.30-17:30 [2.00 hours] session. Attendees can view all posters during the • Thursday, 28 June: dedicated ePoster session, throughout the meeting at Plenary Programme: 08:45-12:00 [2.75 hours] designated touch-screen stations, or on their personal • Friday, 29 June: computer to interact with the poster author. From a Hot Topics Programme: 14:00-17:00 [3.00 hours] single location attendees may browse posters on topic followed by or keyword, provide comments, contact the author Poster discussion: 17:30-1900 [2.00 hours] directly with questions or download the poster for later • Saturday, 30 June: viewing (when allowed by presenter). Authors also Technical Programme: 08:00-09:00 [1.00 hour] have the option to keep their posters online after the Each medical specialist should claim only those hours meeting in Liverpool to reach even the non-attendee of credit that she/he actually spends in the educational ISTH members. activity.

14 ISTH 201211.6.201214:46Page15 Industry Exhibition Industry youasked requireby whichservice theoperator. Emergency callsarefreefrompay phones -you willbe 999 for fire, police, ambulance orcoastguardservices. 10.00-13.00 10:00-19.00 LocalNumbers: Important Saturday, 30June 2012 Friday, 29June 2012 10.00-17.00 Thursda Wednesday, 27June 2012 Exhibition hours: self thefutureofposterpresentation! kindlyseefor your- new innovation for SSCmeetings; A large touch-screensfor easyreadingandbrowsing. The ePoster stationsintheExhibitionHallprovide is no simultaneous translation service provided.is nosimultaneous translation service The Officiallanguageofthemeeting isEnglish. Language for openinghours). Desk” hours astheRegistration Desks(see “Registration thesame Itisopenduring 1 oftheConference Centre. islocatedatRoom11BonLevelThe ISTHSecretariat ISTH Secretariat sibility for personalinjur ISTH andMCIasorganiserscannotacceptrespon- ofresidence. fromtheircountries before departure insurance coverage for travel, healthandaccidents Participants have beenadvisedtoobtainadequate Insurance andLiability Pleaseseedetails onpages97-110. lower ground level. Exhibitionislocatedonthe The SSC2012Industry pants andaccompanying persons. priv Committees GeneralInformation ate property belongingtotheconference par ate property ,2 ue21 10.00-17.00 y, 28June 2012 ies , orlossof, ordamageto, There tici- centrally located, notransfers willbeprovided. entr contact theRegistration Desklocatednearthe For additionaltickets, please a fee of£25perperson. Social Events by ACC Liverpool)& “...the Beatgoeson” Reception(supported “Liverpool Now” attending sessionsorsymposia. mobile phonesandpagersmust beswitched offwhen all tospeakers andotherparticipants, As acourtesy Mobile Telephones f chase theirlunchon-siteattheACC fromoneofthe registr Please notethatlunchisnotincludedinthedelegate Lunches 1£ =1,54USD 1£ =1,24EUR Conversion rates as of1June 2012: (£). Pound istheBritish The officialcurrencyinLiverpool Local Currency to this2 Attendance evening ofBeatlesmusic, danceandfun. willexperience anoutstanding where participants within walking distancefromtheConference Centre, beat thencontinues asof20.00atthePanAm, avenue The from18.00-19.30. free toalleligible participants Thisreceptionis Conference Centre. lower ground level and+1level ofthe reception whichwillbeheldonthe gible delegatesareinvited toattenda On Wednesday, 27June 2012,eli- pro D D ood outletsav r r e e vided atsomelunch-timeSatelliteSymposia. neo h ofrneCnr.Asthevenue is ance oftheConference Centre. s s s s to e o S 02 P ation fee for SSC2012.

c c nd o o d d part oftheeveningpart requiresthepayment of e e : : C C ailab a a s s u u a a e Pleasenotethatlunchmay be le. l l ar ticipants canpur- 15

General Information ISTH 2012 11.6.2012 14:46 Page 16

CommitteesGeneral Information

Name Badges Smoking Participants will receive their name badges when Please note that this is a non-smoking meeting. collecting their meeting documents on site. You are Smoking is neither permitted in or outside the meeting kindly requested to wear your name badge during all halls nor in the exhibition area. meeting events, including the Liverpool Now Recep- tion. Please note that admission to scientific sessions Transportation and the exhibition is restricted to participants wearing No transportation is provided during the conference their badges. since the Conference Venue is very centrally located and most hotels are within walking distance. If you Registration Desk need to arrange for a transfer to the airport, please The registration desk is located on the ground floor, refer to the “Information” menu item on the conference next to the main entrance of the venue. website: www.ssc2012.org where you will find more Opening Hours: information under “Transportation”. Tuesday 26 June 2012: 12.00 - 19.00 Speaker Ready Room Wednesday 27 June 2012 07.00 - 18.00 Room 11A (Level +1) Thursday 28 June 2012 07.30 - 18.30 Speakers are asked to upload their formatted pre- Friday 29 June 2012 07.30 - 18.00 sentations (PowerPoint presentations) at the Speaker Saturday 30 June 2012 07.30 - 13.00 Ready Room at least 2 hours before their session or the day before for an early morning presentation. All Restaurants conference rooms feature state-of-the-art technical Looking for a Restaurant in Liverpool? The restaurant equipment. Audiovisual material will be available for scene in Liverpool has never been more lively and your presentation. diverse with a fantastic mix to suit all taste buds. Go to: Opening Hours: www.liverpool.com/listings/restaurants.html for more Wednesday 27 June 2012 07.30 - 18.00 information. Thursday 28 June 2012 07.30 - 18.30 Shopping Friday 29 June 2012 07.30 - 18.00 Liverpool shopping is world class, which is only fitting Saturday 30 June 2012 07.30 - 13.00 for a city that can shop till it drops. Shoppers are spoilt for choice between gleaming new city-centre shopping Wireless Internet centres to boutique arcades, bohemian streets and Wireless internet will be available on-site. Each farmers markets. delegate will receive a username and password Liverpool ONE, right in the heart of the city, is the shiny with their badge. This wire- new designer Liverpool shopping centre that is home less connection is generously to more than 160 famous high street names, from John sponsored by Inspiration Bio- Lewis to Apple, Topshop to Cath Kidston pharmaceuticals, Inc.

16 ISTH 201211.6.201214:46Page17 Nightlife Destination 2011awarded by TripAdvisor. magazine’s Best UKCity2011,andBritain’s Best Destination in2010and2011,GroupLeisure winning CondéNast backed by numerous accoladesincludingthecity destination for delegatesandvisitors, afact which is Liver District. ofNorth Walesthe stunningscenery andtheLake ship linksgolfcourses, ancientcitieslike Chesterand which offers miles ofbeautifulcoastline, Champion- city fromwhichtoexplore thesurroundingregion, isagreat Liverpool the largestofitskindinEurope. winning retail,leisureandresidentialscheme)being major development projects, One(award Liverpool Prog Ahugeregeneration the oldestChinatown inEurope. Anglican andRomanCatholiccathedrals aswell as exemplified by magnificentcivicbuildings, two iconic isalso cultural heritage doorsteps andourrich onour is right Public art and LadyLever Gallery. Art Walker Gallery; Art Tate Gallery; Slavery Art International Modern Museum; Museum; Maritime Museum; World other UKcityoutsideLondon,including; thananytreasures andmoremuseums andgalleries and humour, ithasanabundance of architectural F.C.) andEverton F.C. (Liverpool Cavern Club),sport well reputationfor asitsworldwide music (Beatlesand As Culture andUNESCO World SiteStatus. Heritage cosmopolitan citiesoffering bothEuropeanCapitalof isoneofEurope’sLiverpool mostvibrant and Liverpool Committees AboutLiverpool ramme hastransformed thecitywithoneof pool haslongbeenregardedasthefr Trav eller UK’s F riendliest iendliest free dedicatedaccommodationbookingservice. pointsintothecity,signage andflagsatentry anda withonboardwelcomeLiverpool announcements, fromLondonto highspeedservice for Virgin Trains’ mes willprovide alldelegateswithexclusive discounts innovative Delegate Welcome andGoodnightsche- Together, the ofasocialitinerary. sunsets aspart attractions from whichtoview thecity’s skylineand gala dinners, thebestaccommodation,aswell as bars inwhichtowinddown afteraconference orhost event spaceswithpanoramic views, restaurants and of delegatesinthecity, providing recommendationsfor The Goodnightcampaignwillcompletetheexperience Delegate Goodnightcampaign. issettobecomeevenLiverpool moreaffable withits 17

About Liverpool ISTH 2012 11.6.2012 14:46 Page 18 ISTH 2012 11.6.2012 14:46 Page 19 ISTH 2012 11.6.2012 14:46 Page 20

Programme at a Glance

20 ISTH 2012 11.6.2012 14:46 Page 21 ISTH 2012 11.6.2012 14:46 Page 22

Programme Overview

Tuesday, 26 June 2012

Trainees’ Fringe Meeting Room 4A

How to start a career in coagulation

08:30 - 13:00 Trainees in research Ian Peake, Gill Lowe

14:15 - 18:00 Practical / on call issues in haemostasis John Pasi, David Keeling and thrombosis

18:00 - 19:00 SSC 2012 Trainees’ Welcome Drinks Reception

22 ISTH 201211.6.201214:46Page23 John Pasi(London) Research opportunitiesinnonmalignanthaematologytheUK Gill Lowe(Birmingham) beginnersguidetoethics Setting upresearchstudies/ A Steve Kitchen(Sheffield) beginnersguidetolaboratorycoagulation A Gill Lowe Introduction Ian Peake Trainees inresearch-partI Chairpersons: Ian Peake(Sheffield) A Mike Laffan (London) Planning aresearchcareer Steve Watson (Birmingham) How togetapaperpublished Sam Machin(London) How towritearesearchgrant/getfellowship Gill Lowe Trainees inresearch-partII Detailed Programme 26June 2012 Tuesday, T H T T H T historical perspectiveinresearchingvonW e e r r o o a a a a w w i i

n n / /

e e C C t t o o e e o o

s s f f s s f f ’ ’ e e t t a a F F e e

r r r r Ian Peake,GillLowe,JohnPasi,DavidKeeling B B t t i i

n n r r a a e e g g

a a C C e e k k

a a

M M

r r e e e e e e e e r r t t

i i i n i n n n g g

C C (supported by Societyfor theBritish Haemostasis and (supported Thrombosis) o o a a g g u u l l a a t t i i o o n n

illebrand’ s disease-highsandlows 0 0 8 8 : : 10:00 -10:30 09:30 -10:00 09:25 -09:30 12:50 -13:20 12:20 -12:50 10:30 -1 11:50 -12:20 1 4 4 R R 1:20 -11:50 5 5 R R o o

o o - - o o

o o 1 1 m m m m 7 7

: : 4 4 1:00 3 3 4 4 A A 23 B B 0 0

Tuesday ISTH 2012 11.6.2012 14:46 Page 24

Detailed Programme Tuesday, 26 June 2012

Practical / on call issues in haemostasis and thrombosis - part I John Pasi Clinical issues from abnormal coagulation tests David Keeling (Oxford) 14:15 - 14:45 Clinical and laboratory Issues in Trevor Baglin (Cambridge) 14:45 - 15:15 On call issues in obstetric haematology Beverly Hunt (London) 15:15 - 15:45 Tea / Coffee Break Room 4B Practical / on call issues in haemostasis and thrombosis - part II David Keeling On call transfusion Issues with a focus on NAIT Mike Murphy (Oxford) 16:15 - 16:45 On call issues in inherited bleeding disorders Mike Markis (Sheffield) 16:45 - 17:15 Issues in diagnosis and management of antiphospholipid syndrome Mike Greaves (Aberdeen) 17:15 - 17:45

SSC 2012 Trainees’ Welcome Drinks Reception 18:00 - 19:30

Upper Galleria (sponsored by the Faculty of Health & Life Sciences, University of Liverpool)

24 ISTH 201211.6.201214:46Page25 83 20 Thrombosis&haemostasisissuesin 08:30 -12:00 Time Wednesday, 27June 2012 13:15 -15:00 00 40 “...andtheBeatgoes on” 20:00 -24:00 “LiverpoolNow”Reception (supportedby ACC Liverpool) 18:00 -19:30 17:30 - 15:30 Educational Session L L Programme Overview u u n n c c h h B B r r e e a a k k - -

O O n n

Y Y Title Inherited bleedingdisorders Thrombotic microangiopathies child health Thrombosis &haemostasisIssuesin women’s health Thrombosis &haemostasisIssuesin critical infectionandtrauma Thrombosis &haemostasisissuesin h ieNsem“etteEpr”Ssin Halls2E,2F, 2L, 2N Sessions The MikeNesheim“MeettheExpert” treatment Point-of-care &personalised Anti-phospholipid syndrome o o u u r r

O O w w n n (Hall 2E) (Hall 2F) (Hall 2N) (Hall 2L) Hl F Jecko Thachil &HideoWada (Hall 2F) Hl N MarcoCattaneo (Hall 2N) Hl E ThomasOrtel (Hall 2E) Hl L PaulHarrison&ChanggengRuan (Hall 2L) Anthony Chan&PaulMonagle Sabine Eichinger&FloraPeyvandi Agnes Lee&Jeffrey Zwicker Chairpersons Steven Kitchen 25

Wednesday ISTH 2012 11.6.2012 14:46 Page 26

Detailed Programme Wednesday, 27 June 2012

Educational Session 08:30 - 12:00

Thrombosis & Haemostasis Issues in Cancer Hall 2E Chairpersons: Agnes Lee (Canada), Jeffrey Zwicker (USA) Overview with learning objectives Agnes Lee (Canada) 08:30 - 08:45 Session one: State-of-the-art updates Jeffrey Zwicker (USA) Complexities in tissue factor measurement and standardization Nigel Key (USA) 08:45 - 09:15 Roles of CRP and D-dimer in diagnosis, treatment and prognosis Ingrid Pabinger (Austria) 09:15 - 09:45 Screening for occult malignancy: where does the evidence stand? Marc Carrier (Canada) 09:45 - 10:15 Tea / Coffee Break Exhibition hall, lower level Session two: Controversies & debate Agnes Lee (Canada) Debate: incidental VTE: to treat or not to treat Yes: Howard Liebman (USA) - No: Menno Huisman (The Netherlands) 10:30 - 11:15 Debate: outpatient thrombo-prophylaxis in cancer patients Yes: Lord Ajay Kakkar (United Kingdom) - No: Alok Khorana (USA) 11:15 - 12:00

Thrombosis & Haemostasis Issues in Critical Infection and Trauma Hall 2F Chairpersons: Jecko Thachil (United Kingdom), Hideo Wada (Japan) Overview with learning objectives Jecko Thachil (United Kingdom), Hideo Wada (Japan) 08:30 - 08:45 Session one: Day-to-day dilemmas How I manage in critically ill patients Andreas Greinacher (Germany) 08:45 09:15 The relationship between inflammation and thrombosis in critically ill patients Hugo Ten Cate (The Netherlands) 09:15 - 09:45 How I manage peri-operative coagulation issues Sibylle Kozek-Langenecker (Austria) 09:45 - 10:15

26 ISTH 201211.6.201214:46Page27 Sabine Eichinger(Austria),FloraPeyvandi(Italy) Overview withlearningobjectives Chairperons: Tim Goodship(UnitedKingdom) Current persepctivesinthemanagementofatypicalhaemolyticuremicsyndrome Alister Craig(UnitedKingdom) Malaria andthrombosis:relevanceofvWF& Karim Brohi(UnitedKingdom) Acute CoagulopathyofTrauma: RelevanceoftheProteinCpathway Session two:Emergingtranslation Jacqueline Conard(France) How Iadvisecontraceptioninrelationtothrombophilia Claire McLintock(NewZealand) How Imanagewomenwithmechanicalheartvalvesduring pregnancy Shirley JohnsonMemorialLecture Ian Greer(UnitedKingdom) How Imanagerecurrentmiscarriageinrelationtothrombophilia Session one:Thrombotictendency T T T T T T e e e e ealdPormeWdedy 27June 2012 Detailed Programme Wednesday, h h a a a a r r

o o / / / /

m m C C C C o o o o b b f f f f o o f f f f e e e e s s e e e e i i Sabine Eichinger(Austria),FloraPeyvandi(Italy s s

B B B B

& & r r r r e e e e

a a a a H H k k k k a a

e e m m o o s s t t a a s s i i s s

I I s s s s u u e e s s

i i n n

W W o o m m e e n n ’ ’ s s

H H e e a a ) l l t t h h

E E E E x x x x h h h h i i i i b b b b i i i i t t t t i i i i o o o o n n n n

h h h h a a a a l l l l l l l l , , , , 09:45 -10:15 09:15 -09:45 08:45 -09:15 11:30 -12:00 10:30 -11:00 11:00 -11:30 l l l l o o o o w w w w H H e e e e r r r r a a

l l l l l l e e e e l l

v v v v 2 2 e e e e 27 L L l l l l

Wednesday ISTH 2012 11.6.2012 14:46 Page 28

Detailed Programme Wednesday, 27 June 2012

Session two: Bleeding tendency How I manage ITP in pregnancy Drew Provan (United Kingdom) 10:30 - 11:00 How I manage and coordinate care of the carrier in pregnancy Claude Negrier (France) 11:00 - 11:30 How I treat menorrhagia in women with bleeding disorders Rezan Abdul-Kadir (United Kingdom) 11:30 - 12:00

Thrombosis & Haemostasis Issues in Child Health Hall 2N Chairpersons: Anthony Chan (Canada), Paul Monagle (Australia)

Overview with learning objectives Anthony Chan (Canada), Paul Monagle (Australia) Session one: State-of-the-art updates Can childhood be prevented? Fenalla Kirkham (United Kingdom) 08:45 - 09:15 Management of post-thrombotic syndrome in children Shoshana Revel-Vilk (Israel) 09:15 - 09:45 Bleeding in children with major organ failure Christine MaCartney (United Kingdom) 09:45 - 10:15

Tea / Coffee Break Exhibition hall, lower level Session two: Controversies & debate Will the newer still require monitoring? Adults Trevor Baglin (United Kingdom) - Children Christoph Male (Austria) 10:30 - 11:00 Debate: Thrombophilia testing in children, with a few specific exceptions, is a waste of time Yes Suzan Williams (Canada) - No Elizabeth Chalmers (United Kingdom) 11:00 - 11:30 Chronic severe ITP in children. Rituximab should be offered before splenectomy Yes Paula Bolton-Maggs (United Kingdom) No Jenny Despotovic (USA) 11:30 - 12:00

28 ISTH 201211.6.201214:46Page29 Munther Khamashta(UnitedKingdom) Novel therapiesinadditiontoanticoagulationfor APS Katrien Devreese(Belgium) Guidance inlaboratorytestingtodiagnose APS PG deGroot(TheNetherlands) New mechanisticunderstandingin APS Session: fromlaboratorytopatient Thomas Ortel(USA) Overview withlearningobjectives Chairperson: Munir Pirmohamed(UnitedKingdom) Pharmacogenetics ofwarfarininpersonalisingtreatment atpoint-of-care Alastair Nimmo(UnitedKingdom) Point-of-care globalhaemostasistestinginoperatingtheatres Dianne Kitchen(UnitedKingdom) Assessing qualityinpoint-of-carehaemostasistesting Session: fromlaboratorytopatient Steven Kitchen(UnitedKingdom) Overview withlearningobjectives Chairperson: A E P A E P ealdPormeWdedy 27June 2012 Detailed Programme Wednesday, o o d d n n i i u u t t n n i i c c - - t t P P - - a a o o h h t t f f i i o o o - o - C C n n s s a a p p a a Thomas Ortel(USA) Steven Kitchen(UnitedKingdom) r r h h l l

e e o o S S

l & l & e e i i p p s s P P i i s s d d e e i i

o o r r S S n n s s y y o o

n n n n d d a a r r l l o o i i s s m m e e e e d d

T T ( ( A A r r e e P P a a S S t t m m ) )

e e n n t t

1 1 3 3 : : 14:30 -15:00 14:00 -14:30 13:30 -14:00 13:15 -13:30 14:30 -15:00 14:00 -14:30 13:15 -13:30 13:30 -14:00 1 1 5 5

H H H H - -

a a a a 1 1 l l l l 5 5 l l l l

: : 2 2 2 2 0 0 E E F F 29 0 0

Wednesday ISTH 2012 11.6.2012 14:46 Page 30

Detailed Programme Wednesday, 27 June 2012

Thrombotic Microangiopathies Hall 2L

Chairpersons: Paul Harrison (United Kingdom), Changgeng Ruan (China)

Overview with learning objectives Paul Harrison (United Kingdom), Changgeng Ruan (China) 13:15 - 13:30

Session: from laboratory to patient Understanding vWF-ADAMTS13 in vivo Karen Vanhoorelbeke (Belgium) 13:30 - 14:00 Diagnosing and treating Thrombotic Thrombocytopaenic (TTP) Marie Scully (United Kingdom) 14:00 - 14:30 Translational approaches to TTP Flora Peyvandi (Italy) 14:30 - 15:00

Inherited Bleeding Disorders Hall 2N Chairperson: Marco Cattaneo (Italy)

Overview with learning objectives Marco Cattaneo (Italy)

Session: from laboratory to patient Advances in diagnosing congenital disorders Alan Nurden (France) 13:30 - 14:00 Safety, efficacy issues with haemophilia factor concentrates and the emerging treatments Mike Makris (United Kingdom) 14:00 - 14:30 New considerations and treatment paradigms for David Lillicrap (Canada) 14:30 - 15:00

Tea / Coffee Break Exhibition hall, lower level

30 ISTH 201211.6.201214:46Page31 Paula T Chairpersons: PanAm - Albert Docks(tickets availableforpurchasefromregistrationarea) Upper andLowerGalleria(supported by ACC Liverpool) Bjarne O Bjarne Paula Tracy (USA) Tissue factor Pier MannucciItaly(Italy) Cheng HockToh (UnitedKingdom) Haemophilia Steve Watson (UnitedKingdom) Y Platelets Robert Montgomery(USA) David Lillicrap(Canada) Von Willebrand disease Nuala Booth(UnitedKingdom) Johanthan Foley(USA) Gregory Lip(UnitedKingdom) Paul Kim(Canada) Atrial fibrillation&arterialthromboticdisease Sam Schulman(Canada) Fletcher B.Taylor (USA) Venous thromboembolism Björn Dahlbäck(Sweden) Hugh Hoogendoorn(Canada) Protein Cpathway otis Senis(UnitedKingdom) “... andtheBeatgoeson” T M T M ealdPormeWdedy 27June 2012 Detailed Programme Wednesday, SSC 2012“LiverpoolNow”Reception h h e e e e e e

t t M M

racy (USA), Yotis Senis(UnitedKingdom),ChengHockToh (UnitedKingdom),DavidLillicrap(Canada) / t t h h i i sterud (Norway) k k e e e e

E E N N Johanthan Foley(USA),HughHoogendoorn(Canada),PaulKimFletcherB.Taylor (USA), x x e e p p s s e e h h r r e e t t s s i i m m

“ “ M M e e e e t t

t t h h e e

E E x x p p e e r r t t ” ” S S e e s s s s i i o o n n s s

1 1 5 5 : : 3 3 0 0

- -

1 1 6 6 : : 3 3 0 0

/ /

18:00 -19:30 20:00 -24:00 1 1 6 6 : : 15:30 -16:30 15:30 -16:30 15:30 -16:30 15:30 -16:30 16:30 -17:30 16:30 -17:30 16:30 -17:30 16:30 -17:30 3 3 0 0

- -

1 1 Hall 2N Hall 2N Hall 2E Hall 2L Hall 2F Hall 2L Hall 2F 7 7 Hall 2 : : 3 3 31 0 0

Wednesday ISTH 2012 11.6.2012 14:46 Page 32 ISTH 201211.6.201214:46Page33 ieCompany 12:15 -13:45 Time Title 09:00 -09:30 RelevanceoftheSSCtotranslationalmedicine 08:30 -09:00 Time Thursday, 28June2012 18:15 -19:45 Company 18:15 -19:45 Time Title Lillicrap David & Falanga Anna Pro-thrombotic markers and global 15:30 -18:00 hemostatic tests (Auditorium1) 15:30 - 14:00 Time 1 10:00 -10:30 09:30 -10:00 1 1:30 -12:00 1:00 -11:30 Satellite Symposia SSC Session Satellite Symposia Presidential Plenary:SSCinTranslation S S Programme Overview y y m m p p o o s s i i u u m m

Sanofi Pfizer Novo Nordisk T Marion BarnhartMemorialLecture University ofLiverpool Bayer HealthCare FrancescoRodeghiero standingcommitteepublicsession(Hall2E) ISTH BAT JamesDouketis Plasma coagulationinhibitors(Room12) HideoWada Fibrinolysis (Room3B) Predictive variablesincardiovasculardisease(Room3A) Factor XIandthecontactsystem(Hall2F) Disseminated IntravascularCoagulation(DIC)(Hall2L) From genetotherapyII: Thrombocytopaenia Pia GlasGreenwaltMemorialLecture From genetotherapyI:Haemophilia Arthur BloomMemorialLecture Emerging translationII:NETs &thrombosis Kenneth M.BrinkhouseMemorialLecture Emerging translationI:Complement&coagulation Collen Foundation-LifeSciencesResearchPartners Award o o ranslational medicineinthrombosisandhaemostasis n n

W W i i d d e e n n i i n n g g

P P a a r r t t i i c c Title VTE prophylaxisin2012:whereweareandgoing(Hall2L) Clinical leadershipinhaemophilia-settingnewstandards?(Hall2F) Pharmacokinetics inhaemophilia:guidingpatientcare(Hall2E) i i p p a a t t i i Little bigmedicine(Hall2N) thromboembolism -apractical consideration Novel oralanticoagulantforthe managementofvenous(Hall2E) Title o o n n Steven Kitchen Garret FitzGerald Cheng-Hock Toh Markus Huber-Lang Ann Gils Thomas Renne Speaker Kenneth Kaushansky Edward Tuddenham Denisa W Chairpersons agner A A u u d d i i t t o o r r i i u u m m

33 1 1

Thursday ISTH 2012 11.6.2012 14:46 Page 34

Detailed Programme Thursday, 28 June 2012

Presidential Plenary 08:30 - 12:00

Presidential Plenary: SSC in Translation Auditorium 1

Chairpersons: Cheng Hock Toh (United Kingdom), Henri Bounameaux (Switzerland) Welcome and introduction 08:30 - 08:45 Relevance of the SSC to translational medicine Cheng-Hock Toh (United Kingdom) 08:45 - 09:00 Marion Barnhart Memorial Lecture Translational medicine in thrombosis and haemostasis Garret FitzGerald (USA) 09:00 - 09:30 Arthur Bloom Memorial Lecture From gene to therapy I: haemophilia Edward Tuddenham (United Kingdom) 09:30 - 10:00 Pia Glas Greenwalt Memorial Lecture From gene to therapy II: thrombocytopaenia Kenneth Kaushansky (USA) 10:00 - 10:30

Tea / Coffee Break Exhibition hall, lower level

Collen Foundation - Life Sciences Research Partners Award Emerging translation I: complement & coagulation Markus Huber-Lang (Germany) 11:00 - 11:30 Kenneth M. Brinkhouse Memorial Lecture Emerging translation II: NETs & thrombosis Denisa Wagner (USA) 11:30 - 12:00

34 ISTH 201211.6.201214:46Page35 Characterising thePKprofileofturoctocogalfa:resultsfromGUARDIAN Andreas Tiede (Germany) Steven Pipe(USA) Concluding remarks All Panel discussion Peter Collins(UnitedKingdom) FIX (N9-GP):populationPKmodellingandsimulations Exploring theclinicalapplicationofrecombinantglycoPEGylated Camilla BuöenStenmo(Denmark) pathfinder Assessment ofrecombinantglycoPEGylatedFVIII(N8-GP): Steven Pipe(USA)StephanieSeremetis(Denmark) Welcome andintroduction Pharmacokinetics inhaemophilia:guidingpatientcare Chairperons: David Keeling(UnitedKingdom) Concluding remarks All Panel discussion Susan Mather(UnitedKingdom) Delivering bestclinicalpracticethroughpartnerships John Pasi(UnitedKingdom) Defining clinicaloutcomes-optimisingexistingresources Gerry Dolan(UnitedKingdom) Developing anevidencebasetosupportbestpractice Alison Rylands(UnitedKingdom) Specialised servicesinhaemophilia-anationalpolicy perspective David Keeling(UnitedKingdom) Welcome andintroduction Clinical leadershipinhaemophilia-settingnewstandards? Chairperson: N S P N S P ealdPormeTusa,28June 2012 Detailed Programme Thursday, a f a f o o i i z z t t v v e e e e o o l l r r

l l i i N N t t

e e o o TM

r r S S d d 1 -afirsthumandosetrial Steven Pipe(USA),StephanieSeremetis(Denmark) David Keeling(UnitedKingdom) y y i i s s m m k k p p

o o s s i i a a

TM trials 1 1 2 2 : : 13:40 -13:45 12:20 -12:35 13:00 -13:20 12:40 -13:00 12:15 -12:20 12:50 -13:05 12:20 -12:40 13:35 -13:45 13:20 -13:35 13:20 -13:40 13:05 -13:20 12:35 -12:50 12:15 -12:20 1 1 5 5

H H H H - -

a a a a 1 1 l l l l 3 3 l l l l

: : 2 2 2 2 4 4 35 E E F F 5 5

Thursday ISTH 2012 11.6.2012 14:46 Page 36

Detailed Programme Thursday, 28 June 2012

Sanofi Hall 2L Chairpersons: Job Harenberg (Germany), Lord Kakkar (United Kingdom)

VTE prophylaxis in 2012: where we are and where we are going Welcome and introduction Job Harenberg (Germany) 12:15 - 12:20 New understanding of properties Ludovic Drouet (France) 12:20 - 12:35 Anticoagulants: from clinical trials to real life Russell D. Hull (Canada) 12:35 - 12:50 Anticoagulants in medical prophylaxis: where do we stand? Roger D. Yusen (USA) 12:50 - 13:05 Biosimilar LMWHs: regulatory perspectives Job Harenberg (Germany) 13:05 - 13:20 Anticoagulation: challenges in the coming years Lord Kakkar (United Kingdom) 13:20 - 13:35 Questions and answers and closing remarks Lord Kakkar (United Kingdom) 13:35 - 13:45

SSC Sessions 14:00- 15:30

Pro-thrombotic Markers and Global Hemostatic Tests Auditorium 1

Chairpersons: Anna Falanga (Italy), David Lillicrap (Canada) Part I Advantages and limitations of clot-lysis assays Jonathan Foley (USA) 14:05 - 14:20 Elevated related markers in patients with malignant diseases associated with DIC or DVT Hideo Wada (Japan) 14:20 - 14:35 Overall discussion part I Anna Falanga (Italy), David Lillicrap (Canada) 14:35 - 14:45

36 ISTH 201211.6.201214:46Page37 T Y Treatment ofDICwithrhthrombomodulin Carl-Erik Dempfle(Germany) Fibrin relatedmarkers Nielsen (Denmark),JeckoThachil(UnitedKingdom) Chairpersons: Anna Falanga(Italy),DavidLillicrap(Canada) Overall discussionpartII Armando Tripodi (Italy),ElenaSantagostino(Italy) agents inhaemophilia The useofglobalcoagulationassaystoevaluate:treatmentswithby-passing Grigoris Gerotziafas(France) inpatientswithacquiredhypercoagulablestate and VKA The useofglobalcoagulationassaystoevaluate:treatmentswithLMWHs Part II Jecko , pathologicalcoagulationandDIC’? Shinichiro Kurosawa(USA) and thesharedfeatures? DIC andthromboticmicroangiopathy:whatarethedifferences Satoshi Gando(Japan) DIC andCOT/ACOTSintrauma Chairman’s report Ikuro Maruyama(Japan) DAMPs/PAMOs in DIC Hyun KyungKim(Republicof Korea) The prognosticvalueofthrombomodulin expressiononmonocytessubset? Jorn Nielsen(Denmark) Topics ondiagnosisofDIC adashi Matsushita, Tatsuhiko Kuroda Yoichi Sakata(Japan) un Mimuro,Hoyu Takahashi, IsaoKitajima,Hajime T S D S D ealdPormeTusa,28June 2012 Detailed Programme Thursday, S S i i s s C C s s Thachil (UnitedKingdom) e e

S S m m e e i i s s n n s s a a i i t t o o e e Hideo Wada (Japan),Satoshi Gando(Japan),HyunKyungKim(RepublicofKorea),Jorn n n d d s s

I I n n t t r r a a v v a a s s c c u u l l a a r r

C C o o a a g g u u l l a a t t i i o o n n

( ( D D I I C C suji, Y suji, ) )

utaka Eguchi, 1 1 5 5 15:15 -15:30 15:00 -15:15 15:55 -16:20 15:30 -15:55 14:45 -15:00 16:45 -17:00 16:30 -16:45 16:20 -16:30 17:45 -18:00 17:30 -17:45 17:15 -17:30 17:00 -17:15 : : 3 3 0 0 H H - -

a a 1 1 8 8 l l l l

: : 2 2 0 0 37 0 L 0 L

Thursday ISTH 2012 11.6.2012 14:46 Page 38

Detailed Programme Thursday, 28 June 2012

Factor XI and the Contact System Hall 2F

Chairpersons: Thomas Renne (Sweden), Jonas Emsley (United Kingdom), David Gailani (USA), Keith McCrae (USA), Joost Meijers (The Netherlands), Christine Mannhalter (Austria), Ophira Salomon (Israel)

Bleeding in FXI deficiency Factor XI -setting the scene Paula Bolton-Maggs (United Kingdom) 15:30 - 15:50

Genetics and genomics Genotypic variations of complement factors and phenotypic effects Christine Mannhalter (Austria) 15:50 - 16:05 Epidemiology and genetics of aPTT and contact factors Gordon Lowe (United Kingdom) 16:05 - 16:20

Tea / Coffee Break Exhibition hall, lower level

Activation of factor XII Structure of the FXII protease domain Jonas Emsley (United Kingdom) 16:30 - 16:45 Functional insights into FXII contact activation Coen Maas (The Netherlands) 16:45 - 17:00

Novel functions of FXI and the contact system in thrombosis Characterization of factor XII autoactivation by a physiological Nicola Mutch (United Kingdom) 17:00 - 17:15 Contact system activation by microparticles Helen Philippou (United Kingdom) 17:15 - 17:30 Contact pathway inhibition: characterization of effect on clot formation Henry Spronk (The Netherlands) 17:30 - 17:40 Targeting factor XII inhibits the pathological process of formation on ruptured plaques in vivo and in vitro Judith Cosemans (The Netherlands) 17:40 - 17:50 A chromogenic FXIa method with low interference for in-process and final testing of immunologlobulin preparations Steffen Rosén (Sweden) 17:50 - 18:00

38 ISTH 201211.6.201214:46Page39 Alex Spyropoulos(USA) application totheperioperativesetting Weighting ofthrombosis andbleedingriskinclinicaltrials: Jerrold Levy(USA) can plateletfunctionassayspredictbleeding? Managing patientsonantiplateletdrugswhoneedsurgery: Beverly Hunt(UnitedKingdom) how touseandinterpretcoagulationtests? Managing patientsonneworalanticoagulantswhoneedsurgery: Marc Samama(France) how tominimizeriskforthrombosisandbleeding? Managing patientsonneworalanticoagulantswhoneedsurgery: James Douketis(Canada) Sessions objectives Alex Spyropoulos(USA) in theperioperativesetting Part A: newprojectonthedeterminantsofthrombosisandbleedingrisk (USA), Chairpersons: Scott Kaatz(USA) CHADS2 andCHADS2VASc todetermine stroke risk:oneorboth? Karel Moons(TheNetherlands) Patient riskscores:howto assess theirusefulnessinclinicalpractice? Shinya Goto(Japan) decisions aboutwhichanticoagulanttouse riskforstrokeandbleeding:howthis informs Assessing patients’ Paul Kyrle(Austria) an update The Austrian studyonrecurrentvenousthromboembolism (AUREC): James Douketis(Canada) Part B:updateofSSC-Relatedactivities T P T P ealdPormeTusa,28June 2012 Detailed Programme Thursday, e e r r a a e e

d d / /

i i Alex Spyropoulos(USA),ShinyaGoto(Japan),KarelMoons(TheNetherlands) C C c c o o t t i i f f v v f f e e e e e e

V V

James Douketis(Canada),FrederickSpencer Alberto Tosetto (Italy),RichardWhite B B a a r r r r e e i i a a a a k k b b

l l

e e s s

i i n n

C C a a r r d d i i o o v v a a s s c c u u l l a a r r

D D i i s s e e a a s s e e

E E x x h h i i b b i i t t i i o o n n

h h a a l l l l , , 15:30 -15:35 17:30 -17:45 16:30 -16:45 16:10 -16:30 15:50 -16:10 15:35 -15:50 17:45 -18:00 17:15 -17:30 17:00 -17:15 l l R R o o w w o o e e o o r r m m

l l e e

3 3 v v e e A A 39 l l

Thursday ISTH 2012 11.6.2012 14:46 Page 40

Detailed Programme Thursday, 28 June 2012

Fibrinolysis Room 3B

Chairpersons: Ann Gils (Belgium), Jonathan Foley (USA), Shirley Uitte de Willige (Netherlands), Paul Kim (Canada), Osamu Matsuo (Japan), Tetsumei Urano (Japan), Nicola Mutch (United Kingdom), Craig Thelwell (United Kingdom) An update on WHO International Standards: a report on the Urokinase study; a proposal to replace the plasmin IS and other ongoing projects Craig Thelwell (United Kingdom) 15:30 - 16:00 Measuring the mechanical properties and fibrinolytic potential of blood clots formed via the tissue factor pathway of coagulation Jonathan Foley (USA) 16:00 - 16:20

Tea / Coffee Break Exhibition hall, lower level

Alpha-2-antiplasmin: a heterogeneous fibrinolysis inhibitor Shirley Uitte de Willige (The Netherlands) 16:40 - 17:00 Roles of kringle domains in plasminogen activation and plasmin activity Paul Kim (Canada) 17:00 - 17:20 What’s in a name? An evaluation of TAFI/pro-CPU nomenclature Jonathan Foley (USA) 17:20 - 17:40

Plasma Coagulation Inhibitors Room 12

Chairpersons: Steven Kitchen (United Kingdom); Piet Meijer (The Netherlands), Laurent Mosnier (USA), Elisabetta Castoldi (The Netherlands), Tilman Hackeng (The Netherlands), Richard Marlar (USA)

Welcome and update on subcommittee projects Steven Kitchen (United Kingdom) 15:30 - 15:40

Session 1: effects of new oral anticoagulants on plasma coagulation inhibitor testing Steven Kitchen (United Kingdom); Piet Meijer (The Netherlands) The effect of rivaroxaban on laboratory testing for coagulation inhibitors: experience from ECAT surveys Piet Meijer (The Netherlands) 15:40 - 15:55

40 ISTH 201211.6.201214:46Page41 Michael Spannagl(Germany) Genotype andlaboratoryphenotypeofhereditaryproteinSdeficiency Hiroko Tsuda (Japan) quality control Total proteinSassaysystem:clinicalsignificanceandpre-analytical K Hickey(UnitedKingdom) eruya (USA) Stability of AT, PCand APC-R inwholeblood Jun onclotbasedproteinCandSassays The effectofCRP (UnitedKingdom),Richard Marlar(USA) Steven Kitchen Session 2 Elisabetta Castoldi(TheNetherlands) generationasanintermediatephenotypeforgenetic studiesonvenousthrombosis Eveline A. Bouwens(USA),LaurentMosnier(USA) Novel assaysforEPCRencryptionandcellular APC resistance Laurent Mosnier(USA),Tilman Hackeng(TheNetherlands) Session 3 Andreas Hillarp(Sweden) Effects ofrivaroxabananddabigatranonplasmainhibitortesting Bob Gosselin(USA) Effects ofdabigatranonPC,PSand AT assays ealdPormeTusa,28June 2012 Detailed Programme Thursday, T 17:10 -17:25 17:40 -18:00 16:10 -16:25 16:55 -17:10 16:40 -16:55 16:25 -16:40 17:25 -17:40 15:55 -16:10 41

Thursday ISTH 2012 11.6.2012 14:46 Page 42

Detailed Programme Thursday, 28 June 2012

ISTH BAT Standing Committee Public Session Hall 2E Chairperson: Francesco Rodeghiero (Italy) Introduction Presentation of the ISTH-Bleeding Assessment Tool (BAT) Standing Committee operative rules and projects Francesco Rodeghiero (Italy) 16:05 - 16:20 Rockefeller University repository Barry Coller (USA) 16:20 - 16:35

Ongoing/planned projects Jeroen Eikenboom (The Netherlands), Paul Monagle (Australia) Bleeding phenotype of severe VWD3 versus milder VWD forms: current experiences and future perspectives Augosto Federici (Italy) 16:35 - 17:35 Preliminary data on bleeding manifestations in adult controls and adults with Type 1 VWD Paula James (Canada) 16:35 - 17:35 Defining the incidence of bleeding in normal adults Alberto Tosetto (Italy) 16:35 - 17:35 Towards harmonization of different BATs in rare congenital bleeding disorders K Mussallam (Italy), Flora Peyvandi (Italy) 16:35 - 17:35 Proposals and suggestions from the attendees 17:35 - 17:55 David Lillicrap (Canada), Sabine Eichinger (Austria) Conclusions Francesco Rodeghiero (Italy) 17:55 - 18:00

42 ISTH 2012 11.6.2012 14:46 Page 43

Detailed Programme Thursday, 28 June 2012

Satellite Symposia 18:15 - 19:45

Bayer HealthCare Hall 2E Chairperson: Ander Cohen (United Kingdom) Novel oral for the management of venous thromboembolism - a practical consideration Welcome and introduction Ander Cohen (United Kingdom) 18:15 - 18:20 EINSTEIN PE results and their impact on VTE treatment Ander Cohen (United Kingdom) 18:20 - 18:45 Treating VTE: the single drug approach Gerry Dolan (United Kingdom) 18:45 - 19:05 Orthotep Presentation Jan Beyer-Westendorf (Germany) 19:05 - 19:15 Novel anticoagulants in clinical practice – panel discussion and close Ander Cohen (United Kingdom), Gerry Dolan (United Kingdom), Jan Beyer-Westendorf (Germany), Simon Nobel (United Kingdom), Raj Patel (United Kingdom) 19:15 - 19:45

Symposium on Widening Participation 18:15 - 19:45

University of Liverpool Hall 2N

Chairperson: Mike Parker (Liverpool Vision) Little Big Medicine Welcome to school students Mike Parker (Liverpool Vision) Nourishing the creative mind Richard Piper (Roald Dahl Foundation) The emerging importance of nanomedicine Andrew Owen (University of Liverpool) Panel discussion with scientist, clinician and industry Andrew Owen (University of Liverpool), Saye Khoo (Royal Liverpool University Hospital), Geoff Wainwright (2Bio)

43

ISTH 2012 11.6.2012 14:48 Page 44

Programme Overview

Friday, 29 June 2012

SSC Session

Time Title Chairpersons 08:00 - 09:30 Joint session Von Willebrand Factor Flora Peyvandi & Paula James and Factor VIII and IX (Hall 2E)

09:30 - 12:00 Von Willebrand Factor, part I (Hall 2E) Jeroen Eikenboom Factor VIII and IX, part I (Hall 2F) Flora Peyvandi Perinatal/pediatric (Hall 2L) Paul Monagle Animal models (Hall 2N) Susan Smyth 08:00 - 12:00 anticoagulant (Room 3A) Thomas Ortel Platelet physiology (Room 3B) Paul Harrison Vascular biology (Room 4) Françoise Dignat-George Biorheology (Room 12) Michael King

Satellite Symposia

Time Company Title 12:15 - 13:45 Daiichi Sankyo Novel anticoagulation for venous thromboembolism - (Hall 2E) new perspectives and treatment strategies Stago DIC - The next frontier in thrombosis and haemostasis (Hall 2F)

14:00 - 17:00 Hot Topics Halls 2L and 2N

17:00 - 19:00 ePoster Session

20:00 - 22:00 Football Match - Europe versus the World

44 ISTH 201211.6.201214:48Page45 Johanna KremerHovinga(Switzerland) General discussion Khaled Musallam(Italy) Bleeding scoreinrarebleedingdisorders Alberto Tosetto (Italy) What typeofscoringsystemisnecessaryinhemophilia Barry Coller(USA) Web basedBleeding Assessment Tool (BAT) Francesco Rodeghiero(Italy) Update fromthestandingcommitteeonBleeding Assessment Tool Paula James(Canada) Introduction Bleeding scores Chairpersons: Imre Bodo(Hungary) Comparison ofVWFactivity assays Koichi Kokame(Japan) Gene mutationanalysisfor Upshaw-Schulmansyndrome Johanna KremerHovinga(Switzerland) International referencepreparationfor ADAMTS13 activity Imre Bodo(Hungary) Standardization ofthehighqualitymultimerassay:aHamburg-Budapest project Anthony Hubbard(UnitedKingdom) Review oftheavailableWHOISforallVWF-relatedanalytes, andVWFppcalibration (USA) Thomas Abshire Standardization ofassays Chairpersons: (USA), JorgeDiPaola V J S V J S ealdPormeFia,29June 2012 Detailed Programme Friday, o o o o S S i i n n C C n n

t t W W

S S S S i i e e l l e e l l s s e e s s s s b b s s i i r r o o i i Flora Peyvandi(Italy),PaulaJames(Canada) Jeroen Eikenboom(TheNetherlands),DanielHampshire(United Kingdom),Thomas a a o o n n n n n n s s d d : :

V V

F F o o a a n n c c

W W t t o o i i r r l l , , l l e e p p Yoshihiro Fujimura(Japan),PaulaJames(Canada),ImreBodo(Hungary), b b a a r r r r a a t t

n n I I

d d

F F a a c c t t o o r r

a a n n d d

F F a a c c t t o o r r

V V I I I I I I

a a n n d d

I I X X 0 0 8 8 : : 10:30 -10:40 08:05 -08:25 09:05 -09:25 08:45 -09:05 08:25 -08:45 08:00 -08:05 10:40 -10:55 10:15 -10:30 10:00 -10:15 10:55 -1 0 0 Abshire 0 0

H H H H - -

a a a a 1 1 l l l l 2 2 l l l l

: : 2 2 2 2 1:05 0 0 45 E E E E 0 0

Friday ISTH 2012 11.6.2012 14:48 Page 46

Detailed Programme Friday, 29 June 2012

VWF, VWD and TTP registries Jorge DiPaola (USA) VWF database Daniel Hampshire (United Kingdom) 11:05 - 11:20 Platelet type- VWD registry/database Maha Othman (Canada) 11:20 - 11:35 International registry on acquired von Willebrand syndrome Augusto Federici (Italy) 11:35 - 11:45 Hereditary TTP registry Johanna Kremer Hovinga (Switzerland) 11:45 - 12:00

Factor VIII and IX, part I Hall 2F Chairpersons: Flora Peyvandi (Italy), Leonard Valentino (USA), Claude Negrier (France), Midori Shima (Japan), Jan Astermark (Sweden), Kathelijn Fischer (The Netherlands), Steven Pipe (USA) Report on SSC-FVIII&FIX activity 2010-2011 Flora Peyvandi (Italy) 09:30 - 09:40 Projects reports I Guy Young (USA), Alok Srivastava (India) Standardization of whole blood viscoelastic measurement of clot formation and clot stability Meera Chitlur (USA) 09:40 - 09:50 Standardization of methods for performing the thrombin generation test Claude Negrier (France) 09:50 - 10:00 Standardization of methods for performing the clot wave form analysis Midori Shima (Japan) 10:00 - 10:10 General discussion Projects reports II: FDA and EMEA regulatories: clinical trial requirements Flora Peyvandi (Italy), Mike Makris (United Kingdom) New regulation of FDA for rare disorders Nisha Jain (USA) 10:20 - 10:30 New European guidelines for clinical trials in rare disorders Anneliese Hilger (Germany) 10:30 - 10:40 Clinical trial design for haemophilia Donna DiMichele (USA) 10:40 - 10:50

46 ISTH 201211.6.201214:48Page47 V Establishment ofaregistry ofhomozygousproteinC John Puetz(USA) useinneonatesandchildren Evidence forFFP Shoshana Revel-Vilk (Israel) Systematic assessmentofPTStheuppervenoussytem Madhvi Rajpurkar(USA) Measurement oflongtermconsequencesspecificorgan thrombosis Suzan Williams(Canada) IVC filtersinchildren Paul Monagle(Australia) Introduction andupdateontheworkofSSC Guy Young(USA) Chalmers (UnitedKingdom), Chairpersons: General discussion Flora Peyvandi(Italy) Consensus definitionsinrarebleedingdisorders Alok Srivastava(India) Consensus definitionsinhaemophilia Anthony Hubbard(UnitedKingdom) Potency labellingofclottingfactorconcentrates:update Peter Collins(UnitedKingdom) Using pharmacokineticstoindividualizetreatment:update Steven Kitchen(UnitedKingdom),LeonardValentino (USA) Projects reportsIII icky Price(Canada) T T P T T P ealdPormeFia,29June 2012 Detailed Programme Friday, e e e e e e a a a a r r

i i / / / / n n

C C C C a a t t o o o o a a f f f f f f f f l l e e e e / / P P e e e e

e e Paul Monagle(Australia),PaoloSimioni(Italy),MarianaBonduel(Argentina),Elizabeth B B B B d d r r r r i i e e e e a a a a a a t t k k k k r r

i i c c

Anthony Chan(Canada),ChristophMale(Austria),JannaJourneycake(USA), E E E E x x x x h h h h i i i i b b b b i i i i t t t t i i i i o o o o n n n n

h h h h a a a a l l l l l l l l , , , , 09:15 -09:45 08:15 -08:45 09:45 -10:15 08:45 -09:15 08:00 -08:15 10:30 -1 11:20 -11:30 11:10 -11:20 1 1 l l l l o o o o 1:40 -11:50 1:30 -11:40 w w w w H H e e e e r r r r a a

l l l l l l e e e e l l

v v v v 1:00 2 2 e e e e 47 L L l l l l

Friday ISTH 2012 11.6.2012 14:48 Page 48

Detailed Programme Friday, 29 June 2012

Brief updates on ongoing SSC projects Antiplatelet therapy in children Janna Journeycake (USA) 11:00 - 11:10 HIT in children Guy Young (USA) 11:10 - 11:20 Point-of-care testing in children Paul Monagle (Australia) 11:20 - 11:30 Investigation of the bleeding child Paolo Simioni (Italy) 11:30 - 11:45 Conclusion and planning Paul Monagle (Australia) 11:45 - 12:00

Animal Models Hall 2N

Chairpersons: Susan Smyth (USA), Cecile Denis (France), Nigel Mackman (USA), Toshiyuki Miyata (Japan), David Motto (USA), Hugo Ten Cate (The Netherlands), Timothy Nichols (USA), Eva-Maria Muchitsch (Austria), Tom Knudsen (Denmark)

ARFI ultrasound method of detecting bleeding and documenting hemostasis in the hemophilic and VWD dogs Timothy Nichols (USA) 08:05 - 08:30 Pharmacokinetics and pharmacodyanmics of recombinant canine FVIIa in dogs Tom Knusden (Denmark, Novo Nordisk AS) 08:30 - 08:55 Pro-hemostatic agents in a pig model of Henry Spronk (The Netherlands) 08:55 - 09:20 Assessment of thrombogenicity Eva-Maria Muchitsch (Austria, Baxter Innovations GmbH) 09:20 - 09:45

Tea / Coffee Break Exhibition hall, lower level

48 ISTH 201211.6.201214:48Page49 (Italy) Amsterdam, TheNetherlands,June29-July4,2013 (USA), BasdeLaat(TheNetherlands),Tatsuya Chairperons: Guido Reber(Switzerland) antibodies Problems andpossiblesolutions inthedetectionofantiphospholipid PG deGroot(TheNetherlands) Diagnosis oflupusanticoagulantsinthepresencenew anticoagulanttherapies Lupus anticoagulants Katrien Devreese(Belgium), Thomas Ortel(USA) Standardization oftheantiphospholipidantibodyassays Tatsuya Atsumi (Japan) and internationalstandardization Phosphatidylserine dependentantiprothrombinantibodies: significance Bas deLaat(TheNetherlands) Conformation ofbeta-2-glycoproteinI Silvia Pierangeli(USA) of measurementforanti-beta-2-glycoproteinIantibodies Update oncriteriaantiphospholipidtaskforceandestablishingunits Anticardiolipin, anti-beta-2-glycoproteinI,andantiprothrombinantibodies Planning forthe59 Alexandra Schiviz(Austria,BaxterInnovationsGmbH) Bleeding phenotypeandcoagulationvariablesofBALB/c,C57BL/6129S1/Svmice Jasimuddin Ahamed (USA) Contributions ofplateletTGF- Andy Weyrich (USA) Platelet signaturesinmiceandhumans Hugo Ten Cate(TheNetherlands) Coagulant proteinsinmurinemodelsofatherosclerosis L L ealdPormeFia,29June 2012 Detailed Programme Friday, u u p p u u s s

A A n n t t Thomas Ortel(USA),KatrienDevreese(Belgium), Armando Tripodi (Italy),SilviaPierangeli i i c c o o a a g g u u th l l Annual SSCMeetingwithXXIVISTHCongress: a a n n t t

ͱ 1 invitroandvivotoplasmaTGF- Atsumi (Japan),GuidoReber(Switzerland),Vittorio Pengo ͱ 1 anditsbiologiceffects 10:00 -10:25 09:30 -10:00 09:00 -09:30 08:30 -09:00 08:00 -08:30 10:25 -10:50 10:00 -10:30 10:30 -11:00 10:50 -11:15 11:40 -12:00 11:15 -11:40 R R o o o o m m

3 3 A A 49

Friday ISTH 2012 11.6.2012 14:48 Page 50

Detailed Programme Friday, 29 June 2012

New assays Update on the annexin A5 resistance assay and proposal for an SSC trial analogous to the anti-D1 study Jacob Rand (USA) 11:00 - 11:30 Proposal for new guidelines for diagnosis of APS Proposed guidelines for the diagnosis of antiphospholipid syndrome Vittorio Pengo (Italy) 11:30 - 12:00

Platelet Physiology Room 3B

Chairpersons: Paul Harrison (United Kingdom), Paolo Gresele (Italy), Christian Gachet (France), Dermot Kenny (Republic of Ireland), Diego Mezzano (Chile), Andrew Mumford (United Kingdom), Marco Cattaneo (Italy), Alan Nurden (France) Introduction and overview Paul Harrison (United Kingdom) 08:00 - 08:15 Guidelines for the diagnosis of platelet disorders Survey update Paolo Gresele (Italy) 08:15 - 08:40 Consensus of working group Paolo Gresele (Italy) 08:40 - 09:05 Platelet type VWD Maha Othman (Canada) 09:05 - 09:30 Therapeutic monitoring of anti-P2Y12 drugs Dirk Sibbing (Germany) 09:30 - 10:00

Tea / Coffee Break Exhibition hall, lower level

Analysis of the platelet transcriptome New generation sequencing, transcription profiling and whole exome analysis of platelet disorders Kathleen Freson (Belgium) 10:30 11:00 Thrombogenetics Graham Kiddle (United Kingdom) 11:00 11:30 In vitro microfluidic devices Johan Heemskerk (The Netherlands) 11:30 12:00

50 ISTH 201211.6.201214:48Page51 Detection andcharacterizationofcirculatingendothelialcellstheirprogenitors François Lanza(France) Function ofGPVanditsutilityasamarkerthrombosisincardiovasculardisorders Andreas Ludwig(Germany) ADAMs mediatedsheddinginvascularbiology Elaine Raines(USA) Metalloproteinase sheddinginfluencingleukocytefunction Elizabeth Gardiner(Australia) Shear-induced releaseofplateletreceptorsbymetalloproteinases Elizabeth Gardiner(Australia),PeterNewman(USA) Shed proteins/receptors Chairpersons: Alain Brisson(France) platelets bycryo-electronmicroscopy Characterization ofmicroparticles frombloodplasmaandactivated John Nolan(USA) microvesicle byflowcytometry Challenges andopportunitiesformultiparameteranalysis ofcellderived Nigel Key(USA),FlorenceToti-Orfanoudakis (France) Determination andcharacterizationof(circulating) microparticles Fran (The Netherlands),ElizabethGardiner(Australia) Peter Newman(USA),FlorenceToti-Orfanoudakis (France),NigelKey(USA),RienkNieuwland Florence Sabatier(France) with prognosissignificance percutaneous coronaryintervention:areflectofendothelial responsetoinjury Changes incirculatingendothelialcellsandtheirprogenitors during Jamie Case(USA) of immatureandmaturecirculatingendothelialcells Flow cytometricidentificationandfunctionalcharacterization Gianpaolo Fadini(Italy) Endothelial progenitorcellmeasurementforassessmentofcardiovascularrisk T V T V ealdPormeFia,29June 2012 Detailed Programme Friday, e e a a a a s s ç

c c oise Dignat-George(France),JohnGriffin(USA) / /

u u C C l l o o a a f f r r f f e e

B B e e

i i Fran B B o o r r l l o o e e a a g g ç k k y y oise Dignat-George(France),MichaelBerndt(Ireland,Republicof),JohnGriffin(USA),

. E E x x h h i i b b i i t t i i o o n n

h h a a l l l l , , 08:30 -08:45 08:00 -08:15 08:45 -09:00 08:15 -08:30 10:30 -10:45 10:15 -10:30 09:30 -09:45 09:15 -09:30 09:00 -09:15 l l o o w w R R e e o o r r o o

l l m e e m v v

e e 51 4 4 l l

Friday ISTH 2012 11.6.2012 14:48 Page 52

Detailed Programme Friday, 29 June 2012

Is decrease of microparticles related to improvement of hemostasis after the treatment in hemophilia A Jovan Antovic (Sweden) 10:45 - 11:00 Effect of different triggering techniques on MP analysis by Micah Mooberry (USA) 11:00 - 11:15 Flow cytometry-based standardized microparticle counting: forward or side scatter Philippe Poncelet (France) 11:15 - 11:30 Development of standards for MP determination Rienk Niewland (The Netherlands) 11:30 - 11:45 Closing remarks Françoise Dignat-George (France) 11:45 - 12:00 Biorheology Room 12

Chairperons: Michael King (USA), Lawrence Brass (USA), Shaun Jackson (Australia), Armin Reininger (Switzerland), Mitsuhiko Sugimoto (Japan), Keith Neeves (USA), Owen McCarty (USA) Part 1: in vitro assays of thrombosis and haemostasis under flow Michael King (USA) Platelet aggregates as prerequisite for fibrin polymerization under flow Armin Reininger (Switzerland) 08:05 - 08:25 Fibrin generation within thrombi generated in antibody-induced hemophilic whole blood under flow condition: In vitro evaluation for hemostatic effects of anti-hemophilic agents Mitsuhiko Sugimoto (Japan) 08:25 - 08:45 Fibrin formation under flow correlates to FVIII levels in hemophilia A in a tissue factor-collagen flow assay Keith Neeves (USA) 08:45 - 09:05 Characterization of the physical parameters of mass, volume and density of platelet aggregates and thrombus formation Owen McCarty (USA) 09:05 - 09:25 Methods and readouts for investigating the effects of fluid shear stress on haemostatic and inflammatory responses of endothelial cells Gerard Nash (United Kingdom) 09:25 - 09:45 Tea / Coffee Break Exhibition hall, lower level

52 ISTH 201211.6.201214:48Page53 Michael King(USA) Multiscale simulationofplatelettetheringandtranslocation Jef a populationofmathematicalmodels Estimating therobustnessandfragilityofcoagulationcascadeusing Aaron Fogelson(USA) of plateletsandproteinstowithinthethrombus Modeling plateletdepositionandcoagulationunderflow:transport Tom Diacovo(USA) novelplatformformultiscalemodelingofhumanthrombi A Johan Heemskerk(TheNetherlands) approach Multiparameter assessmentofthrombusformation:asystemsbiology Scott Diamond(USA) simulation ofthrombosisandbleeding High throughputmicrofluidicsandplateletphenotypingforpatient-specific Armin Reininger(Switzerland),MitsuhikoSugimoto(Japan) thrombus growthunderflow Part 2:multiscalemodelingandhighthroughputassaysof Gregory Welcome andintroduction and treatmentstrategies Novel anticoagulationforvenousthromboembolism -newperspectives Chairpersons: Sebastian MSchellong(Germany) Edoxaban -currentevidence ofanewonce-dailyfactorXainhibitor Gregory YH Lip(UnitedKingdom) New perspectiveswithnovel anticoagulants,beyondvenousthromboembolism Henri Bounameaux(Switzerland) Venous thromboembolism-aclinicians view D S D S ealdPormeFia,29June 2012 Detailed Programme Friday, f Varner (USA) a a a a t t i i i e i e c c l l h h l l i i YH Lip(UnitedKingdom),HenriBounameaux(Switzerland) t t i i

e e S S

S S a a n n y y Gregory YH Lip(UnitedKingdom),HenriBounameaux(Switzerland) m m k k y y p p o o o o

s s i i a a 1 1 2 2 : : 12.20 -12:40 10:15 -10:35 10:35 -10:55 09:55 -10:15 13:00 -13:20 12:40 -13:00 12:15 -12:20 1 10:55 -1 1 1 1 1:35 -12:00 1:15 -11:35 5 5

H H - -

a a 1 1 l l 3 3 l l

: : 2 2 1:15 4 4 E E 53 5 5

Friday ISTH 2012 11.6.2012 14:48 Page 54

Detailed Programme Friday, 29 June 2012

Edoxaban in venous thromboembolism - what can the HOKUSAI-VTE study tell us? Harry Büller (The Netherlands) 13:20 - 13:35 Panel discussion / Q&A All 13:35 -13:40 Meeting close Gregory YH Lip (United Kingdom), Henri Bounameaux (Switzerland) 13:40 - 13:45

Stago Hall 2F Chairpersons: Cheng-Hock Toh (United Kingdom), Fletcher B. Taylor Jr. (USA) DIC - The next frontier in thrombosis and haemostasis Welcome and introduction Cheng-Hock Toh (United Kingdom), Fletcher B. Taylor, Jr. (United Kingdom) 12:15 - 12:20 Mission: impossible-DIC protocol Cheng-Hock Toh (United Kingdom) 12:20 - 12:45 Platelets in DIC and severe sepsis Bernd Jilma (Austria) 12:45 - 13:10 Laboratory innovation in the management of patients with severe sepsis Françoise Dignat-George (France) 13:10 - 13:35 Concluding remarks Cheng-Hock Toh (United Kingdom) 13:35 - 13:45

Hot Topics 14:00 - 17:00 Basic Science (see page 68) Hall 2 L

Chairpersons: Michael Berndt (Ireland), Pieter Reitsma (The Netherlands)

Clinical Science (see page 69) Hall 2 N

Chairpersons: Anna Falanga (Italy), Henri Bounameaux (Switzerland)

ePoster Session 17:00 - 19:00

Football Match - Europe versus the World 20:00 - 22:00

54 ISTH 2012 11.6.2012 14:48 Page 55 ISTH 2012 11.6.2012 14:48 Page 56

Programme Overview

Saturday, 30 June 2012

Technical Session

Time Company Title 08:00 - 09:00 Inspiration Biopharmaceuticals, Inc. Assay techniques for recombinant porcine FVIII and recombinant human FIX (Hall 2E)

SSC Session

Time Title Chairpersons 09:00 - 13:00 Von Willebrand Factor, part II (Hall 2E) Jeroen Eikenboom Women’s health issues in thrombosis and haemostasis (Hall 2F) Sabine Eichinger Control of anticoagulation (Hall 2L) Walter Ageno Hemostasis and Malignancy (Hall 2N) Agnes Lee Factor VIII and IX, part II (Room 3) Flora Payvandi Platelet immunology (Room 12) Yves Gruel Factor XIII and fibrinogen (Room 4A) Hans Kohler

14:00 - 16:30 SSC Business Meeting Room 12

56 ISTH 201211.6.201214:48Page57 lieGa Uie igo) atnLLeeandDougaldMonroe(USA) Elaine Gray(UnitedKingdom),MartinL Questions andanswers Dougald Monroe(USA) Recombinant humanFIX Elaine Gray(UnitedKingdom) Factor IXassay Lee(USA) Martin L Recombinant porcineFVIII Dougald Monroe(USA) Welcome andintroduction Assay techniquesforrecombinantporcineFVIIIandhumanFIX Chairperson: Thomas VWD internationalprophylaxis (VIP)study Robert Montgomery(USA) Zimmerman project(ZPMCB-VWD) Anne Goodeve(UnitedKingdom), CarloCastaman(Italy) EUVWD cooperativegroup Augusto Federici(Italy) European projectontype3VWD Daniel Hampshire(UnitedKingdom),ImreBodo(Hungary) Multicenter studiesonVWD (USA), (USA), PaulaJames(Canada),JohannaKremerHovinga (Switzerland), ImreBodo(Hungary),JorgeDiPaola Chairpersons: Technical Session I V S I V S ealdPormeStra,30June 2012 Detailed Programme Saturday, n n o o S S s s n n C C p p

W W i i

r r Y S S a a Abshire (USA) oshihiro Fujimura(Japan) i i e e l l t t l l i i s s e e o o s s b b n n i i Dougald Monroe(USA) r r o o

Jeroen Eikenboom(TheNetherlands),DanielHampshire(United Kingdom),Thomas Abshire a a B B n n n n i i s s o o d d

p p

F F h h a a a a c c r r m m t t o o a a r r , , c c p p e e a a u u r r t t t t i i

c c I I I I a a

l l s s , , I I n n c c . . 08:00 -09:00 0 0 9 9 : : 08:50 -09:00 08:20 -08:35 09:15 -09:30 08:35 -08:50 08:05 -08:20 08:00 -08:05 09:45 -10:00 09:30 -09:45 09:00 -09:15 0 0 0 0

H H H H - -

a a a a 1 1 l l l l 3 3 l l l l

: : 2 2 2 2 0 0 E E E E 57 0 0

Saturday ISTH 2012 11.6.2012 14:48 Page 58

Detailed Programme Saturday, 30 June 2012

WIN (Willebrand in Netherlands) Frank Leebeek (The Netherlands) 10:00 - 10:15 Canadian type 3 VWD study Paula James (Canada) 10:15 - 10:30 Belgian-Czech cooperation in the Brno-VWD study Alain Gadisseur (Belgium) 10:30 - 10:45

Tea / Coffee Break Exhibition hall, lower level Genetic modifiers of VWF levels Johanna Kremer Hovinga (Switzerland), Jeroen Eikenboom (The Netherlands) Potential role of novel VWF clearance pathways David Lillicrap (Canada) 11:15 - 11:30 Genetic variability as a determinant of in vivo release of VWF Frank Leebeek (The Netherlands) 11:30 - 11:45 Genetic modifiers of VWF antigen levels in healthy young adults Karl Desh (USA) 11:45 - 12:00 Genetic modifiers of VWD in large pedigrees: association and linkage Jorge DiPaola (USA) 12:00 - 12:15

Animal studies Mouse modifiers of VWF Jordan Shavit (USA) 12:15 - 12:30 Modifier screens in zebrafish and possible application to VWF Jordan Shavit (USA) 12:30 - 12:45 General discussion and concluding remarks

Womens Health Issues in Thrombosis and Haemostasis Hall 2F

Chairpersons: Sabine Eichinger (Austria), Takao Kobayashi (Japan), Claire Phillip (USA), Andra James (USA), Barbara Konkle (USA), Rezan Abdul-Kadir (United Kingdom), Claire McLintock (New Zealand), Saskia Middeldorp (The Netherlands)

Educational activities Educational program of SSC meetings: overview and future perspectives Sabine Eichinger (Austria) 09:05 - 09:10

58 ISTH 201211.6.201214:48Page59 Y Heparanase procoagulantassayinwomenonhormonaltherapy Astrid vanHylckama-Vlieg(TheNetherlands) Hormone useandtheriskofvenousthrombosis:clinicalissues Saskia Middeldorp(TheNetherlands) Update oninvestigatorinitiatedtrialsinwomens issues(Highlowstudy, ALIFE II) Ian Greer(UnitedKingdom) 3. Thrombophiliaandpregnancycomplications Saskia Middeldorp(TheNetherlands) 2. PreventionofVTEinpregnantwomenatincreasedrisk Ian Greer(UnitedKingdom) 1. Thromboprophylaxisaftercaesareansection therapy guidelineson ACCP Closing remarks Sabine Eichinger(Austria) what isrelevantforwomen andgirls Report fromthebleedingassessment toolstandingcommittee- T Initial reportofamulticentercaseseriesinJapan of severepostpartumhemorrhage: Recombinant activatedfactorVII(rFVIIa/NovoSeven)in themanagement Claire Phillip(USA) Menorrhagia workinggroup Benjamin Brenner(Israel) Pregnancy andmalignancy and haemostasis Spotlight on Report onthewomen symposium 201 Benjamin Brenner(Israel) akao Kobayashi(Japan) ona Nadir(Israel),BenjaminBrenner(Israel) T T ealdPormeStra,30June 2012 Detailed Programme Saturday, e e a a

/ /

C C , andpregnancy o o f f f f e e e e

B B “malignancy andwomens healthissuesinthrombosis r r 1 e e a a k k

’ ’ s healthissuesinthrombosisandhaemostasis “venous thromboembolism,thrombophilia,antithrombolic ” 02 aeitupdateofrelevantchanges 2012: panelists E E x x h h i i b b i i t t i i o o n n

h h a a l l l l , , 10:15 -10:30 09:15 -10:15 09:15 -10:15 12:30 -12:50 12:00 -12:30 09:10 -09:15 09:15 -10:15 10:50 -11:15 11:30 -12:00 1 l l o o 1:15 -11:30 w w e e r r

l l e e v v e e 59 l l

Saturday ISTH 2012 11.6.2012 14:48 Page 60

Detailed Programme Saturday, 30 June 2012

Control of Anticoagulation Hall 2L Chairpersons: Walter Ageno (Italy), Rebecca Beyth (USA), Elaine Hylek (USA), John Olson (USA), Gualtiero Palareti (Italy), Henry Watson (United Kingdom), Trevor Baglin (United Kingdom)

Update on the laboratory monitoring of the vitamin K antagonists Validation of certified plasmas for ISI calibration and INR derivation Ton van den Besselaar (The Netherlands) 09:00 - 09:15 INR simplified: the PT/INR line S. Ibrahim (United Kingdom) 09:15 - 09:30 Intra-individual variation of INR in -treated patients: consequences for desirable analytical precision Ton van den Besselaar (The Netherlands) 09:30 - 09:45

WHO-SSC collaborative study on low molecular weight heparin Results of the 3rd international standard for low molecular weight heparin Elaine Gray (United Kingdom) 09:45 - 10:00

The laboratory monitoring of the new oral anticoagulant drugs (NOACs) Which tests should we use? Armando Tripodi (Italy), Marc Samama (France) 10:00 - 10:35 When and how to measuring new oral anticoagulants (NOAC): working towards a recommendation from the subcommittee on control of anticoagulation Trevor Baglin (United Kingdom) 10:35 - 10:50 Update on SSC activities: Elaine Gray (United Kingdom) 10:50 - 11:00

Clinical experiences with the NOACs Major orthopaedic surgery, venous thromboembolism, atrial fibrillation: reports from daily clinical practice J. Beyer (Germany) 11:00 - 11:15 Atrial fibrillation: gaps in trials and current practice Elaine Hylek (USA) 11:15 - 11:30 Venous thromboembolism: gaps in trials and current practice Giancarlo Agnelli (Italy) 11:30 - 11:45

60 ISTH 201211.6.201214:48Page61 Walter Ageno (Italy) Splanchnic veinthrombosis Update onresearchactivityunusualsitethrombosis (Italy) Walter Ageno of patientstreatedwiththeNOACs Proposal foranSSCrecommendationtheguidanceonmanagement Henry Watson (UnitedKingdom) Management ofobesepatientswiththeoldandnewanticoagulants Sam Schulman(Canada) with theNOACs Suggestions forthemanagementofinvasiveproceduresandbleedingevents Peter Kamphuisen(TheNetherlands) Update oncurrentevidencesfromtherealworldandpresentationofongoingstudies Bleeding inpatientsreceivingNOACs:problemsandpossiblemanagement Agnes Lee(Canada) Updates onclinicaltrialsand Alok Khorana(USA) 2012 ACCP Dominique Farge(France) International guidelinesforantithromboticsincancerpatients Marc Carrier(Canada) Defining VTEinoncologytrials Marina Marchetti(Italy) Standardization oftissuefactorassays Agnes Lee(Canada) Session one:updateoncurrentprojectsandclinical trials (USA) Howard Liebman(USA),IngridPabinger(Austria),Wolfram Ruf(USA),MarcCarrier(Canada),JeffreyZwicker Chairpersons: Gualtiero Palareti(Italy) Proposal ofanSSCproject:internationalregisteronanticoagulatedpatients H H ealdPormeStra,30June 2012 Detailed Programme Saturday, e e m m o o s s t t a a s s guidelines oncancer-associated thrombosis i i s s Agnes Lee(Canada),MarinaMarchetti(Italy),Dominique Farge (France), Alok Khorana(USA),

a a n n d d

M M a a l l i i g g n n a a n n registries c c y y

12:30 -12:45 12:00 -12:15 12:55 -13:00 12:45 -12:55 12:15 -12:30 10:20 -10:40 10:00 -10:20 09:40 -10:00 09:20 -09:40 09:00 -09:20 1 1:45 -12:00 H H a a l l l l

2 2 N N 61

Saturday ISTH 2012 11.6.2012 14:48 Page 62

Detailed Programme Saturday, 30 June 2012

Tea / Coffee Break Exhibition hall, lower level Session two: new proposals and hypotheses Alok Khorana (USA) Prothrombotic state and metastasis in preclinical models Wolfram Ruf (USA) 11:00 - 11:20 The role of genetic polymorphisms in thrombosis and colorectal cancer Carla Vossen (The Netherlands) 11:20 - 11:40 Biomarkers in clinical practice Cihan Ay (Austria) 11:40 - 12:00 Competing risks in oncology trials Jeffrey Zwicker (USA) 12:00 - 12:20 Registry on incidental PE Marcello Dinisio (Italy) 12:20 - 12:40 New oral anticoagulants in CAT Agnes Lee (Canada) 12:40 - 13:00

Factor VIII and IX, part II Room 3

Chairpersons: Flora Peyvandi (Italy), Marilyn Manco-Johnson (USA), Raimondo De Cristofaro (United Kingdom), Donna DiMichele (USA), Anthony Hubbard (United Kingdom), Steven Pipe (USA), Carmen Escuriola (Germany) Clinical issues Marilyn Manco-Johnson (USA), Carmen Escuriola (Germany) The incidence of inhibitors in long terms experience in prophylaxis Erik Berntorp (Sweden) 09:00 - 09:10 Research of determinants of inhibitor development among previously untreated patients with haemophilia (RODIN study) Marijke van den Berg (The Netherlands) 09:10 - 09:20 Extending prophylaxis around the world - What doses can we start with? Alok Srivastava (India) 09:20 - 09:30 Immunotolerance induction using plasma derived products Carmen Escuriola (Germany) 09:30 - 09:40 ITI International study project Charles Hay (United Kingdom) 09:40 - 09:50 General discussion

62 ISTH 201211.6.201214:48Page63 reportonthecollaborativestudytocalibrateWHO2 A Elaine Gray(UnitedKingdom) Rupert Sandbrink(Bayer) to pharmacologicalevidence Evolution ofclinicaltrialsinhaemophilia:fromsimple replacement Stephanie Seremetis(NovoNordisk) of safetyandefficacy Development ofnewrFVIIIandrFIXmolecules:clinicallaboratoryevaluation Martin Lee(InspirationBiopharmaceuticals) with porcinefactorVIII Measuring clinicalefficacyandlaboratoryparametersinpatientstreated Donna DiMichele(USA),StevenPipe(USA) Critical issuesonevaluationofefficacytreatmentinhemophilia 4 Raimondo DeCristofaro(UnitedKingdom), Anthony Hubbard(UnitedKingdom) Standardisation issues Peter Turecek (Baxter) during clinicalstudies2012 andbeyond Novel assaysfornovelhemophilia therapies-practiceofclinicaltesting Brian Colvin(Pfizer) Pfizer Standardised specificassaysorgeneraltestsofhaemostatic potential? Behring) Debbie Bensen-Kennedy(CSL the rIX-FP Clinical researchchallengesindevelopingnovelcompounds totreathemophilia: Jurg Sommer(BiogenIdec) and globalhemostasisassays rFVIII-Fc andrFIX-Fcfusionproteinsthroughfieldstudies, exvivocoagulation Correlation ofpotencyassignmentandclinicalperformance of General discussion Sanj Raut(UnitedKingdom) FVIII Inhibitorsassay(SMIA):anewapproachinmeasurement Craig Thelwell (UnitedKingdom) for factorVIIconcentrate th T T ealdPormeStra,30June 2012 Detailed Programme Saturday, e e international standardforFIIandX,concentrate a a

/ / s viewonprecisescience orclinicalrelevance

C C o o f f f f and rVIII-SingleChainexperience e e e e

B B r r e e a a k k

nd international standard E E x x h h i i b b i i t t i i o o n n

h h a a l l l l , , 10:20 -10:30 10:10 -10:20 10:30 -10:40 12:00 -12:10 1 11:40 -11:50 11:10 -11:20 11:20 -1 11:00 -11:10 11:30 -11:40 l l o o 1:50 -12:00 w w e e r r

l l e e v v 1:30 e e 63 l l

Saturday ISTH 2012 11.6.2012 14:48 Page 64

Detailed Programme Saturday, 30 June 2012

A clinically validated technology for elongating the half life of coagulation factors, enabling a 1\ prolonged haemostatic activity in hemophilic animal models Gili Hart (Prolor Biotech) 12:10 - 12:20 General discussion

Platelet Immunology Room 12 Chairpersons: Yves Gruel (France), Andreas Greinacher (Germany), Hartmut Kroll (Germany), Yoshiaki Tomiyama (Japan), Donald Arnold (Canada), Beng Chong (Australia)

Drug-induced and autoimmune thrombocytopenia Donald Arnold (Canada), Beng Chong (Australia) Standardization of methods/ evaluation of drug-induced ITP testing Donald Arnold (Canada) 09:05 - 09:20 Animal model of drug-induced ITP Beng Chong (Australia) 09:20 - 09:35 In vivo animal model of drug-induced thrombocytopenia: the clinical relevance of anti-protamine sulfate antibodies Tamam Bakchoul (Germany) 09:35 - 09:50 Drug-induced antibody effects on Beng Chong (Australia) 09:50 - 10:05 Application of PLT antibody testing in ITP trials: the effect of rituximab on PLT antibodies in ITP Donald Arnold (Canada) 10:05 - 10:20

Alloimmune and isoimmune thrombocytopenia Yves Gruel (France) Usefulness and biological aspects of a national registry of donors for the treatment and prevention of alloimmune thrombocytopenia Françoise Boehlen (Switzerland) 10:20 - 10:35 Usefulness of surface plasmon resonance technology for monitoring pregnancies with expected NAIT Tamam Bakchoul (Germany) 10:35 - 10:50 Development of antibodies to ͰIIbͱ3 in a French cohort of Glanzmann thrombasthenia patients Mathieu Fiore (France) 10:50 - 11:00

64 ISTH 201211.6.201214:48Page65 Sanj Raut(UnitedKingdom) of the2 International collaborativestudy forthevalueassignment de Maat(TheNetherlands),JohnWeisel (USA) Final discussionandperspective Greifswald Group(Germany) of thesourcePF4 Difference betweenenzymeimmunoassaysinthehigh heparinstepareindependent François Mullier(Belgium) forrapiddiagnosisof type-IIHIT AcuStar HIT-IgG andHIMEA Yves Gruel(France) Prospective evaluationofalateralflowimmunoassay Lorenzo Alberia (Switzerland) a single-centerexperiencewith1,291patients Rapid exclusionorconfirmationofheparin-inducedthrombocytopenia: Christopher Ward (Australia) Functional assaysforHITin Australia: wheredotheyfitincurrentalgorithms? Greifswald Group Validation ofthemultiplateassayforHITdiagnosis Andreas Greinacher(Germany) Heparin-induced thrombocytopenia-diagnosisofHIT J Rollin Gene variationsandmodulationofFcRlla-dependentplateletactivation D Leroux(France), Y using SPR Binding studyofHITantibodiestoPF4modifiedbyenoxaparinoligosaccharides Andreas Greinacher(Germany) Heparin-induced thrombocytopenia-pathogenesisofHIT (Switzerland), HelenPhilippou(UnitedKingdom),V Chairpersons: T F T F ealdPormeStra,30June 2012 Detailed Programme Saturday, e e a a a a c c

t t / / o o

C C r r nd

o o X X International Standardforfibrinogen, concentrate-anupdate f f f f I I e e I I e e I I

a a Hans Kohler(Switzerland),SanjRaut(UnitedKingdom),Marguerite Neerman-Arbez B B n n r r e e d d a a

k k F F

ves Gruel(France) i i

b b r r i i n n o o g g e e n n

erena Schroeder(Switzerland), Aida Inbal(Israel),Moniek E E x x h h i i b b i i t t i i o o n n

h h a a l l l l , , 09:05 -09:25 12:20 -12:30 12:00 -12:10 12:30 -12:40 12:10 -12:20 11:50 - 12:00 1 1 11:20 -11:30 l l R R o o 1:40 -11:50 1:30 -11:40 w w o o e e o o r r m m

l l e e

4 4 v v e e A A 65 l l

Saturday ISTH 2012 11.6.2012 14:48 Page 66

Detailed Programme Saturday, 30 June 2012

Modeling fibrinogen deficiency in the zebrafish Marguerite Neerman-Arbez (Switzerland) 09:25 - 09:45 An international, collaborative study on the standardisation of the permeability measurement of fibrin clot structure: methodological considerations and implications for healthy control values Moniek de Maat (The Netherlands), John Weisel (USA), Marlien Pieters (South Africa), Anettas Undas (Poland), Rita Marchi (Venezuela), Colin Longstaff (United Kingdom), Robert A.S. Ariëns (United Kingdom) 09:45 - 10:05 Fibrinogen gamma measurements Moniek de Maat (The Netherlands) 10:05 - 10:25 In vivo measurement of FXIII activity and fibrin formation in real time Helen Philippou (United Kingdom) 10:25 - 10:45

Tea / Coffee Break Exhibition hall, lower level

Current practice in investigation of FXIII deficiency; data from UK NEQAS (blood coagulation) Ian Jennings, Isobel Walker, Timothy Woods, Steven Kitchen, Dianne Kitchen (United Kingdom) 11:00 - 11:20 First case of FXIII-A type II deficiency Vytautas Ivaskevicius (Germany) 11:20 - 11:40 Project on value assignment for FXIII B-subunit (total & free) to the WHO 1st IS Factor XIII plasma (2/206) Hans Kohler, Verena Schroeder (Switzerland), Sanj Raut (United Kingdom) 11:40 - 12:00 Factor XIII B: just a carrier of factor XIII A subunit or a plasma protein of its own right? Laszlo Muszbek (Hungary) 12:00 - 12:20 Japanese criterion 2012 for the diagnosis and treatment of acquired hemorrhaphilia XIII/13 Akitada Ichinose (Japan) 12:20 - 12:40 A novel point-of-care test for the detection of anti-factor XIII antibodies in patients with autoimmune hemorrhaphilia XIII/13, by using immunochromatography Yasuo Magari, Shoichi Kawato, Keiko Ninomiya, Masayoshi Souri, Akitada Ichinose (Japan) 12:40 13:00

SSC Business Meeting - Room 12 14:00 - 16:30

66 ISTH 2012 11.6.2012 14:48 Page 67 ISTH 2012 11.6.2012 14:48 Page 68

Hot Topics Schedule

Friday, 29 June 2012 HTB04 14:45-15:00 STRUCTURE OF FACTOR XI IN COMPLEX Hot Topics 14:00 - 17:00 WITH A HIGH MOLECULAR WEIGHT KININOGEN PEPTIDE

Basic Science Hall 2 L S. S. Wong* (United Kingdom) - G. Hall - H. Stennicke - J. Emsley Chairpersons: Michael Berndt (Ireland), Pieter Reitsma (The Netherlands) HTB05 15:00-15:15

HTB01 14:00 -14:15 INVOLVEMENT OF 2-ANTIPLASMIN IN DENDRITIC THE ITIM RECEPTOR G6B-B IS A CRITICAL GROWTH DURING MEMORY FORMATION REGULATOR OF ACTIVATION, E. Kawashita* (Japan) - Y. kanno - H. Asayama - K. Okada - PLATELET PRODUCTION AND FUNCTION S. Ueshima - H. Kaji - O. Matsuo - H. Matsuno A. Mazharian* (United Kingdom) - Y. J. Wang - J. Mori - S. Heising - B. G. Neel - S. P.Watson - Y. A. Senis HTB06 15:15-15:30 MODULATION OF TAFI-DEPENDENT REGULATION OF HTB02 14:15-14:30 FIBRINOLYSIS BY EXTRACELLULAR HISTONES PLATELET GENE THERAPY CORRECTS THE L. O. Mosnier* (USA) - D. Rozenshteyn HEMOPHILIC PHENOTYPE IN IMMUNOCOMPROMISED HEMOPHILIA A MICE TRANSPLANTED WITH HTB07 16:00-16:15 GENETICALLY MANIPULATED HUMAN CORD BLOOD STEM CELLS TISSUE FACTOR EXPRESSING NEUTROPHILS INITIATE COAGULATION ON INJURED VESSEL WALLS Q. Shi* (USA) - E. L. Kuether - J. A. Schroeder - S. A. Fahs - R. R. Montgomery R. Darbousset - G. Thomas - S. Mezouar - T. Renne - N. Mackman - F. Dignat-George - L. Panicot-Dubois — HTB03 14:30-14:45 C. Dubois* (France)

NUCLEAR FACTOR (NF)-”B IS A MAJOR REGULATOR HTB08 16:15-16:30 OF BLOOD INDUCED JOINT DAMAGE IN A MURINE MODEL OF HEMOPHILIA A EGFP-EGF1 PROTEIN CONJUGATED PEG-PLGA NANOPARTICLES FOR CEREBRAL THROMBI D. Sen* (India) - A. Chapla - N. Walter - V. Daniel - TARGETING DRUG DELIVERY S. Yesupatham - A. Srivastava - G. R. Jayandharan W. Shi* (China) - Y. Hu - H. Mei - J. Deng - B. Zhang - C. Chen - F. H. Wang - T. Guo

68 ISTH 201211.6.201214:48Page69 .H o .G ri .S Heyderman S. Craig -R. G. Toh -A. C.-H. Downey - Esmon-C. T. Faragher -C. Molyneux-B. E. M. D Wassmer - C. Moxon* (UnitedKingdom)-S. A. C. .Io Jpn .Nkhr .Maruyama Nakahara -I. Ito*(Japan) -M. T. F S C E L Hot Topics Schedule Hot Topics A O .Mle .V hsl .E alr-K .Seydel - B. Taylor -K. E. Chisala- T. V. Milner-N. A. . E X O HTB10 HTB09 C Q S T A T R S U G O

A E U O R C S L F S E T A

P L R T F L R I A O O U O T R N L I T O

A

D E A N R I I N C N

I H D

N C I

S I

C N R T E F E O R L C N A E E E M B P S R M T

A O A A R L R T

E I S M O

E A N L L I L

N T I A C O K R I

S T P I A I A 16:45-17:00 16:30-16:45 N

R G A

S I T E - R. Caughey Bauer- T. A. Liebman-K. A. Zwicker* (USA)-H. J. P Sautet- Roy -A. Riou -P.-M. Samama* (France) -B. M. C. C Bezemer - D. -I. DeHaan*(TheNetherlands) G. H. .Cmiot .Nueg-B Furie Neuberg -B. Campigotto-D. F. Buchbinder- Bullock -E. Lenz-A. J. Raghavan -H. V. C. Chairpersons: (Switzerland) .Y Vossen Y. C. B H F A I P B A O M P N MismettiandtheFONDACAST studygroup . O E R R .Dge .L ese-P .Risa-A .Arellano- R. Reitsma-A. H. LeCessie-P. Doggen -S. J. . F E HTC03 HTC02 HTC01 C E C F U

R .T H. C T A P N

I L E l l L M F A i i oosy-S ata-C .Kslr-J Eneman Kessler -J. — M. Mantha-C. Rosovsky -S. E A O R A V D T n n I N A R R R N I E W I A c c n .J eln-L .Br .R Rosendaal- R. Bare-F. A. Devlin -L. J. ong -J. P N D R S

N I a C a P - L A N G O Y T K l l A T E E

N :

M N I S S R T R V M

T O

S H E I I I E

H c c S I Z N N P N C E R i i N E E A O e e

U Anna Falanga (Italy), Henri Bounameaux Henri (Italy), Falanga Anna P R

O O O

T D I n n F L X

N O T F M I U c c - A O E J C E V

P e e S T B V N N U S A E O E

O E T T D R T R R N D N H S P A Y I S T N T , O

R R . C W I U N R G C B U O O A O S O I E

L S T M S P I

M E N N L H L

T H T B L S - O E P

H S Y O E E S

F R W ( U R L D L T S T I O A T E

R O U H

I M S P V / X V G R D M E H E O I A S Y I

I B C S S M A T L

O W E

K E A S I R C D E

C L E I O I T R

S M

U T I F H O K I I B L

S

14:00 -14:15 T

T A E O 14:30-14:45 14:15-14:30 P S R E R N R L U I C

O A I E W E S

H H L X S D

M E

F a a T A I O A C I l l U P G l l F C

T A D 2 2 H I T R Y O

T O 69 N N ) I N N R

Hot Topics ISTH 2012 11.6.2012 14:48 Page 70

Hot Topics Schedule

HTC04 14:45-15:00 HTC08 16:15-16:30

INDIRECT COMPARISON OF EFFICACY AND SAFETY NOVEL MHC PEPTIDE- T CELL RECEPTOR OF DABIGATRANS RE-LY, RIVAROXABANS ROCKET- INTERFACES ARE NECESSARY FOR INHIBITOR AF, AND APIXABANS ARISTOTLE TRIAL IN PATIENTS FORMATION IN MILD/MODERATE WITH NON-VALVULAR ATRIAL FIBRILLATION SECONDARY TO MIS-SENSE GENOTYPES J. Harenberg* (Germany) - S. Marx - H.-C. Diener - G. Lip - D. P. Hart* (United Kingdom) - S. Skelton - D. S. Moss - V. Marder - C. Weiss - M. Wehling K. Gomez - C. Sansom - A. Shepherd

HTC05 15:00-15:15 HTC09 16:30-16:45

AUTOANTIBODIES DIRECTED AGAINST DOMAIN I OF SPATIAL BLOOD COAGULATION IN THE PRESENCE OF BETA2-GLYCO-PROTEIN I INDICATE AN INCREASED ANTI-TFPI APTAMER BAX499 IN HEMOPHILIA A RISK FOR THROMBOEMBOLIC PATIENTS AFTER FVIII INFUSION EVENTS IN PATIENTS WITH ANTIPHOSPHOLIPID L. A. Parunov* (Russia) - N. P. Soshitova - O. A. Fadeeva - ANTIBODIES. A PROSPECTIVE COHORT STUDY A. N. Balandina - K. G. Kopylov - M. A. Kumskova — S. Zuily* (France) - B. De Laat - V. Regnault - F. Guillemin - K. E. McGinness - M. A. Panteleev - F. I. Ataullakhanov - P. Kaminsky - R. Albesa - G. Norman - P. G. De Groot — R. G. Schaub - J. C. Gilbert T. Lecompte - D. Wahl

HTC06 15:15-15:30 HTC10 16:45-17:00

WHOLE-EXOME SEQUENCING IDENTIFIES NOVEL RISK THE INCIDENCE OF FACTOR VIII INHIBITORS IN SEVERE HAEMOPHILIA A FOLLOWING A MAJOR VARIANTS FOR THROMBOTIC STORM PRODUCT SWITCH IN THE UK: APROSPECTIVE T. L. Ortel* (USA) - G. Beecham - D. Hedges - P.Whitehead CONTROLLED STUDY IN 1214 PREVIOUSLY TREATED - A. Beecham - S. E. Hahn - J. W. Lawson - D. Erkan — PATIENTS L. R. Brandao - A. H. James - M. J. Manco-Johnson - R. Kulkarni - C. S. Kitchens - M. A. Pericak-Vance - J. M. Vance C. R. M. Hay* (United Kingdom) - P. Collins - B. Palmer - R. Liesner - E. Chalmers - D. Hart - S. Rangarajan - HTC07 16:00-16:15 S. Ragarajan - K. Talks - M. Williams -

A NOVEL GENETIC VARIANT OF THE CYTOSOLIC PHOSPHOLIPASE A2 ALPHA ASSOCIATED WITH AND DUODENAL ULCERS IN AN ITALIAN FAMILY E. M. Faioni* (Italy) - C. Razzari - G. Podda - M. Trinchera - G. Fontana - M. Cattaneo

70 ISTH 201211.6.201214:48Page71 Chairperson: A A A A ePoster Session T T T T E A E A T T T T xhibition halllower level n n 0 0 0 0 2 4 1 3 t t i i t t h h r r J .J Sidelmann-J. Bladbjerg- J. J. Leppin-E.-M. Skov* -A. (Denmark) and M. Schmidt- Jamal -A. Turpie* (USA)- W. G. A. - E. Clark Garcia-N. Delate-D. Witt*(USA)- T. M. D. .Hrneg-E Ramacciotti-J. Harenberg-E. J. McGeehan- Walenga -E. M. Jeske* (USA)-J. W. T S R P S B R I O C B T X P E E D o o N . R H T Q N E U L L A H O I E E R m m T S A E E R R. E E M O R G S A U M A E K ye .Aeo-F etl .Crowther Dentali-M. Ageno-F. Hylek - W. B WARPED Consortium E E A R b b C P G R X Nigel Key (USA Key Nigel I I L O R P

V M I asn-L atvn .Ket .Haas Kreutz-S. Mantovani -R. Lassen -L. D D T O A I

E o o A L M E A R S A T R M E I I I P F I P R t t R N N E : A T U L V I i i N

E A E V Y A c c E T I Y

G C G E P N P S N A R U H

N

D O T

O N G H O t t

R T A I T R C A I

h N h D F O O A

S

F I O N O T F C E Y

e e

R

T N N T M X D H V T , M

N r r R H M I -

A E

R I A G M a a F I T A D B E N E Y R A B O O E A p p P M Gram O E S

T

C A

N H M M R y y D L M A S E E E I N O C I E I

) I T B I

C R M P A G F N R

L R H W O A

V J A F B A

O E A I

O K P T C E E C I A O S D N G T - I R R R N T

F O T A L V U H D I I

O T T C R I O N N I E O C

S N I C E K P A O O T R S N E R M

R N O H A L T I

S S N S T N ,

E H F G N Y W I .

H A R O T T areed E E L V P O L O A H E E N A

I O O E

N R R C P S E S X S N T I A T F U T S

I E T S O A E I U R T N I N

F D R O D U R A T I I N Y S E C N L I A A I N N L L T G A A A A A T T T T T T T T T T 0 0 0 0 0 9 8 7 6 5 V. Y. T - K. Agnelli Giustozzi-G. M. Donini- Natalini-A. Flamini-G. -O. Mariani E. A. Bose- Cheung-G. Duffett* (Canada) -A. D. L. J - Harrison Shaw -J. (New Zealand)-J. Harper* P. M. Vedovati* Rondelli- (Italy) -F. C. Becattini-M. C. .Chattree-B S. Jayakody Arachchillage* (UnitedKingdom)- D. A E M T I A E V T P ( U T O P O S P S O P O .Shmeleva* (RussianFederation) - V. S D Harrison . A H H H V R R R U U N N N E T V U N N A

V aetio .Mtino-L Papayan - Matvienko -L. Namestnikov -O. Soldatenk T Forster Wells -P. T A R E I ocman .Cmoee-R Balzarotti- Camporese-R. Boncompagni -G. E N O R O P O D T E T E T L N L T H I A L

I O P I R E O A C G X

P - I alks O C ) A S N W S E L U G ? O N

I

O M H E G G A O T E M A C A I R

A E N O T R R R Y M T E B F E

P A

A E T A E C S 2 G N A T E Y L E N O M E S G V I

L - K

O O A W A V I

W T Y O A

S L

F E P U

O P ov D X M

I N Y V Y E

A U O E T G O N I L F I F I V T

E

S A P

L S S W S A oisn-L iet-P Kesteven Rivett -P. Robinson-L. . A R O T R I I H

H T R N I L O R U P

T

S N

T F E O T

T A O

C S T A T

T O T I L

R D

H P A E O F - I S O F T A U O E O N O F T F E

E R R T P N

I

E R S L

W

E D E F E C A A R T E T O S I

F O

I T N - E R M T A H F

O H S R I

: M C F S A O I R M E T T O

S N E E E A M

I R A I B L L D S E C H P N I D U E T

N B M R O

A M I A

C

A E E N G N

R P V A I E P D C L U L A T C

N

T L R G E

E A E

P W U A E I N N T Y E

S T I E X E

R O N C L T E I

A F E Y

I S T P M O T U

O E

T I S O G T E C

17:00 -19:00 S Y E E Y S F K E E S T H K R E A I

N R

T O

N N P C I V I R

C M N N N T I U H T H I T N O E O T E G C I E F D E

N I A N A P S A N M E N E

Y P G R A C I M E L T R R C T A B

N M

E R R I W

I I . R O N O A N D

V A T E O I S I

N R N I H T C K C F I D H S 71 E Y E

ePosters ISTH 2012 11.6.2012 14:48 Page 72

ePoster Session Exhibition hall lower level 17:00 - 19:00

ATT10 PROPHYLAXIS OF POSTOPERATIVE VENOUS ATT16 EMERGENCY REVERSAL OF VITAMIN K THROMBOEMBOLISM: PURSUIT OF A ANTAGONISTS WITH PROTHROMBIN RATIONAL SYSTEMATIC APPROACH COMPLEX CONCENTRATE: THE EVERYDAY A. V. Vardanyan* (Russian Federation)- PRACTICE R. B. Mumladze - E. V. Roitman - D. D. Dolidze - P.Toth* (United Kingdom) - K. Robinson - L. I. Patrushev - M. Shieh S. Laidlaw - R. Maclean - J. van Veen - K. Hampton - M. Makris ATT11 SAFETY AND EFFICACY OF BRIDGING WITH LOW MOLECULAR WEIGHT : ATT17 BIOSIMILAR ENOXAPARINS AVAILABLE FOR A SYSTEMATIC REVIEW CLINICAL USE IN BRAZIL: STRUCTURE AND P. Eijgenraam* (The Netherlands) - H. ten Cate - HAEMOSTATIC EFFECTS A. ten Cate-Hoek B . F. Glauser* (Brazil) - B. C. Vairo - S. N. Oliveira - L. P. Cinelli - M. S. Pereira - P. S. Mour o ATT12 VARIANCE GROWTH RATE: A SUPERIOR METHOD TO MONITOR ORAL ATT18 DABIGATRAN EXPERIENCE IN NEW ANTICOAGULATION THERAPY ZEALAND A. V. Sharda* (USA) - G. Johnson - M. Kuskowski M. Stephens - D. Pollock - P. Harper* (New Zealand) ATT13 EUROPEAN ACTION ON ANTICOAGULATION (EAA) EVALUATION OF THE UK NATIONAL ATT19 ROLE OF SULFATED GALACTANS ON HEALTH SERVICE (NHS) IMPROVEMENT THROMBOSIS AND ANTITHROMBIN GUIDELINES FOR SAFETY INDICATORS IN INTERACTION ANTICOAGULATION OF ATRIAL FIBRILLATION S. N. M. De Oliveira* (Brazil) - R. C. Fonseca - (AF) P. D. S. Mourao L. Poller* (United Kingdom) - S. Ibrahim - T. Baglin - J. Jespersen ATT20 DEVELOPING AN IPHONE APP FOR THE MANAGEMENT OF THE ANTICOAGULANT ATT14 INFREQUENT REMOVAL OF RETRIEVABLE DABIGATRAN IVC FILTERS P. Harper* (New Zealand) L. Furmark* (USA) - J. El Amm - D. Mobarek - C. Faselis - F. Rickles - A. Aggarwal ATT21 THE ROLE OF LMWH IN PREVENTION OF DEEP VEINS THROMBOSIS AND PULMONARY ATT15 PREDICTION OF OPTIMAL WARFARIN EMBOISM IN PATIENTS WITH SEVERE MAINTENANCE DOSE USING ADVANCED MULTIPLE TRAUMA ARTIFICIAL NEURAL NETWORKS D. Danchev* (Bulgaria) - N. Petrov - D. Zidarova M. Pugliano* (Italy) - E. Grossi - G. M. Podda - S. Gabba - G. Carpani - A. Verri - M. Buscema - E. M. Faioni - M. Cattaneo

72 ISTH 201211.6.201214:48Page73 Chairperson: C C C C C C ePoster Session C E C E F F F F F F B B B B B B xhibition halllower level o o S S S S S S a a 0 0 0 0 0 0 g g 5 3 7 6 2 1 u u l l a a .J. Phillips - K. G. -K. McCarty J. Baker* (USA)-O. M. S. .M. M. .Mullier F. Hematologische Laboratoria) Hematologische Laboratoria) group new anticoagulantsofthe VHL (Vereniging LeFlem Gerotziafas -L. G. S Stavelin - V. Kristoffersen* (Norway) -A. A.-H. J. .Oaoa UA .Neeves Onasoga*(USA)-K. A. .K. A. T M S C T T I T D R F C N P P S S B N F N t t H E E H I O R ans-G .Kristensen B. Vannes -G. . T U U I O O R E E A E A B i i O Hardij* (Belgium)-J F o o U C S R E R O I C Henry Spronk (The Netherlands) (The Spronk Henry V T N L E A A S R L T M n n T D H

L H O E F O G G - O C U S A I A Stroobants* (The Netherlands) andw Stroobants* (TheNetherlands) A

I I O N A Y Samama* (France) -C N L E Rees M N O , M M B E U U M T f f N

O a a

W C V I R O G N L A F B L L E Q M E A O c c E P L E O A A G C M E

U T T U E L t t O S A L M T T

o o D I E Y R E U S I T N E C U

C N F I I E r r

? E O R T

M O L

D

O s s M

F

D F T N

N I A C F

N N A A C

O F O S I S E T B B O N E S H

T T

A

R T C

, R A

D W S T R a a N I I O L E O A O M A

S A

U s s T C I

V

F S N Q L N R S N A A i i H B E E

E c c T E D U A

T A O N S

E I

U

-.Dg-B Chatelain- B. - Dogn .-M. S I F G

M I Y

N E S S

T U

O D N N A I F Q S A C

I I G I c c T T N E C O C O C D , T U L i i I O : N

O e e T R N V E A R R E A A

O S n n E R A Guinet- . E O N

A C S N R L I c c R S G L

N S

T H T A E F I e e

I

N U Y C

I I A I L B R N

F O M N G

O L O R O T I O I

N C C A V A U H W P A R F G H I N A I Y T E C D A

T I T O R

T N T E A I S O N E O O G L

R N I R I N N or I

Y Z O

E T king E S F H E C C C C C C F F F F F F B B B B B B S S S S S S 1 1 1 0 1 0 2 3 1 9 0 8 .Geiter-M. S. Mager- Kaufmann-J. Wagner* (Austria) - V. L. .Lindhoff-Last E. .V P. - Hoylaerts Vanassche* (Belgium) - M. T. Raut*(UnitedKingdom) S. (Ger Fuchs* Kroening-B. Solecka -M. Kannicht-B. C. - A. Gribkova* Spiridonova (RussianFederation) - V. I. S Mager- Kaufmann-J. Wagner* (Austria) - V. L. R T P T D S T S F I T V M T ( A F P T N V A W H H E E U R etr-M ete .Siegemund - Leitner-A. Geiter-M. . T I E E A M D I E T V W T A C C C R R R I N R B A A R erhamme I O O A P E obtno-E Sinauridze Gorbatenko -E. A P I F H H many) O O F C I M F S L O R R L

G : H ) A O O N N I T M M U E

T O A

T A A C Y P S I O R O R S T R A B B C O X

T O L T T N

M C 1 M C T E I I T R S A N A A O N N N 3 E E H L M A I A T B A ? M B O

T

C W S O I R I I N R N

A N E I H N N N E N E

Leitner L T O C

U C S N N

R

H H R S A I N - V ¤ T E . M C E

T O I I

P S E O - T Y B B A

D

T

M P

M A R E V O N A I

I U U T T T I A R N V A O N N

B N R I W R O I A L T

O D O I

T N A E N E D R H U E L I A

I N I L N U S

- - T I U U S A I C X M F D L

M T D S O A T : A M E F A H A A E -

P I I C R T T E P S B

O A

B N D A O I I T I E R L N

O R N N N I D I A A N I G R C A A E V

A

N G

A N F D P T T O T H A N I N

V R T A

E E L 17:00 -19:00

T O T F N I T T D Y I N A D N H L D R I

F E O

I A

A E T S I T

E

A A F

C S V I F S A A N T M N

A

N N H F A I D I S S C B A E H C A D

O T N I A S T R L R W I T

I

R O B Y Y O O

A I I O V E N N I ¤

Y V Z N F T V W C R E I O

W E T F R R W 73 F S

ePosters ISTH 2012 11.6.2012 14:48 Page 74

ePoster Session Exhibition hall lower level 17:00 - 19:00

CFBS14 ACUTE PHASE PROTEINS REDUCE HISTONE- CFBS19 IMPACT OF THROMBIN AND FXA INHIBITORS INDUCED PLATELET AGGREGATION AND (DAIGATRAN, APIXABAN, AND RIVAROXIBAN) COAGULATION ACTIVATION ON PT/APTT ASSAYS ON IL S. T. Abrams* (United Kingdom) - J. Manson - INSTRUMENT/REAGENT SYSTEMS T. Liu - F. Baluwa - V. Barrera - K. Brohi - J. Hammelburger* (USA) - R. Bottenus - J. Thachil - G. Wang - C. H. Toh M. Triscott

CFBS15 CTP - A CLINICALLY VALIDATED CFBS20 STRUCTURE OF THE FXII PROTEASE DOMAIN TECHNOLOGY FOR ELONGATING THE HALF J . Emsley* (United Kingdom) - M. Pathak LIFE OF COAGULATION FACTORS, ENABLING A PROLONGED HAEMOSTATIC ACTIVITY IN CFBS21 INFLUENCE OF VKA, UFH OR LMWH HEMOPHILIC ANIMAL MODEL TREATED PLASMA IN RIVAROXABAN G. Hart* (Israel) - M. Zakar - P. E. Monahan - MEASUREMENT WITH DIFFERENT METHODS A. Bar-Ilian - O. Hershkovitz - E. Fima BASED ON FX OR FXA ACTIVITY M. M. Samama* (France) - C. Guinet - CFBS16 INFLUENCE OF CRYSTALLOID DILUENTS L. Le Flem - J. Amiral CONCENTRATION ON THROMBIN GENERATION: COMPARISON OF NACL AND CFBS22 PHARMACODYNAMIC OF BOVINE AND MANNITOL PORCINE HEPARINS G. O. Ogweno* (Kenya) - N. K. Gikonyo - L. A. C. T. Teixeira* (Brazil) - P. A. D. S. Moura~o - W. Mwanda - F. Bukachi - T. Peters A. M. F.Tovar - J. R. Lugon - S. M. Rembold

CFBS17 SPATIAL FIBRIN CLOT FORMATION IN CFBS23 SEMULOPARIN AND IT’S COMPONENT PLASMA INDUCED BY SURFACE- OLIGOSACCHARIDES RELEASE IMMOBILIZED TISSUE FACTOR: ASSAY ENDOGENOUS TFPI IN A MOLECULAR DEVELOPMENT AND STANDARDIZATION WEIGHT DEPENDENT FASHION. N. Korotina* (Russian Federation) - O. Khrapkova PHARMACODYNAMIC IMPLICATIONS - T. Vuimo - A. Balandina - E. Lipets - S. Karamzin J. Fareed* (USA) - H. Khan - E. Litinas - - O. Fadeeva - I. Spiridonov - M. Panteleev - J. Cunanan - D. Hoppensteadt - C. Viskov F. Attaulakhanov CFBS24 DIFFERENTIATION OF NEWER ORAL ANTI-XA CFBS18 INTERIM RESULTS FROM A GERMAN AND ANTI-IIA AGENTS WITH A REFERENCE PROSPECTIVE POST-MARKETING TO THE REGULATORY FUNCTIONS OF SURVEILLANCE OF TREATMENT OF VON THROMBIN WILLEBRANDS DISEASE WITH A NEW J. M. Walenga* (USA) - J. Fareed - GENERATION VWF/FVIII CONCENTRATE D. Hoppensteadt - W. Jeske - O. Iqbal - A. Gray - I. Scharrer - M. v. Depka - S. Alesci - J. Feddern - B. Lewis O. Hegener* (Switzerland) - J. Kadar - W. Miesbach

74 ISTH 201211.6.201214:48Page75 C C C C C ePoster Session E E F F F F F B B B B B xhibition halllower level S S S S S 2 2 2 2 2 6 8 7 9 5 .Kluko A. K B. .Bclr Sizrad .Laguna Bichler*(Switzerland)-P. J. Sommer J. .Glhai-M Yavarian -M. Galehdari H. P - Cortez Fonseca* (Brazil) -R. C. J. R. B Zhang- Liu-X. Li- T. (USA)-X. Driessler* F. .azm E. Elsadeik- Ghoneim-A. R. Azzam*(Egypt)-H. H. T S U B U Q I D G T O D T T F A P E C N .D .Moura S. D. A. . H H H U T R R V ag-H in .Lk-G .Pierce- F. Luk-G. Jiang-A. Yang -H. . L A N O N I N U C E C S A E A R E E C I O B T N E T T M E A E I eikhaei* (IslamicRepublic ofIran) -M. N E L D

I A O R I O X D S E C D T P A L G U D D E N E P T M T S U A

H S O I .hassan-S y -M. A A R I A N I I A L A Y R N C R sa-V ork .J Komrska -M. wska - V. B E C O N T T R E A T C T L I G T O

O

R I D N S T C E E I D D O A E S N

M E A Y E N O D

T D T E I

N

S E Z I L N P N I A

B E N

N I F T N

H P A D S A E

O S I D O E

~ H E R A

T T O O O S

A E F C

o M T 3 R T T I R E C T W F R O

D

I T I E M O E R

C I E O H

E D N A N

T S S X N M A E M

U N O M E H S

A

I T S O O I C L C L T L B N E R N

E C M O A T O A S O F R M I T D elsharawy .

S T N I V

A T

W E U

R - M R P R W D R

I N O

E V N I N T I H H Y R N

B M O O N A I I I N T H T T N

T A

E I T I T H ( - W I N

T

I R H 1 W C G H A D O W E I I A I

O O B

O T O I N V I I S F I H B E C A N L ansen - I I N M T W

A

O T I A S

S T O P T L T A E G E O N D T E O E U

R O F L F M N R U

M B

R L E

I R A B

R C ¤ L F R W V

O C L O ) A A A L I A : E P T I O T I N F N T N N O E H E U H T

Nasiri - Nasiri D I D R I

C

S L W A I

I L A V N A N I Y T I L G

I D I H A

C C C C C C F F F F F F B B B B B B S S S S S S 3 3 3 3 3 3 5 4 3 1 0 2 .A. I. .N ies-A .Blnia-F .Ataullakhanov I. Balandina-F. N. Lipets-A. N. E. Besser Colah-M. S. Whitbread- Luddington-J. R. Gray - S. Monagle*(Australia) - Attard-P. Ignjatovic V. Cini -C. K. Bremme- Chaireti*(Sweden) -K. R. L. C M. N. Macdonald*(UnitedKingdom)- G. S. T C C I D D H D I C T C M T C T C P G D P N A H H H H Y . O H O L L O E H A E U U - F Jiang* (China)-X. .Gsaso .L Lindahl L. Gustafsson- T. M. T Bannister -E. T R O O R R S Jiang* (China)- E T T R R W I U I M T L L A D I Shcherbina* (RussianFeder E F

E O O O T T A E O D U R D E A

G E I

T C R T D N M M M I E B M S F F R I O

I N I T M O T T R N N R E O O F B B B O E P I

E S

E I

E G C N I O I I A R N N H S N O N N N U C

C P G E

N U D S M

O A A T O F

L H L T G I

D N

Y T E E M

N A M O P I G A T N

N E N I D

S O T M H R O F O H E A C E O T N I T A E F

I O O

E 3 E E N N N rmn .Jnis-F Falter - Jenkins-F. -D. Ortmann T L B E S E M R

S

S M N E C O

A E I R D

M R .Za .Ruan Zhao -C. Y. O G T I E T M

M R P C G E A O P A O E F O A N Wang B Y N S P C I Y T R M N

R T A I T F

T E N I T

O O I B S A S A O

I C

R C I I G B T Y T O N

C I N N N

N A A H R V R P P E D N

T

F A U A D E I A U U S

N U X

O R R S U R S A S S S O I R E O I F S R A I L

I I A I G N I N E D

ation) -

P U N I 17:00 -19:00 V B L W C N G

E G

Y T E O W L B Y G I N L

I

T V E N Y N S I C F E

N T H E S L

N

E

L T F H A

E L

A E W D A I 1 E S V B P ? I F O

R E R

I / F N C E L I E N

L C T C 75 T O T

ePosters ISTH 2012 11.6.2012 14:48 Page 76

ePoster Session Exhibition hall lower level 17:00 - 19:00

CFBS36 ITI WITH A VWF-STABILISED FVIII CONCEN- CFBS42 DO HAEMOSTATIC PARAMETERS VARY TRATE IN HAEMOPHILIA A PATIENTS WITH DURING THE COURSE OF THE MENSTRUAL INHIBITORS AND A POOR PROGNOSIS FOR CYCLE? ITI SUCCESS: PROGRESS REPORT ON OCTA- R. Chaireti* (Sweden) - K. Bremme - NATE IN THE OBSERVATIONAL OBSITI STUDY K. M. Gustafsson - T. L. Lindahl N. Zozulya - O. Plysch - V. Vdovin - T. Andreeva - P. Svirin - T. Severova - E. Shiller - N. Klimova - CFBS43 HOW DO FEMALE HORMONE LEVELS M. Benedik-Dolnicar - F.Velasco - M. Campos - AFFECT THE HAEMOSTASIS DURING THE J. Bichler* (Switzerland) - C. Escuriola - W. Kreuz COURSE OF THE MENSTRUAL CYCLE? R. Chaireti* (Sweden) - K. Bremme - CFBS37 EVALUATING THE PRECISION AND K. M. Gustafsson - T. L. Lindahl ACCURACY OF THE LABORATORY MEASUREMENT OF ANTI-PORCINE FACTOR CFBS44 COAGULATION AND FIBRINOLYTIC VIII ANTIBODIES PARAMETERS IN NIGERIAN TYPE 2 M. L. Lee* (USA) - E. Gomperts - K. Biron - H. Levy DIABETICS WITH MICROVASCULAR COMPLICATIONS CFBS38 TISSUE FACTOR, A POTENT STIMULATOR OF O . Awodu* (Nigeria) - J. Obieche - M. Enosolease CULTURED ENDOTHELIAL CELLS - C. Omoti M. M. Meiring* (South Africa) - W. Allers - E. Le Roux - P. Badenhorst CFBS45 COAGULATION MARKERS AND REHEOLOGY PROFILES IN SOME NIGERIAN PREGNANT CFBS39 QUANTIFICATION OF MENORRHAGIA IN WOMEN WOMEN WITH VON WILLEBRANDS DISEASE R. A. Anyanwu* (Nigeria) - C. K. Lele - AND RARE BLEEDING DISORDERS A.-R. M. Momoh - E. Uko S. Halimeh* (Germany) - H. Rott - M. Siebert CFBS46 IMMUNE TOLERANCE THERAPY IN CHILDREN CFBS40 STUDY OF THE EFFICACY OF ROUTINE USE WITH FVIII INHIBITORS: PROGRESS REPORT OF RECTAL MISOPROSTOL IN THE V. Vdovin - P. Svirin - E. Shiller - T. Andreeva - PREVENTION OF POST-PARTUM N. Klimova - N. Osmulskaya - A. Momot - HAEMORRHAGE IN RURAL NIGERIA A. Mamaev - I. Blazhievich - Y. Smirnova - M. A.-R. Momoh* (Nigeria) J. Bichler* (Switzerland) - L. Okladnikova

CFBS41 FREQUENCY OF FACTOR XIII DEFICIENCY AMONGST PATIENTS WITH RARE BLEEDING DISORDERS IN PAKISTAN: A MULTICENTER EXPERIENCE A. Naz* (Pakistan) - T. S. Shamsi - H. patel - K. Shaikh - M. Nadeem - M. Borhany - N. Ahmed - A. Imran - S. Amanat

76 ISTH 201211.6.201214:48Page77 Chairperson: F F F F F F ePoster Session V V V V V F E F E B B B B B xhibition halllower level i i b b 0 0 0 0 0 r r 5 3 2 4 1 i i n n o o l l P. Hill- Seth-M. Pike* (UnitedKingdom)-R. G. ok*(aaa .S laan .Othman -M. Elbatarny S. oukh* (Canada)-H. Nash M. Matsuno H. - B Fareed Cunanan-J. Hoppensteadt*(USA)-J. D. .Dn*(hn)-H e .Si-Y Hu Shi- Y. Mei- W. Deng*(China)-H. J. K. Kokado - Kawashita -A. Kanno*(Japan) -E. Y. M. N W T D T T B T R D A A A O N P S E M E y y H H I H Y F F C C L O R L E E E A N s s E S I Bolton-Maggs - A. Cumming - J. Burthem - Burthem Cumming-J. Bolton-Maggs -A. kd .Usia-H ai-O Matsuo- Kaji-O. Ueshima-H. Okada -S. T A P Lewis . F F T R R N E Fran M D V T T N i i O V

D S s s T H E E S H I I

O O T O E E U O M O I U V V H

A A

C C M H A a a L L M M H C A A P E N R N E T T T O

2 n n E oise Dignat-George (France) Dignat-George oise ç I T A T Y E F

B B T S O N E L I - P d d S P E I V O R P D I A I A O O O T D O M B C L I

M D E O T F N

S V V R I E N

E A R G F N O B B

I

E

- a a T T A L C L F D T S

I I D O E : A Y B O A N N I T s s A A I H M L A A P Y N B G

M R R F c c O E T S S E R R B N L S I R

U u u

I

G D O N G A T S T E N P A O O I F

I l l L G I

O O O E N C

D E R C a a S O N I B U F A B T A T G O G U G N r r M O O

Y

L G N V R F

T I Y L

T R L R E V T B B M I H T I M I R I N Y I T B T H E N A N A A N

i i B

A U S I R

o o E R A R T I P O P

C R

N I A N I T M l l F O T N O O O H H S

o o G E

C A R F

G A C R

E S

Y Y A M g g G E S T I T E E N L N

D - I

N y y I T N B A I S U C I C S / O V T H N I I D U N O E

A L O P T P A

N B

I T

D T A M B D A

L L O T N R Y

O I E Y Y T I A S

O

I N J I T T

P A F E D V S

P S 2 U R U O H S A

A S I

G U A S G T S A E R R

R T E F N I I

A O

E T N O H ( 2 D T T O N M G A X E E A

T A B I D F B I I N A ) N F F F F F V V V V V B B B B B 1 0 0 0 0 0 9 8 7 6 Nwl*(ntdKndm .F Standeven F. Newell* (UnitedKingdom)-K. Jackson L. Pease -C. J. Grant -R. J. - P. Maruyama Shimizu-I. - T. Henskens C. Cate, ten- M. Y. Lance-H. D. Spronk-M. H. M. Kuiper* - (TheNetherlands) H. M. J. A. - Kleinegris . F. Oerle,van -M.-C. R. .Miur N. Shrestha- Ito-B. Hashiguchi*(Japan) - T. T. A. Golovina - Silina*(RussianFederation) -O. N. G. R. Bowling - Glover -R. (USA)-S. Gabriel* A. D. L. O R R G B A T M L L A E L D P X H B I M S D Y Y I E N T

P R I L O - Y E R U I V A I M C E D M. C M M ioav .Papayan Nikolaeva -L. .Stravitz T. A R O J C P D E P L L O T E I N E R I O N - U P P A R E H O G O M O C R W D L T O T D T H H C S O N O T N D -

E L E I T E a - T

F I P F I

A T H A I A O - A

F R M P N F H A C N A D I C U N C N C I E N O N

E O E

I E A R A E L L R F L G H L D A C N S R aaao-K Takenouchi Oyama - Nagasato-K. Y. .

D D E L O N R T A U O E I T I

Y H D

A

O V

E I O H T C C I T R A T

I C F V

O I L E E S T G R Y T E H N P N

E L E

A N N I

L O V P

A R E

N E

D D O O A , C ( T

E E R N N S O A G O

F

F F U C V N R R F

E S

L A M F

T

A A T F L U I P B F O I S G C

O B /

B A E I P S A I L P L L I N T T L B R

S O A C

C E A O L C R E L U O I R

I T C T T E F U

N I A O O M O T E R V I I O E ) A L N E L N O A D M M

X

E A L R D L A X N O D M L P

R O P E

S V R

E Y I T V

L A I X I L

T T H T

E N V Y S S A

I A N I I E N E O I I S C I S A

I L 17:00 -19:00 G I C C S S A N J S - S M I I S A A S U T T D H I E

D O E T I E E

I

N R

A I O V R I L F N

N T O T

Y 2 I O I T N R

T

S I

N T / I O H A A R N O Y Y K H S N N C E

R

T E

A F D

L A U M H O N O I N T A E E A F D R E D 77 L

L

ePosters ISTH 2012 11.6.2012 14:48 Page 78

ePoster Session Exhibition hall lower level 17:00 - 19:00

FVB11 ACTIVATED PROTEIN C (APC) AND FVB17 THROMBIN GENERATION ON ENDOTHELIAL THROMBIN MODULATE CARDIOMYOCYTES CELLS IS INITIATED BY BOTH INTRINSIC AND CONTRACTILITY VIA A PROTEASE EXTRINSIC ACTIVATION AND SHOULD BE ACTIVATED RECEPTOR -1 (PAR1)- CARDIAC CARRIED OUT IN LOW SERUM CONDITIONS TROPONIN I (CTI) PATHWAY I. Geenen* (The Netherlands) - M. Post - D. Molin Y. Alhamdi* (United Kingdom) - G. Wang - - R. van Oerle - H. Ten Cate - H. Spronk C.-H. Toh FVB18 THE RESEARCH OF INTER-RELATIONSHIP FVB12 NITRIC OXIDE FROM ENOS REDUCES BETWEEN ADAMTS13 AND HUMAN ABDOMINAL AORTIC ANEURYSMS MICROVASCULAR ENDOTHELIAL CELLS DEVELOPMENT IN A MOUSE MODEL WITH A. Wang* (China) - Z. Yu - Z. Ma - K. Ding - HUMAN-LIKE HYPERCHOLESTEROLEMIA X. Liu - J. Wu - Z. Sun - C. Ruan S. Momi* (Italy) - P. Gresele FVB19 ANALYSIS OF SYNTHETIC AND BIOLOGICAL FVB13 CILOSTAZOL IMPROVES AN ACCUMULATION MICROPARTICLES ON SEVERAL FLOW OF Aµ BY LRP-1 EXPRESSION ON CYTOMETRIC PLATFORMS ENDOTHELIAL CELLS M. Mooberry* (USA) - N. Fisher - M. S. Carraway - H. Yasui* (Japan) - Y. Kanno - E. Kawashita - C. B. Smith - R. Kasthuri - B. Udis - R. Zucker - H. Nakagawa - M. Yamanaka - H. Matsuno N. Key

FVB14 PROCOAGULANT PHOSPHOLIPIDS ACTIVITY FVB20 STANDARDIZATION OF FLOW CYTOMETRY- IN CEREBROSPINAL FLUID FROM PATIENTS BASED MICROPARTICLE ANALYSIS FOR WITH INTRACEREBRAL HAEMORRHAGE CYTOMETERS USING SIDE SCATTER FOR P.Van Dreden* (France) - B. Woodhams - SIZE MEASUREMENTS A. Rousseau - G. Hue - A. Lavoinne - M. Vasse P. Poncelet* (France) - S. Robert - A.-M. Faussat - C. Gameiro - F. Mullier FVB15 CLEAVED HIGH MOLECULAR WEIGHT KININOGEN STIMULATES JNK/FOXO/MNSOD FVB21 THE ANGIOGENESIS AND ANTI-FIBROSIS PATHWAY FOR INDUCTION OF ENDOTHELIAL EFFECTS OF HUMAN ADIPOSE-DERIVED PROGENITOR CELL SENESCENCE STEM CELLS OVEREXPRESSING HUMAN X. Zhu* (China) - M. C. Yoder - R. W. Colman - HGF ON ACUTE Y. Wu X. Zhu* (China) - J. Wu - Z. Sun - X. Cai - W. Zhu - X. Liu FVB16 IS A PREDICTOR OF NEW-ONSET DIABETES IN HYPERTENSIVE AND CORONARY HEART DISEASE PATIENTS? G.-P. G.-P. Jong - T. Ma* (Taiwan) - L. Tien

78 ISTH 201211.6.201214:48Page79 Chairperson: H H H H H ePoster Session H E D D D D D H E C C C C C xhibition halllower level a a 0 0 0 0 0 e e 2 5 4 3 1 m m o o r r S h*(S)-W y-M .Johansen - E. L. Jy-M. Ahn*(USA)- L. W. S. Watson P. S. Artoni Maino-A. Tuana -A. Lotta* (Italy)-G. Peyvandi Lecchi-F. - A. L. - G. Chan V. Lordkipanidze* (UnitedKingdom)-M. M. .Yu Cia .Wang You* (China)-X. G. B Foley - Okaisabor*(UnitedKingdom)-J. O. O. Y O H D F H H P B S P U D L A C O A O O F r r . A A I oesn-C Rea Sorenson-C. . E L

G L L h h I E E E S E E L F N F P G M S A. C C E A Q A O

a a M E R Mike Makris (United Kingdom) (United Makris Mike A T

G T E H F 9 U I T T E T T .Lw .B aod-T .Warner - D. Dawood - T. B. Lowe -B. C. E g g

D T I U I L Horstman -C - O A R 9 O T V M N S O O E E D C

i i D - A E C E S S c c E F T T I L L T U R R I T

V R N N T G

T T A D

O E H E R L D D I

N E A O C G R O G X ? G O T T

E -

A M E R T A H i i

I U R

I

N

M E M s s A N N I R D F S X I S S I I E C C

o o

C

1 G S U E ? O E E T Y O A I A S A

T

N r r R

- M T S P N

F D N P N d d L F A A D G F U

R O E R U

C I Y O D H H

e e D N O

E H S R A Y C C P L O .Bidot J. . T

r r A R I

M D R N S E C T ( L E s s T ) A O T I 9 P E

O

O W I I

A E M Q

W S R D S A O 6 G M A E M ( ( M I R N

U O - C C

O

T I N I N N I R E P W S A O T N A E : I I S -

l l N

A D T R C C H

S i i S T A

P S A E P n n T S I R E

E L I R

T U E

G H

P A L A O G i i W U P

E I A c c D E S B L D S I T T E G N I O L P S a a G I

L P

S I I O I R T A R P I E O C E

S

l l L O A A E D T ) ) ( H N M N L N E D R C

F R

N T

I A N A

A

D T G F T

E

- O D M O

C R G S I T A

S U ?

N A O - E V I P F E Y T E E :

T N T B S C E E M F A

)

D N U T I H : B I T E R F O

N E L H

T A D P A E E F C C Y I N T D

E Y T S R B R T E E T

R A I Y

S O W I C N I S L Y L T R

A M L

T I E

E O D Y T F

I E D O

S Y O F I N N E N R H H H H H H D D D D D D C C C C C C 1 1 0 0 0 0 1 0 9 8 7 6 y .M ioi-F Peyvandi Siboni-F. M. Oya -S. Baronciani- Canciani-L. G. T. Stufano* (Italy)-M. Montgomery R. R. F Cairo- Shamsi-A. Borhany* (Pakistan) - T. M. J Abdelw M. Ribeiro -L. Martins N. Salvado - Oliveira -R. C. -A. Martinho P. T - Saturnino Silva Pinto*(Portugal) -H. C. C Schroeder- A. Kuether -J. L. Shi*(USA)-E. Q. F N. Heath- Daniels*(UnitedKingdom)-A. S. A V V D M G D A ( P S G F G V I F I F N N V Peyvandi . . ogl-O Shaker Koegel -O. . . Fidalgo - D. Marques - E. Gonalves - Gonalves Marques-E. Fidalgo-D. . A O O O V V W F N U .Pry-S .Fh .C Gill- C. Fahs -J. A. Perry -S. L. . E E R E E U

W H T V culn-S Raut McMullan -S. I oz .L ac .T alai-I Garcia Pagliari -I. T. La Marca-M. Cozzi -S. I I N N R F B V T N N O T I B I F I I I I I F I B I T A E E

O T : E

R U C G T W W F C E P Y I T N L R T T H T I I P R E X

P E N I I I O P T O I Y A O L L O E

O C N E ) N O O E S P L L P

S

R N T R

M

A ahab* (Egypt)-M. A C S

E E F G M ( E A S W O

S V T N S

Y B

B B - N A E E O I M

P S W I N D S V

E R C R Y T N A N I F H

I N O E H

T H F

A A A L A L E I T

D E N S

H C N I Y D : U N

N P M

B A P C I N O S

S E O

S

S D A V D I W G H R I O O T M I S C F A I N K I

S N ) V A O O D I N F T

D

R E

G L I

A R O G E A S T O Y I R G A N L E S E N A M E

C T

P

E F E

P T S E N I T

T A C T N E

O B A A

N E T A I I I O N O T T

O T A L R N P I W V S C T R

I F A T R C

V A H C E E A O Neer I E

E E L

N T F E N I R Y P

L N R L

R S ( I A

A D

V E R V D I E T R

A N A C 17:00 -19:00 N A

W

O I F Y man-Arbez - F N E F A

F T T D A F P A A T D L F D O E I E

O E C A C I E P ) A R G V C

T P T N T R A C

E Y T V I O T O T

E O Q

P B

I I A I R R O N I D N E U T O I S

T E N N I

I X T A I R S N T I H N I A E S 79 I

Y A Y D

ePosters ISTH 2012 11.6.2012 14:48 Page 80

ePoster Session Exhibition hall lower level 17:00 - 19:00

HDC12 COMBINED APTT AND WAVEFORM ANALYSIS HDC17 MATERNAL HETERODISOMY/ISODISOMY OF INCREASES THE DIAGNOSTIC CAPABILITY CHROMOSOME 4 IN A CHILD WITH OF STANDARD APTT ASSAYS CONGENITAL AFIBRINOGENEMIA L. Leong* (USA) - P. Ramsey - L. Tang - D. Sim - CONTAINING A NOVEL TRP293X MUTATION IN J. E. Murphy - V. Laux - T. Myles FIBRINOGEN Bµ-CHAIN GENE Q. Ding* (China) - Q. Ouyang - X. Xi - X. Wang - HDC13 PRESENTATION AND MANAGEMENT OF H. Wang ACUTE CORONARY SYNDROMES (ACS) AMONG ADULT PERSONS WITH HEMOPHILIA Laboratory studies (PWH): INITIAL RESULTS OF AN Laboratory studies INTERNATIONAL, RETROSPECTIVE, Chairperson: Steve Kitchen (United Kingdom), Meyer-Michel TEN-YEAR SURVEY Samama (France) P. F. Fogarty* (USA) - M. E. Mancuso - R. S. Kasthuri and GEHEP, Global Emerging LSPE01 DIFFERENCES IN EXPOSURE OF THE Hemophilia Experts Panel DOMAIN I EPITOPE OF BETA2- I IN COMMERCIAL ELISA HDC14 FLUORESCENT QUANTITATION PCR METHOD KITS FOR THE DIAGNOSIS OF THE APPLIED TO DO CARRIER AND PRENATAL ANTIPHOSPHOLIPID SYNDROME DIAGNOSIS IN HAEMOPHILIA A AND B L. Pelkmans* (The Netherlands) - FAMILIES WITH LARGE H. Kelchtermans - M. Ninivaggi - T. Lindhout - P. G. de Groot - Y. Lu* (China) B. de Laat

HDC15 THROMBIN GENERATION, LSPE02 MEASUREMENT OF ANTI-ADAMTS13 THROMBODYNAMICS AND NEUTRALISING AUTOANTIBODIES: A IN THE PATIENTS COMPARISON BETWEEN CBA AND FRET WITH DIFFERENT BLEEDING PHENOTYPE OF ASSAYS SEVERE HEMOPHILIA A I. Mancini* (Italy) - C. Valsecchi - R. Palla - I. Tarandovskiy* (Russian Federation) - M. T. Bajetta - G. Casoli - L. A. Lotta - F. Peyvandi A. Balandina - M. Panteleev - M. Kumskova - K. Kopylov - F. Ataullahkanov LSPE03 MODELING PHYSIOLOGICAL AND CYTOKINE DATA TO PREDICT OUTCOME HDC16 GENETIC DEFECT OF F9 GENE AND H. Hardway - D. Stearns-Kurosawa* (USA) - POLYMORPHISMS IN IMMUNE RESPONSE S. Kurosawa GENES ASSOCIATED WITH HIGH TITER INHIBITOR DEVELOPMENT AND ANAPHYLAXIS IN ONE HEMOPHILIA B CASE J. Zhou* (China) - Q. Ding - Y. Lu - J. Dai - H. Wang - X. Wang

80 ISTH 201211.6.201214:48Page81 L L L L L S S S S S S ePoster Session E E P P P P P xhibition halllower level E E E E E 0 0 0 0 0 5 7 8 6 4 J Bailly- Douxfils*(Belgium)-N. Minet-J. V. .R oeda .C Cannegieter C. Rosendaal-S. R. F. M. - Negari Seyed-S. Mortaz Balooch-L. S. Mullier F. - Dogn Chatelain-J.-M. B. .Ahmadinejad Z. N. M. L. Lijfering - M. - Timp*(TheNetherlands) W. F. J. .Hrneg Gray .Mr .Kraemer Marx-R. -S. Harenberg*(Germany) J. .Kr R. Marx- Schulze -S. -A. Harenberg*(Germany) J. D A M A D T K P I P D T F P L P D P R -.Osle .Caean-I Elalamy - Chatelain-I. Osselaer-C. .-C. E A R H H R R

C N L L I E E I U U F A A .Fitra .van Hylckama Vlieg - -A. Flinterman E. T hazdh- .Frai-K Atarodi- Farhadi -K. E. Ahmadzadeh - V A A R O E Maghsudlu - Ahmadinejad* (IslamicRepublic ofIran) - E E U T T E L F G N S I E S S

E E V O D T E M S E E mer -C D E I N L M A M A R R I N T I

M R

P I C F R S O P A L A N M M T A A E L B U T A

E E S G R S

F , , E I I N O I I T L P N N N I V N

O

N S S S

T H I U S E L A A C E E C D E E O R

I N A I O T T L A N

E T S O R R W . I V S

V E C I I D R - P F T

O O U U A M I T O I C E G E

C E

D T L M M N I N eiss W B C F M T R C G - U Y U

R , , I

R I

O O G E N U F P

T E P A N. A A A

O A F F N S O E H R A

O L N N N O

C D T C T

-

Amirizadeh - Amirizadeh R I R D W D D R I D N A F I

T I E R E O A

I S

T

E G

E V H O U U

H E H N U B R N A F A R

I R R R E T E I T T R I G E

I G R

G F O A

I N I

P O

V N G R N G V O H O L A A T I F

E E N R E E R L A X

T R R

F F N

T R

G E E E L R A F S

I A I W N R O I Y D

B G

R B A D A T H C

- A U R

O O A N O E M I E T C I N P P S I N

S M M O N A L P I D I

N T

D L

A R E S L I I U S N A N E N T

E V C

T

R S D S 3 I I E I Y O

1 I A D : 8 N N

D L L L L L S S S S S P P P P P E E E E E 1 1 1 1 0 3 2 1 0 9 .J a edn-K .Moons G. van Delden-K. J. J. Dinkelaar - -J. yte* (TheNetherlands) Molenaar J. P. Joutsi-Korhonen L. Lassila- Pakkanen -R. Helin*(Finland)-A. T. Spronk M. tenCate-H. van -H. Oerle R. A. S - Kleinegris Loeffen* -M.-C. (TheNetherlands) R. R. Koek - L. -H. Schouten*(TheNetherlands) J. H. I. - Robert Gerotziafas* Galea-F. (France) - V. G. M B V A I F L P V C E C T A H D C R P C I U N N O A A O .Luee-P limn-D Fens - Pluijmen-D. Loubele-P. T. . R E E G P R L U E I I O O S A llm .Elalamy Elalamy -I. E

V R D Le V uea-G .Gesn .J Janssen - J. Geersing-K. J. Oudega -G. D L B W N T P P R O E T E L G T N N A E U I I - W A E O O L I F H

A C T D A R C F O R B C D C I R R U R O R U N I R E A E C E E O F R T A R E I L L O T D S A E A D D G N F A N

X B A D M Y

F I T

N L U

F

B S T - O O T T A I V

A A S A Y I O T G P U

R R N I

H E A M B N S C U E L T A H T R R A N E D A D R L A I

S I U T E I

I R T O O Y T I T T U C S

C

U O N M O E T R A Y O A R

E F N T E A T M C M S

R R A O U

B A A

M

S L I O T E A S Y O I O R

B T I P N N N

X W

B L V F M D S

O F O Y N N E I D

A I O A

S

A

O A O T E

M I P S A A A M A

C C T R C

N Y

I R N

I R A L N N P N A R O A U A S I Y

D

T

A

T O T R A

T H D G E R R

L P P T L

I E B O I T T N O O N R I X I I E R O E D A B Z N D L H I O D

I C S F

P O O B P E I V S E P G A

R T

T L P

L L O E T M A D T D V U A S D O

O

H U E E T H E A N F T R R

S

I A R A R E C S S O

M O

E I R I 17:00 -19:00 O E P A P F E A N C I I O T F B R N I T O L E X O T N

A I D H

M I O D E V

C T G E A N N R T B H N

C H I E R B V D T S B

A I E A I T O C A

L T E E O I Q

A G S E P H D N I F R O L D N T G U T S A N E - D

I O M Y D D U D

E R

R O - D I P S A D E A I M S N E T L E Y M I E - E E S 81

P : R D X :

ePosters ISTH 2012 11.6.2012 14:48 Page 82

ePoster Session Exhibition hall lower level 17:00 - 19:00

LSPE14 THE COST-EFFECTIVENESS OF "POINT OF LSPE20 EVALUATION OF PRO C GLOBAL ASSAY AS A CARE D-DIMER TESTS TO RULE OUT DEEP SCREENING TEST FOR THROMBOPHILIA IN IN PRIMARY CARE WOMEN WITH ADVERSE PREGNANCY J. Hendriksen* (The Netherlands) - G. J. Geersing OUTCOME - S. van Voorthuizen - A. ten Cate-Hoek - A. Naz* (Pakistan) - N. Hossain - T. S. Shamsi - M. Joore - K. Moons - E. Koffijberg N. Khan

LSPE15 FIBRIN-RELATED MARKER COMPARISON IN LSPE21 THROMBODYNAMICS ASSAY IN HEALTHY SEPSIS: CORRELATION TO GLOBAL AND AND DISEASED SUBJECTS MOLECULAR PARAMETERS OF A. N. Balandina* (Russian Federation) - HAEMOSTATIC DYSFUNCTION E. N. Lipets - N. P. Soshitova - J. M. H. Toh* (United Kingdom) - G. Ken-Dror - D. M. Polokhov - S. A. Vasilev - M. A. Panteleev - C. Downey F. I. Ataullakhanov

LSPE16 LARGE INTER-INDIVIDUAL VARIATION OF THE LSPE22 CHARACTERIZATION OF THE ROLE OF PHARMACODYNAMIC EFFECT OF CANCER CELLS IN THE PROMOTION OF ANTICOAGULANT DRUGS ON THROMBIN THROMBUS FORMATION UNDER SHEAR GENERATION S. M. Baker* (USA) - O. J. McCarty - S. Bloemen* (The Netherlands) - C. H. Hemker - M. A. Berny-Lang - G. W. Tormoen R. Al Dieri LSPE23 PROLONGED CLOT LYSIS TIME IS A RISK LSPE17 LABORATORY RECOMMENDATIONS FOR THE FACTOR FOR VENOUS THROMBOSIS MONITORING OF RIVAROXABAN A. Karasu* (The Netherlands) - A. van Hylckama J. Douxfils* (Belgium) - F. Mullier - C. Chatelain - Vlieg - R. Luddington - C. A. Baglin - S. Robert - B. Chatelain - J.-M. Dogn F. R. Rosendaal - T. P. Baglin

LSPE18 LABORATORY RECOMMENDATIONS FOR THE LSPE24 LYOPHILIZED NORMAL AND ABNORMAL MONITORING OF DABIGATRAN LUPUS CONTROL PLASMA CAN BE USED J. Douxfils* (Belgium) - F. Mullier - C. Chatelain - FOR ASSAY CONTROL IN DRVV AND APTT S. Robert - B. Chatelain - J.-M. Dogn BASED LUPUS ANTICOAGULANT TESTS L. Wagner* (Austria) - V. Kaufmann - J. Mager - LSPE19 COMPARISON OF PROTHROMBINASE-BASED S. Geiter - M. Leitner APC RESISTANCE ASSAY AND FV LEIDEN GENOTYPING I. Horvat* (Croatia) - D. Coen Herak - R. Zadro

82 ISTH 201211.6.201214:48Page83 L L L L S S S S ePoster Session E E P P P P xhibition halllower level E E E E 2 2 2 2 6 8 7 5 J Ibrahim - Poller* (United Kingdom)-S. L. A. Vignoli - Marchetti-A. Diani*(Italy)-M. E. L. Abdulkadyrov - Hait*(RussianFederation) -K. E. J. Ibrahim - Poller* (United Kingdom)-S. L. ( C T B M ( A U E T P M I M D S A F V D N P E Jespersen . R H I O U T Y N E N O N I E D O Y M Jespersen D T A A aaa .Golovina Papayan -O. Falanga

O E N

R N T D R F U A E ( T / L G A U E I M

I R S M O

I N . L H E N E C W

) C P V N M / . N I O A P C

R E U T I O T R I T T O N I L B N C P E M E L

U ) I R H I A O O P V S

T . O G T L T R A L 2 L O A E G A T I E E C ) E I N I 3 T

N A A

O

N P / L N R U D W F A A 1 B I Y

C R

T N O E E N G A O

N L

F L R

P O T B

H I R

A C A A W C

T A I R N - A A

I R O R E

T T T

N N E A T T

A D T N L E E H H R U L E G I I

I R R L O I I

I E O O A D D E N A R R D G A S

E

I N X C T

N D N N

S E N E P

A O N H F W H

H

T

A E T T

Y P ( T A ( I T M O W A E I E I C I E

L R S

E I O D C

W C N D B N P H A

I I I R E F T P T N N ) V A A I D

I E A

N M T A I O H N

R

O A A R N R W

P ) O H

A N

A R E O T N G R A I C S C P N E N

T T I T

P D M S R T M O R E E O L B I I

H E C

O P (

E I R N O U N A A C

U M N O R R O R V N

E G L T

L Y F S C E S D T T E E A H I A R U C H

S A E I I I

( A G L M R E L A P O L L L ) E N L

D

T S O U O L E M I P A F L D

N I S

E N S L L S M M O N O W

H R I A O

N

D N F B E F O H T E A E R I

I

T F E I ) N ( T L E O W M E T D O I T O G N R A L W Y ) S L

L L L L S S S S P P P P E E E E 3 2 3 3 1 9 2 0 F. - M. V. Parovichnikova - N. Vasiliev -E. A. S. Urnova N. S. A. acheva* (RussianFederation)- E. Sinauridze- I. Mendeleeva -E. P. - L. Ataullakhanov I. Panteleev -F. A. M. I. N. E. A. Lerede- - Giaccherini T. Marchetti*(Italy)-C. M. M. .N. A. E. Gil- Rupa-Matysek*(Poland) -L. J. A P A G C P A T U P I T A A C W C N H H T S R U E L S N S L H O .Scebn .M oohv-A .Poletaev - V. Polokhov -A. M. Shcherbina-D. A. E I .Ataullakhanov I. H G. Wojtasin Maggioni -M. T R A O Gr S R E E T S I I N A A L M N I H T O Komarnicki E I R B T M A L R E L A E Savchenko - aadn .N ies-I .Gribkova - V. Lipets-I. N. Balandina -E. Tarandovskiy D. - Soshitova -I. P. Lipets -N. Balandina* (RussianF G A E

Y Y S I

A A M R M A A T L F F R

L T ) S P G D C O A

A N O F

U E Y F I I M Y T E T E I C N T R E R L T I F sa-K adl-A oik .Dytfeld Nowicki -D. Zajdel-A. -K. ska

I E B N E M E C T A N Y

( O

M F H O A D N R I R T L

U T E P N A A E G E A

T

I I

T L R V L N T

L O Z O F A T G

( T H A E L I O E A T F D F ) ) L O R ei .Falanga Cefis -A. I R

R A R

T G P N E T W F

M A N P R T E I O I L H C

T ) O A L I H Y

I R G I E T

M O ( Y B T S

N B L T E A E A H

A S Y

T N B M A L

H S E L A T N

O

O

W E O

B T O O E U Y M I N ( T F O C A S O H G

E A M F B A I O T

F C E N

T E R

L R J R H ederation) - O L A B S ) H T O

E O

Y A

F A R I

N C T O P I R N C A T A T N M P A O A

A R O O D I G T R S

H S A C T M I L T 17:00 -19:00 S U R N M P I U I I Y

I A N E S E P B B

A C Y

B L

L P

Z A

N O ( T R

E A I I C

A M O N T N I T A D A T D A T A I E

S M N T I E Y T

I L T O B E T

E H N D I N

O ) B N H F Y N

D E T A I N

I N

O T O S B M A S D R N D I 83 C S I P N S

,

ePosters ISTH 2012 11.6.2012 14:48 Page 84

ePoster Session Exhibition hall lower level 17:00 - 19:00

LSPE33 COMPARISON OF THE USE OF TFPI PBS02 RAPID RECRUITMENT AND BLOCKAGE AND PLASMA DILUTION TO MICROAGGREGATE FORMATION OF HUMAN INCREASE THE SENSITIVITY OF THROMBIN PLATELETS BY THE COLONIZING GENERATION ASSAY TO MEASURE THE BACTERIUM STREPTOCOCCUS ORALIS PROCOAGULANT ACTIVITY OF UNDER SHEAR RATES THAT MIMIC MICROVESICLES PHYSIOLOGICAL CONDITIONS D. Gheldof* (Belgium) and Mullier François, D. Tilley* (Ireland) - C. Douglas - S. W. Kerrigan Chatelain Bernard, Dogn Jean-Michel, Chatelain Christian PBS03 THREE DIMENSIONAL RECONSTRUCTION OF INTACT HUMAN INTEGRIN ALPHAIIBBETA3 IN LSPE34 LUPUS ANTICOAGULANT SCREEN AND A PHOSPHOLIPID BILAYER NANODISC CONFIRM REAGENTS UTILIZING THE FX W.-S. Choi* (USA) - W. J. Rice - B. S. Coller ACTIVATING VENOM FROM VIPERA LEBETINA PBS04 PLATELET FLOW-INDUCED PROTRUSION M. D. Goldford* (USA) (FLIPR) FORMATION IS A SHEAR AND CALPAIN INDUCED PROCESS LEADING TO LSPE35 CORRELATION OF PEAK THROMBIN RESULTS OBTAINED BY TGA MEASUREMENT PLATELET DISINTEGRATION AND THE ON CEVERON¤ ALPHA TGA USING FAST FORMATION OF PROCOAGULANT MICROPARTICLES SETTING AND STANDARD SETTING C. Tersteeg* (The Netherlands) - H. Heijnen - L. Wagner* (Austria) - V. Kaufmann - J. Mager - G. Unzeitig G. Pasterkamp - C. Floris - R. T. Urbanus - C. Maas - I. Hoefer - E. M. Mak-Nienhuis - LSPE36 IMPACT OF CYP3A4*1G POLYMORPHISM ON V. De Angelis - P. G. de Groot - M. Roest PLASMATIC CONCENTRATION PROFILE OF PBS05 SYNERGY OF PLATELET RECEPTORS IN RIVAROXABAN (XARELTO¤) ASSESSED BY THROMBUS FORMATION: A MICROARRAY COAGULATION ASSAYS APPROACH J. Douxfils* (Belgium) - F. Mullier - C. Chatelain - S. M. De Witt* (The Netherlands) and Moniek B. Chatelain - J.-M. Dogn M. Lamers, Frauke Swieringa, Roger Kruchten, Richard, W. Farndale, Kenneth J. Clemetson, Platelet basic science Judith M. E. M. Cosemans, Johan W. M. Heemskerk Chairperson: Yotis Senis (United Kingdom) PBS01 DISCOID PLATELET AGGREGATIONS PBS06 DEPLETION OF PLATELETS IN B16/F10 WITHOUT DISRUPTION MELANOMA TUMOR BEARING MICE VISUALIZED BY IN VIVO MOLECULAR PREVENTS MATURATION OF NEWLY IMAGING, AND CONTRIBUTION OF FORMED TUMOR BLOOD VESSELS INFLAMMATORY CYTOKINES J. Wu* (China) - R. Li - M. Ren - N. Chen - M. Luo S. Nishimura* (Japan) - M. Nagasaki

84 ISTH 201211.6.201214:48Page85 P P P P P P ePoster Session B B B B B B E E S S S S S S xhibition halllower level 0 0 1 1 1 0 9 8 2 1 0 7 - S. Hefelfinger Forest -K. Li-C. Ku* (USA)-M. N. D. .Gandhi P. Cheng Gardiner-J. E. E. .Lzrv .Chizhik Lazareva -S. I. S Kuharenko - -L. Drozd*(Belarus) L. R. Qiao- (Australia) Shen-J. - Arthur* Y. F. J. - E. Rachmilewitz Dana-E. Shai-M. Malyutin-E. Z. - P. Ongini Conti-E. Falcinelli - V. Momi*(Italy)-E. S. F I C N A I S M O M M A A M A A P A E I S N N O T yozkn-L ei .Medvedeva - Gelis-E. Syroezhkin-L. . H

F C X

L O I F I O O O O T N T P T F C i-Y hn-R .Andrews Lu- - Y. K. Chen-R. Ni - Y. H F A O A R T

N H R E R N D Gresele O L T E P unn .Mrie .Turturro - -N. Martinez -O. Gurnani R iah-D Varon* (Israel) Fibach -D. E T E C I

R F A A R V I H P K E W M L T E O C C R E I T M L I A E A E H L E R L T U

S

T O R E A O T

M C Y R N E O M M Y O I C L S R B S N E X

T T I M T T

- A S O M F C C A O

S F L G I I

I I C T O A D

R A - T R P E U O L E P F A

S O A L E B L N I E E Y T O

N M R C D O H

A R R

O S R S T

S R F C O E E C I N T E Y O C I P

T O L O N T L T O I T E B

A

N T O

H O U

S A R I E H M L L Y R R O O I

N I I F N D T E I A E A D

R V S

O N F N A

P H S T

D

R A N G

I B

F A - U T A C T L I E E P

A S C O C O P O R A S L A Y

S

R T T P E V N S H

R T N M T E P

E A C O O S I I E

E

U

T E N - I D T A C H O M T C D

I R R L I M T

N

I N - E A I A X N A

E E O Y A

H F A T I D D L R I

P T N T

D D O E - R I N O O

I O N A

E H A P A T E

R H

R C A C

N F E P H B T L L A C E N I C - T R D L A I : E R M

C V S E A M T L A T E O T O A E E U U R I T E O N E - - G M R T

S E S I L S S T U Z R E E B L E I T

O A S N Y

E O T R T T E N I T S E C S E I O

S I S I S N N T S

P P P P B B B B S S S S 1 1 1 1 6 4 5 3 .Falanga A. Rosti- Coffetti -A. DaPrada -N. Baldoli-L. - E. C. .Trai Iay .Mrhti-L Russo- Marchetti-L. Tartari* (Italy)-M. . A. Panteleev A. M. Alessi- Nurden-M.-C. T. Ataullakhanov -A. I. F. .Aln Iead .Moran Allen*(Ireland)-N. S. S Glenn- Dovlatova* (UnitedKingdom)-J. N. .Monteiro R. Francischetti - Calvo -I. (Brazil) -E. Mizurini* D. A. Topalov* Federation) (Russian - N. N. D M M A S F C C T A E A B U P A P B A W O etntl .Fox Heptinstall-S. . V H N T X

I R N E Y L O O P O U N N inl .Diani-C. Vignoli -E. .Ykmno-M aal .Loosveld - Canault-M. YakimenkoO. -M. J A U A P T T O T E O R T M N O L L D O T A I O A I D R

T

S E N L O

T P C I P V T E 3 G N I I E M P A C H A

P E R O Y L E

L P G O S H S B R U E R L S A E

P L N H B S I N

O L A T I L T

O

T G E P S T I Y M L I E T A R I N E R N

S B S R R N O O S I E O R L I N

Y T G

O T O C O A A I N O O

E

O S H E L S A

T M C T L

L

T P F D B Q A S O L

I N I I E L I B E

N C

L T D

E O T U ( P F E I A B I A C P N I

G A

T - G

O H I A D A I L C T T T L H

N I D

Y C O N I O

H G T O E I C A B

T

Z T ) A

S L N E A S - T A N Y

R E D I E A S P

Giaccher

S

O V L

I N A B R E T G I S S H S I I

N

T E Y T A

S A R M E G A A A E T Y W C

S I T Y P S R S A C E V -

T D I S

O 2

D R E G E O F F I I A Y E M V N F Y G E O L D R M

X 1 A n .V ini -C. V

17:00 -19:00 E V O L

A

R A I 2 F M T C T A N S O N W T E

O R I V L O E E

T O I L G ∞ O I A R O V R R

L D N O L Y N S M L E S I C

P N P T F P A A D E E I H erzeroli O E T A G - N

D ( I I A - L O N E N D A L I L N C

, I Y T B - D 85 H ) E

ePosters ISTH 2012 11.6.2012 14:48 Page 86

ePoster Session Exhibition hall lower level 17:00 - 19:00

PBS17 CHANGES IN PLATELET (PLT) AGGREGATION PC03 AND THE AND ACTIVATION STATUS DURING STORAGE GENETIC VARIABILITY OF THE IN PLATELET CONCENTRATES (PC) FOR GLYCOPROTEIN 6 GENE IN PATIENTS WITH TRANSFUSION USE VENOUS THROMBOSIS AND PULMONARY A. Vignoli* (Italy) - M. Marchetti - C. J. Tartari - EMBOLISM L. Russo - E. Diani - C. Giaccherini - C. Verzeroli - P. Kubisz* (Slovakia) - D. Kotulicoˇva’ - P. Chudy’ - L. Da Prada - S. Marziali - A. Falanga M. Sˇ kerenˇova’ - R. Pullmann, Sr. - J. Stasˇko

PBS18 EVALUATION OF BABOON PLATELET PC04 IDENTIFICATION OF 61 NOVEL MUTATIONS IN AGGREGATION IN A MULTIPLATE¤ THE ITGA2B AND ITGB3 GENES OF 90 PLATELET FUNCTION ANALYZER PATIENTS WITH GLANZMANN W. J. Janse Van Rensburg* (South Africa) - THROMBASTHENIA: AN ANALYSIS OF R. van Zyl - J. Roodt - S. Lamprecht STRUCTURE-FUNCTION RELATIONSHIPS X. Pillois* (France) - C. Vinciguerra - R. Heilig - Platelet clinical P. Nurden - M. Fiore - A. Nurden

Chairperson: Beng Chong (Australia) PC05 PLATELET SURFACE HIGH MOBILITY GROUP BOX PROTEIN-1 BINDS RECEPTOR FOR PC01 A MUTATION IN ANKRD18A, ANKYRIN ADVANCED GLYCATION ENDPRODUCTS IN REPEAT DOMAIN 18A, CAUSES A SEVERE PLASMA OR ON MONOCYTES IN SEPTIC FORM OF CONGENITAL PATIENTS THROMBOCYTOPENIA J. Thachil* (United Kingdom) - V. Barrera - G. C. Lowe* (United Kingdom) - J. Motwani - B. Djebabri - S. T. Abrams - G. Wang - C. H. Toh M. Williams - M. Simpson - S. P.Watson - N. V. Morgan PC06 A NOVEL MECHANISM OF P-SELECTIN INDEPENDENT MONOCYTE-PLATELET PC02 ACQUIRING AN INHERITED AGGREGATION IN CHILDREN THROMBOCYTOPENIA: CLONAL C. Yip - V. Ignjatovic - P. Monagle* (Australia) - CHROMOSOME ANOMALIES AFFECTING FLI1 C. Attard - M. D. Linden MIMIC INHERITED THROMBOCYTOPENIA OF THE PARIS-TROUSSEAU TYPE PC07 A NOVEL D235Y MUTATION IN THE GP1BA P. Noris* (Italy) - R. Valli - B. Pressato - A. Pecci - GENE ENHANCES PLATELET INTERACTION C. Marletta - R. Invernizzi - L. Mare - WITH VWF IN AN IRANIAN FAMILY WITH C. L. Balduini - F. Pasquali - E. Maserati PLATELET TYPE VON WILLEBRAND DISEASE S. Enayat* (Iran) - S. Ravanbod - M. Rassoulzadegan - M. Jazebi - S. Tarighat - F. Ala - J. Emsley - M. Othman

86 ISTH 201211.6.201214:48Page87 P P P P P P ePoster Session C C C C C C E E 1 1 1 1 0 0 xhibition halllower level 3 4 2 1 9 8 T S. Ramstrom-B. Desmonts -S. Basabe- Kenny -L. Lopez*(Ireland)-D. A. .Gatt A. Laspina- Lofaro -S. - Grima T. -C. Brincat P. Tripodi Mannucci -A. M. P. Suzuki Yoshioka Ikeda -A. Y. Sasaki-S. - Nakase* (Japan) -M. Wu Yang Cataland*(USA)-S. -H. R. .Wn*(hn)-G ag-L a .Ruan Cao-C. Wang -L. Wang* (China)-G. Z. L. - Primignani Chantarangkul* (Italy)-M. V. S T V H R G P G U A A D R C P N P W W T M . H H R R . E

R N E T O A I E E U L A I I N A em .Ceii-M oai-P Rebulla - Jovani -P. -M. Clerici Lemma -M. Debono* (Malta)-F. T T R S E I Q O O O L E W E T N I C L G O D H H A S

O I T M G U P I B R C E -

N T V E

P E R P P M P H A I C R O E A F Y R E O

S L L L E H P L T Y F I N E B T

L E R S A A S E O A

O E L Y L H S O T H

M T T

R E

T P A F A C T O L S R I R C E E E N D M H E T L

C O O T I T C A O M L Y L N

E N A

O E

T S G E P T A E C E M T O G T O L T N I S A I T G C T I T O L C O E E F B

C

S E T T I I

Q U S

S

P T

N L D N O M A A T I

R P C T E S A U

E E

A A I

N T B C L L E O L P R S A N I D T I N R S O

A R E D O Y A D O M O N L T

A I I T A F A N T E T

C I P E S oel .Buttigieg - Bonello -R. S R D K F M A C E O N O I S D

I M

E L D E

L T D P A W L T S A S R

P O N I T I E

E T E U O S G W G A F A E I E H T W S I T R T P 1 G U Y O : N E

N S I R H T

3 A

U oe-.Somers Jose -M. T C A

T S R N

A T I

S

O

P N A W H R R

Y A I N E H

N P

O R F M

M D

I A T A N I E L A A N C S O T O N E O

N

B

T W T S A M

( I H I T D R P E T N M I S O

S F B E M L A A I

T S

F T T C T E O Y V O N L T P E

U H I E T T I C C L T I D ) V A E S E R S R

I I Y O S A A N I Y O

U T L T

T N E R S O

D E S P P P P P C C C C C 1 1 1 1 1 1 7 9 6 8 5 .Ste J. Demkow - Hryniewiecki -M. Kunmierski - T. K. .ElKhair R. Ksie E. A. Czerwinska -Jelonkiewicz* (Poland) - K. Kovacs Stocheci-E. Popescu -C. M. .Sukor U. .F. M. Fogarty F. Knoche-P. (USA)-J. Giermasz* A. H. Vladareanu - M. Popov* (Romania)-A. M. V. D T R P T V E A F D R A P D H P T S A A O A H .mhmd-E .hsen-H .abdella A. husseen-H. A. mohamed-E. S. . V Y E R N R I D O I E E R S Witk V T C uba-M eu-A .Iv .Gaman- Iova -M. M. Begu-A. Bumbea -M. A R S V L E M E E L U M E A I I T E L F E A O O G , E M

L O Ghozlan* (Egypt)-A. A I P L pinska O U U R P T R T , N M P N I

A S R z wk .Dbosi-M Banaszewski - -M. Dbrowski owski -M. A I A L

L R N A E T ycka- Majczynska Chmielak- -Z. O E A D T B E R ini* (Indonesia)-S. I O T B

, C S V S R I N N E O

A H E I R S S I . T O E E A C N L S N C N A T E T E I T R V I N O H Y G D H G Y T T I V F I E

M

I V N S U Y

T E D I O R E P P R C

E O

E

I R A

F A I A L C S I

B N

T P R C

I B A S N I O E E T P N

Y E I T T L

M D S Y A T L R M F

N O E E A A K Y

W

S E R A I E L E R N T A

E E C E E E D N F D Y E

D L : T L ( T E F R U A I

L O I

N I A I T

I N I M G E E O E A. P C R D T G P Setya

T

A L E N M V A T I O Y )

O Saad - A

R M O O R

C D U S N D P T N A I E N Y

Y P N

A U I S P S O 17:00 -19:00 O M N

S L E T w R K W O L

V N A T F W E I ati -

A I E F E F N I T

U S T L T O I N A I R T G H E N L C E F T C H L R E I C L P S T O B S E T

O T A I R T O I O R D N A N S

N 87

I I D N N

ePosters ISTH 2012 11.6.2012 14:48 Page 88

ePoster Session Exhibition hall lower level 17:00 - 19:00

PC20 THROMBIN GENERATION TEST IN THE PE04 COMPLIANCE OF RECOMMENDATIONS WITH MONITORING OF ANTIPLATELET THERAPY FRENCH CLINICAL PRACTICE IN THE EFFECTIVENESS MANAGEMENT OF THROMBOEMBOLISM IN O. Smirnova* (Russian Federation) - PATIENTS WITH CANCER: THE CARMEN Y. Namestnikov - O. Matvienko - STUDY G. Berezovskaya - O. Golovina - M. Sevestre* (France) - D. Farge - P. Debourdeau L. Papayan and Groupe Francophone Thrombose et Cancer

PC21 THROMBOELASTOGRAPHIC TESTING TO PE05 D-DIMER AND ULTRASOUND IN DETERMINE INDIVIDUAL RESPONSE TO COMBINATION ITALIAN STUDY (DULCIS) TO ESTABLISH THE OPTIMAL DURATION OF B. J. Bryant* (USA) - J. Treat - F. Scalia - ANTICOAGULATION FOR VENOUS I. McQueen - P. Sharks THROMBOEMBOLISM: PRELIMINARY RESULTS PC22 EFFECT OF CYTOCHROME P450 B. Cosmi* (Italy) - C. Legnani - A. Ghiraduzzi - POLYMORPHISM ON PLATELET REACTIVITY S. Testa - P.Vittorio - E. Favaretto - G. Palareti AFTER TREATMENT WITH CLOPIDOGREL IN PATIENTS SCHEDULED FOR PERCUTANEOUS PE06 UNUSUAL THROMBOSES AND CORONARY INTERVENTION THROMBOPHILIA: A CASE-CONTROL STUDY A. A. Saad* (Egypt) - A. M. Abd Elsalam - J. Chapin* (USA) - P. Christos - M. T. DeSancho G. M. Kamal - N. F. Abou El-Ezz - R. S. El-Hagracy PE07 MICROPARTICAL-ASSOCIATED THROMBIN Thromboembolic Disorders GENERATION IN PATIENTS WITH POSTTHROMBOPHLEBITIC SYNDROME Chairperson: Paul Kyrle (Austria) O. Matvienko* (Russian Federation) - PE01 MARKERS OF COAGULATION AND Y. Namestnikov - O. Golovina - N. Saltykova INFLAMMATION IN RELATION TO THE POST THROMBOTIC SYNDROME PE09 ONE YEAR EVENT RATE OF SERIOUS A. Bouman* (The Netherlands) - J. Smits - THROMBOSIS AND BLEEDING IN JAPANESE H. ten Cate - A. ten Cate-Hoek PATIENTS WITH MYOCARDIAL INFARCTION, STROKE AND ATRIAL FIBRILLATION PE02 ALTERNATIVE DIAGNOSES OF PULMONARY E. Toda* (Japan) - S. Uchiyama - K. Shimada - EMBOLISM IN PRIMARY CARE H. Origasa - H. Kobayashi - A. Kawamura - P. M. Erkens* (The Netherlands) - W. Lucassen - T. Nagao - Y. Ikeda - S. Goto and the Japan M. V. Heugten - L. Rietjens - G.-J. Geersing - Thrombosis Registry for Atrial Fibrillation, M. Prins - H. T. Cate - J. Stoffers Coronary, or Cerebrovascular Events (J-TRACE)

88 ISTH 201211.6.201214:48Page89 P P P P ePoster Session E E E E E E 1 1 1 1 xhibition halllower level 2 1 0 3 D Khosla- Lester*(UnitedKingdom)-S. A. W. .leCessie-F. S. Hospitals Bir and OutcomesResearchUnit,University Societ ItalianadiMedicinaInter Mannucci andREPOSI(REgistroPOliterapie M. Corrao -P. -S. Salerno Marengoni-F. A. A. - (TheNetherlands) Kleinegris* M.-C. .E. R. M. - Iorio Violi-A. Marcucci*(Italy)-F. M. .C angee .M Lijfering M. W. Cannegieter- C. S. O W D A V P R V S P T T C W R T C H H H R a .Rcado .Pagano andQuality Richardson-D. Ray -M. . E E A D Y E A I O E U A E S e aeHe H tenCate H. ten Cate-Hoek- Y etmni-L aia-A oii-C .Djade- D. Nobili-C. Pasina -A. Tettamanti -L. R R E N N S R O M R A T F R

K L S

T O O O O D I C F D P V I D

P Roach* (TheNether E T T

E O E M U A U U M H O I O S H T O A M E F L S S G Y M I B

F E E R V S

U

A

L

H V O C D T T E R A N H S T E A E H H

T O O S

S A I

O H I T

X O F C N mingham I R R O

C L N O C E A S I R N

O S

O O F U S R

M

T P A O E I

U

R. M M U T

L E A I I R D O A V T N M A S A M V N B B T - A S

E Rosendaal -

L D R

N I T O O E E D P M L E T N I I

H A A L R

T

A E E M W A T E A D T D R N I T I M M S N O A E A D E

I E I O

O

C B B D I S R N L M A I N lands) - B. Siegerink - Siegerink lands) -B. R M N N

O

O U

T

F D I T A L A A

S B H A R L L P A Y E I R S N S O S I I L

A I

C S R S R

N P T D

I E T A S T L O M M N A E A G

I A

I na) Investigators O E A E T M S N T R A

S W V

R R N I E : L : I R A E E A E S W E T M S I

N R E T M ; L L S

A

E H D H T F A K ? E

L W D S R I U E A

D N I T O R C I A I

T C

9 M

E T C H F 0 I E D N A O D N E R P P P P P E E E E E 1 1 1 1 1 8 7 6 4 5 .H en .Y og-L .Lee H. Wong -L. Yeang Y. -S. H. S. (Switzerland) Nendaz* Bounameaux-M. Wuillemin -H. W. Korte- Frauchiger - W. Husmann-B. M. .Y eg Cia .S zhang- Y.-Y. luo Deng*(China)-G.-S. M.-Y. .J. H. Spir D. D - Carrier Kimpton-M. Hogg*(Canada)-M. K. .Cai*(S)-M DeSancho Chapin*(USA)-M. J. P E M R H Q T T T A T R P E C S V C A I M H H H H Coyle Wells -P. . R R E X S X W C E O H O E U E P R R R R S P N P O T O Q S A I S N D I N L T R E L E O O O O O U L P P P U G Ng* (Singapore)- Y. I I E Z C I R I S C O L I M M U H M M H C I k -D T E T S E R A T S I A S S Y Y I Y A N B B E B B E R T S E L M T P

L L

O N O L O O I

T

L D O T I P A A A E P E O - H C uek .Hyz-J Beer - Hayoz -J. Aujesky -D. . S P A S E A

A A F A S X X C N A R N I E R N I M L T C

S T S S I I T T N L S S S

S O O D I Q I B

A

E I

E I E D I

A

V

F F M

N P O G F F A S U N ( N

O N E E E H

G O B I N S L I U T T 3 B L R

D R S Y I O I M E R S D 8 Y S I C R N E D

T

L 9 N : P S

D

E

I

D W I M O M E A

R N A A M I E U E O N N S

L X N E A I I C V O T E L A T T S F S

I I H.

D N E N I U I I M S T G P

H

A I K N C O H N N I A E T E

O

O C E

V en .K. Leong -L. C O F A G A G R E O S ) N U N A E : O N

S I

L E U D P P S L E A T N A E P D H M S

A R K E M S R O P 17:00 -19:00

I O

T E C T

E

E T Y A U I F A I A A R N H E P L E T

A S S E L : T T I N

R I N C M V E S C I M

Z T O T O T E N E I L B E E N

O M F I W T S I N O R D N Siow - A R S B S I L I R T

S O C E I I H Y N S D A S M 89 L I S

ePosters ISTH 2012 11.6.2012 14:48 Page 90

ePoster Session Exhibition hall lower level 17:00 - 19:00

PE19 SIGNIFICANCE OF TISSUE FACTOR-POSITIVE PE24 VENOUS THROMBOEMBOLISM: A REFINED MICROPARTICLES IN THE PATIENTS WITH UNITED STATES COST MODEL WITH LONG- ACUTE PROMYELOCYTIC LEUKEMIA TERM ATTACK RATES Y. Han* (China) - L. Zhou - X. Bai - D. Wu - C. E. Mahan* (USA) - A. L. Woersching - Z. Wang - C. Ruan M. E. Borrego - R. Federici - A. C. Spyropoulos

PE20 SIGNIFICANTLY HIGHER LEVEL OF PE25 COAGULATION FACTOR XIII-B HIS95ARG LIPOPROTEIN (A) AMONG ACUTE POLYMORPHISM AND THE RISK OF CORONARY SYNDROME (ACS) THAN STABLE CORONARY ARTERY DISEASE IN A ANGINA PECTORIS (SAP) PATIENTS OR CROATIAN POPULATION HEALTHY SUBJECTS IN INDONESIAN A. Bronic* (Croatia) - G. Ferencak - R. Bernat - POPULATION J. Dumic - S. Dabelic I. Puspitawati* (Indonesia) - S. Setyawati - D. W. Anggrahini - E. H. Herningtyas PE26 NO CORRELATION BETWEEN AND THE RISK OF PE21 IL-18 AND VASCULAR MINERALIZATION IN RECURRENT VENOUS OR ARTERIAL CORONARY ARTERY DISEASE PATIENTS THROMBOSIS IN PATIENTS WITH A. De La Pea* (Mexico) - B. Valente-Acosta - ANTIPHOSPHOLIPID SYNDROME J. Rupa-Matysek* (Poland) - J. Reese-Parada - A. Contreras-Villaseor - ~ L. Quintanar-Trejo - M. Pea-Duque - L. Gil - E. Wojtasinska - K. Zajdel - M. Martinez-Rios - V. Herrera-Alarcon - K. Ciepluch - M. Lewandowska - C. Linares-Lopez - H. Delgado-Granados - M. Komarnicki M. Flores-Garcia - F. Santibaez-Escobar PE27 DEVELOPING ANIMAL PE22 STUDY ON GENE MARKERS OF THROMBOSIS MODELS OF HEMOLYTIC UREMIC SYNDROME IN CORONARY HEART DISEASE BY MULTI- D. Stearns-Kurosawa* (USA) - C. Leibowitz - ANALYTE SUSPENSION ARRAY C. Mayer - S. Kurosawa TECHNOLOGY W. He* (China) - Y. HU - J. Yu - T. Guo - X. Zhang PE28 COMPLICATIONS ASSOCIATED WITH PICC IN A HOSPITAL FOR HIGH LEVEL PE23 RESULTS FROM THE NATIONAL REGISTRY OF COMPLEXITY OF THE CITY OF MEDELLIN OF THROMBOPHILIC STATES IN SLOVAKIA - COLOMBIA J. Stas~ko* (Slovakia) - I. Plamen~ov - J. Sokol - J. F. Combariza* (Colombia) - S. Roldan - P. Chudy - M. Dobrotov - P. Kubisz K. Galvez - V. Olaya - L. ballesteros - V. palacios

90 ISTH 201211.6.201214:48Page91 P P P P P ePoster Session E E E E E E E 3 3 3 3 2 xhibition halllower level 4 2 3 1 9 - L. Galvez Olaya -K. (Colombia)- Combariza* V. F. J. E. Lederfine- Rabizadeh-D. Inbal*(Israel) -E. A. .Othman M. Siemens- D. Black -R. Toukh* (Canada)-A. M. .Lw*(ntdKndm .Hillis- Lowe* (United Kingdom)-G. . Rumley Woodward -A. Chalmers-M. J. .O jy*(iei)-G wee-O .Ihejirika E. Nwaeke -O. Ajayi* -G. (Nigeria) O. I. G. F T N A P F C P T N S M D P C F U I N A H H I I R R T

O O A S E A E Y B B N T oebu .Brenner Rosenbaum -B. C U D R R O O S R I O A O S V R R E N Ballesteros O T D T O O E I E S D G P C I R I T G V O N N H Y

T L M M I L N A I L S O E

O V

R O A

A H E R I B B H O E L V N E T I G G S A U O O A D E

R S A E

B M E T E E M K L M T I E T I S

I A E Y N M N C S I S O I I Y M C O N C C L S P ,

A -

O E M U A A L B

- S

: C E N I 6 E M L S I N S A S O L T P K

- O V C 2 T I R A A A A

R F S L N E D E

A E P T A T R R E I O D K

C N I T R R I P I P R A A K

E E C I C I C

T A

R R O C C C G E R R N

I S O B M A E O L

R T T I N

T A

S E T F M I D I I T A S S O F V O N E K O T E I R P

E E C S W N D D

E O R I I K L R N

T T N S S

F P

I I W E R I A T I C C

:

C R O 2 P R I A H T H T I A A N

T O A N I C ( S H A E

T N V

F H J T T

N

U N O I E E O G C A F O I E I E T

D L O G K F E L A I N E N O N - R 2 R E D S 2 T

G R

A V )

S

A I A I N - N C

A

N W N D N D C I T S E H

(Austria) Chairpersons: P P P P P E E E E E i T i T n n W W W W W h h

W W r r C C C C C o o o o 0 0 0 0 0 m m 5 4 3 2 1 m m b b P Ry L. R. King- Jones-I. Monagle*(Australia) -S. E. K. .Igat .F let .A Lazzari A. -M. Alberto F. Ingratti -M. M. Bauman E. Lequier-M. L. Monagle Newall -P. Hardikar-F. W. S Rice- M. Wiggins-K. L. Blondon*(USA)-K. M. .S. S. Snchez-Luceros* (Argentina)- A. E. K. e O C M C A C C A L P W T R V M A e o o .Msiot .L amn-S Ghotra - Bauman-S. L. Massicotte-M. M. . O H .Hcbr .M st .L Smith L. Psaty-N. M. -B. Heckbert R. . R n n E N D D O O H L E N O O I - - enru .Mnge-F Newall Monagle-F. Weintraub -P. T I

N N E H H O T M V P I H

N D N D & & L E H Paul Monagle (Australia), Sabine Eichinger Eichinger Sabine (Australia), Monagle Paul I

O E G T L a a O C I erson -A. A D C I ecegee .H rso-A Blanco- Grosso-A. H. Meschengieser -S. A I Monagle* (A C N

C F A E R T U C C e e

E R L R S O T L I I A H C I S m m C S S

N N S T h h E E S A T L R E E

T A

T O i i R

N

T H G o o

O l l C M I

O R T F R d d M H O M r r C E U F

I I r r E A M r r A R D O N R P U I h h

L e e A T N W F T B O E D R N A T A a a n n T I O .Br A. E T O O F O T C P I M g g O

I N

B

O L I T I N srla .Ignatovic - ustralia) - V. I S O Y M i i V C B O N Y L G c c H N I

E M I O E O S

N O

S E uce* (Canada)- E I

H I I S N N O

E S s s W

F N R A O O

I F s s S

I F

A N C N S

I A A F R A u u N U

N

Y S

P D N

A N e e M A P

C T

C M Y / T

s s T F N

O O I A P O

H C I O

S O T D R R R N F I O

K H L L

D A

O E

I P A L I D H T R N N I S O O R G 17:00 -19:00 S B O O D G P W E M U E M M E

G W C A L Y I C O B N A N H R O I T I Z G T T N I A I P I Y L N H I V

A N O M D G G E T C N R U O

H A Y

E L T Y G T N E 91

I E I N

ePosters ISTH 2012 11.6.2012 14:48 Page 92

ePoster Session Exhibition hall lower level 17:00 - 19:00

PEWC06 PREDICTING DEEP VENOUS THROMBOSIS IN PEWC11 MOLECULAR BASIS OF TYPE I PREGNANCY: EXTERNAL VALIDATION OF ANTITHROMBIN DEFICIENCY IN TWO WOMEN THE LEFT CLINICAL PREDICTION RULE WITH RECURRENT VENOUS M. Righini* (Switzerland) - G. Le Gal THROMBOEMBOLISM IN THE FIRST TRIMESTER OF PREGNANCY PEWC07 THE ECONOMIC COSTS OF ROUTINE INR Y. Xia* (China) - Q. Ding - X. Wang - Y. Lu - J. Dai MONITORING IN INFANTS AND CHILDREN J. Gaw - S. Crowley - P. Monagle* (Australia) - PEWC12 HIGHER DOSES OF LOW MOLECULAR S. Jones - F. Newall WEIGHT HEPARIN (LMWH) ARE NEEDED TO ACHIEVE GOAL ANTI-XA LEVELS IN PEWC08 CEREBRAL TE IN ITALIAN INFANTS AND CRITICALLY ILL CHILDREN CHILDREN: DATA FROM THE ITALIAN N. J. Schloemer* (USA) - S. Abu-Sultaneh - REGISTRY OF CHILDHOOD THROMBOSIS S. Hanson - K. Yan - R. G. Hoffmann - (RITI) R. Punzalan - P. Havens C. Gentilomo* (Italy) - P. Saracco - R. Bagna - B. Bassi - M. Agostini - P. Giordano - PEWC13 THE EFFECT OF ANTITHROMBIN L. A. Ramenghi - A. C. Molinari - A. M. Laverda - CONCENTRATES ON ANGIOGENESIS IN M. Grassi - M. C. Putti - A. Suppiej - S. Sartori - SERIOUSLY ILL CHILDREN P. Simioni and Italian Group Of Childhood V. Karlaftis* (Australia) - C. Attard - P. Monagle - Thrombosis Registry V. Ignjatovic

PEWC09 PROSPECTIVE STUDY ON INCIDENCE RATE PEWC14 THE PREVALENCE AND ROLE OF ELEVATED OF NEONATAL AND PEDIATRIC COAGULATION FACTORS VIII, IX AND XI IN THROMBOEMBOLISM IN A SINGLE TERTIARY ARTERIAL THROMBOSIS IN CHILDREN CARE HOSPITAL IN ITALY DURING A 5-YEAR M. Avila* (Canada) - A. Zanette - T. Canil - PERIOD S. Williams - W. Kahr - L. R. Brandao and P. Saracco* (Italy) - A. Viano - R. Bagna - B. Bassi Paediatric Haemostasis Thrombosis - M. Agostini - G. Agnoletti - E. Barisone - D. Farinasso - M. T. Cascarano - L. Barberis - PEWC15 ASSISTED REPRODUCTION TECHNOLOGIES F. Magnetti - E. Gallo - C. Plazzotta - R. Bonaudo FAILURE AND ACQUIRED THROMBOPHILIA: - G. Migliore - C. Gentilomo - B. Pollio - P. Simioni EXPERIENCE OF A SINGLE SPECIALIZED and RITI, Registo Italiano Trombosi Infantili ARGENTINIAN CENTER G. Begue* (Argentina) - A. Snchez-Luceros - PEWC10 OBSTETRICS OUTCOMES ASSOCIATED WITH S. S. Meschengieser - S. H. Grosso - A. Blanco - AN INCREASED LEVEL OF LIPOPROTEIN-A M. F. Alberto - M. A. Lazzari (LP-A) IN THROMBOPHILIC PATIENTS D. Recchi - V. V. Barros* (Brazil) - F. S. Baptista - M. R. D. F. L. Bortolotto - R. P.V. Francisco - M. Zugaib

92 ISTH 201211.6.201214:48Page93 Chairperson: V V V V ePoster Session W W W W a H E a H E n n xhibition halllower level a a F F F F d d 0 0 0 0 e e

4 3 1 2 m m V V o o o o n n r r .Bi Cia .S .Y .Wn .Ruan Wang -C. Yu -Z. Su-Z. Bai*(China)-J. X. B. Wong - Y. Engl- W. Chapman- W. M. Varadi Turecek - -K. L. -P. Reipert M. B. - Horling M. Klamroth-F. Yee T. Gill- T. -R. C. J. A. ida*(S)-P .Jcb .E Shaw E. Jacobi -M. M. iedman* (USA)-P. Haberichter L. Endres-S. L. - J. Baronciani Peyvandi -L. F. C Mannucci - M. Suiter*(Austria) -P. T. .D F D. K. G. Stufano - GarciaOya - F. Pagliari* (Italy)-I. T. M. M A A T T V A A W D C P D W C B r r

A W H O W W

S F N I .Kmtn-M afn-E .Romond- H. Laffan -E. Kempton -M. L. . O h h I E H E I I O N S .Ew M. .Saio-I ishan-M .Ragni- V. Birschmann-M. Shapiro-I. D. T L L F oz .L ac .T Canciani- T. LaMarca-M. Cozzi -S. R S a a N David Lillicrap (Canada) Lillicrap David T T F A T O E i i E C I L L E E l g l g I A O O

H E R l l

B W A E E W H C e e C C i i C N O M C A r O c c S B B E b b T I A

T T T I C L D

B A E D R R A enstein andrhVWFStudy T I M r r D D S O I S L N O T

O a a U

T I A A T F E E I E R

i i G E n n T C E N A C s s N N Y O S B S

R O d d

D F o o

A Y A P T D D R

R O

I

O T F M

r r L C T H E Z

W d d

A d d F O T F E F

O F A

T A E A i i

N e e 2 H A A I s s C

N T I T P T

V C N A V r r D C C e e C E T I E O H E O s s O O / I D a a T T

L E I T D

N

D N D I N N N O O

( ( P E E s s Y D M

I L L E

I

C

e e R C A G

W R S R I

O N a a T ( O B H R E

V E E

P I F E b b H R A Y L L E G A W A N

U R

N I I

E L 1 M N V S s s B S N I F R M E T 0 C T t t O T I E C I A : A u u T

P I B L U I R O I G N

E N N T O d d L U U R L C C

A

E A C

i i R W M R O T A A e e O E T L N Y Y H R N A s I s F I I T I ) N

L

A O

R eam ) )

( D B I A V L V

E N N N O

I N E W S W N F S

M B D O A C D F F B R

C F E : I : V N A A O

A T N O V G G G O N T T O N

) I R D I C

N N V V V V V V W W W W W W F F F F F F 0 0 0 0 0 1 9 8 6 7 5 0 .Mraloe-E Grandone Margaglione- E. M. Villani- Colaizzo -M. Vergura- P. -D. B. Lissitchkov T. A. E. Brown - Male-D. Hofbauer*(Austria) -C. J. C. .Lu*(China) Y. L. Cappucci- Tiscia-F. L. Favuzzi* (Italy)-G. G. .Jing*(Canada) D. N. Balkhair- Kashoob-A. Alkindi-M. S. Matysiak -K. Cabrera - Moret-N. Aznar* (Spain)-A. A. J. F P F T G I H O P T H H R F I ( F S N N A A A V H X H R R E I A E E F E G H F L Fischetti - V. .Reipert M. atgsio-J lebr .Scheiflinger- Oldenburg -F. Santagostino -J. - Pez Woodward -A. K. Antonov -M. C C lOadn .Pathare* (Oman) Al Obaidani-A. I I E E V

E E A E L N I

T P E I H I D T T

B V

A E D N M

E R H M C P I - O O E T A I R N A - P T A O T H T A I T I F R R L T S H E I U O O N I N C P O A I A A O

S

C I R V N S R I H H R B

I - N L X N I D N I H I I F S N

I E E I M I

T

C P T

L S I E D E U ( H G D A N Y M B O A I U aisa-L Gercheva - Zavilska -L. E

¤ A I A S I G I E

C

A E C P O N P aun .Vchoe-E Chinni Vecchione -E. Bafunno -G. R

) F P D

I A

F N Y G O A N A

O

A P I

S H I E N D : O C

C N C E N H N K F T C G E E D O S T F I O

I I A D U E T M L E N V E

O I I M T S M

R X S N I D S E E N A O A R R I P

¤ A I Y C S

L T O

I

L P F

E A ) N R B

N O Y

I I I

T O X F H C A E I R

E S : N P S Y O

T I R S

A C O C M L B M

P P M R

P

T I O O N I E U I O A E E N A

T E I C V H E N N M N

- N R T T

N A P E C

O A C D I T B A E 17:00 -19:00 C T

H E

V H N E E : D I D S

A N E N O I H I N R G T I O S N N T C A U E T U S E E R S A O N R T M T D N

T R R T W C A O A Y I O Y T E N O T F

I P A O P T E P D

M H A H E L F O I E N I L R 93 G I T A

ePosters ISTH 2012 11.6.2012 14:48 Page 94

ePoster Session Exhibition hall lower level 17:00 - 19:00

VWF11 A MACHINE LEARNING APPROACH TO VWF17 PHARMACOKINETICS AND SAFETY PROFILE MERGING AND ANALYZING DATA FROM THE OF A SINGLE INTRAVENOUS DOSE OF CONDENSED MCMDM1-VWD BLEEDING RECOMBINANT FACTOR XIII IN PAEDIATRIC QUESTIONNAIRE PATIENTS WITH CONGENITAL FACTOR XIII A- P. James* (Canada) - J. Grabell - M. Bowman - SUBUNIT DEFICIENCY S. Mollah - B. Coller M. Williams* (United Kingdom) - C. Stenmo - A. Rosholm - R. Tehranchi VWF12 P.E1549K: A NEW MUTATION RESPONSIBLE OF VON WILLEBRAND DISEASE TYPE 2M VWF18 PHARMACOKINETICS OF A NEW RFVIII, A. I. Woods* (Argentina) - A. Sanchez-Luceros - TUROCTOCOG ALFA, IN A. C. Kempfer - E. I. Bermejo - J. C. Calderazzo - ADULT/ADOLESCENT AND PAEDIATRIC A. N. Blanco - S. S. Meschengieser - M. A. Lazzari PATIENTS WITH SEVERE HAEMOPHILIA A. DATA FROM THE GUARDIAN“ 1 AND VWF13 P.M1304V: A NEW MUTATION IN THE A1 GUARDIAN“ 3 TRIALS DOMAIN ASSOCIATED TO ATYPICAL VON E. Santagostino - U. Martinowitz - V. Vdovin - WILLEBRAND 2B PHENOTYPE S. Glamocanin - M. Morfini - F. Abdul-Karim - A. I. Woods* (Argentina) - A. Sanchez-Luceros - G. Dobaczewski - B. Brand - A. Tiede - A. C. Kempfer - E. I. Bermejo - J. C. Calderazzo - C. B. Stenmo* (Denmark) - J. Mo/ ss S. H. Grosso - S. S. Meschengieser - M. A. Lazzari VWF19 EFFECT OF APTT REAGENT AND STANDARD ON PLASMA-DERIVED AND RECOMBINANT VWF14 COMPARISON OF RECOMBINANT FVIII FACTOR IX POTENCY ESTIMATES UTILISATION IN A COHORT OF UK PATIENTS H. Wilmot* (United Kingdom)- J. Hogwood - FOLLOWING A SWITCH FROM A FULL E. Gray LENGTH TO B-DOMAIN DELETED FVIII: A RETROSPECTIVE ANALYSIS OF HOMECARE VWF20 COMPARISON OF QUALITY OF LIFE IN AN DELIVERY DATA AMISH AND NON-AMISH COHORT AFFECTED S. Verma* (United Kingdom) - J. Gama WITH VON WILLEBRAND DISEASE S. Gupta* (USA) - M. Heiman - N. Duncan - VWF15 STANDARDIZATION OF AN APTT-BASED FVIII P. Yoder - R. Montgomery - J. Hinckley - J. DiPaola INHIBITOR SCREENING ASSAY - A. D. Shapiro P. Pinto* (India) - S. Shetty - K. Ghosh

VWF16 INHERITED BLEEDING DISORDERS IN PAKISTANI WOMEN PRESENTING WITH MENORRHAGIA N. Hossain* (Pakistan) - T. Shamsi - A. Naz - A. James

94 ISTH 201211.6.201214:48Page95 P P P P ePoster Session E E E E E E W W W W xhibition halllower level C C C C 1 1 1 1 8 7 9 6 R. Giordano- Saracco -P. Gentilomo*(Italy)-P. C. L. Group OfChildhood Thrombosis Registry SimioniandItalian Indolfi-P. Lasagni-G. - D. Cohen- Levine -J. Desancho*(USA)-R. Shah . Kalish-S. Chapin-R. J. .Zugaib Francisco - V. P. M. -R. Bortolotto L. F. D. R. M. Group OfChildhood Thrombosis Registry A. Bagna- Gentilomo*(Italy)-R. Saracco -C. P. M. T I I W T T V L S W C A I H T T N O H H H E E N O E A A O I F al .V.Gallo - V. in .Agostini-P Viano -M. an .C oiai-M rsi-M .Putti C. Grassi -M. -M. Molinari C. Bagna -A. T T R R R N R W R D L M L A M H O I O O O I I E

N

P E A A P E

L D M M U M A A T

N N R E N I S

S R B B B

T

V E S

R I W

I A O O O N T E I G A S E N R H I S E F E L N O N T G G A Y R S I M M H D N A S I L N ars Bai)-F .Baptista - S. Barros* (Brazil) -F.

O S B B A

N

O

E ( C O T T M O N R O C F

S H F R C T I B L L

Y T

V

I Y E I I I A O D L

S T I C I

N ) T D N A O E H

M

A T C R T D M F R / M R A T O E

SimioniandItalian . O B C C E

I H N M F N O M H H

R : R C

P L I B I D D O D L O O L I I S

A D N M R I I M N C N M T H

E B S

A D A

R

O N P O E I

T E N I F R O : C T I P F O

R E I D I U H I

T C N O R G T I A I L S M E N I E L V I

G A

N A I I T E N A

I N C H S N T Y E T R Y P P P P E E E E W W W W C C C C 2 2 2 2 3 2 1 0 H. Boudjerra - -N. Ouarhlent*() Y. Y. .R. D’AmicoL. - A. - E. Carneiro D. Cassis-J. R. F. Zugaib Baptista- M. Francisco S. - Barros*(Brazil) -F. V. -RP. Bortolotto V. issa - V. L. F. D. R. M. K. M. Venturelli - -U. Barillari Samantha*(Italy)-G. P. D T T P D I R T P T T N E N O H H H H E X L U I E A F Ar Bounecer Turello R A R R D E P D O C D R F C E

O E O O I E L R I E Brand R A N R E V

I M M M O R T ( I V G S N P I E R P E B E B B I

K - L N T A P N I N O O T O C A O

G R R O ão* (Canada) E T C P P P

L P T

I

E T F E R H H O

N D M H A ) G

O I I V : ) O R R L E L B

N A E I P A I S I O N N R A A A N N H L A

T M U

: N P

O Y G

E A A P B C F R L U E D N

T O O Y A E S S S U T I I

S R X O G I

I N T C O C I I

N N S S H C G A F O A

R H T A L W E

A N L I E O I N D O L W W G I T

T M D D U C N

U H M W R C B E 17:00 -19:00 A L

H T O E O N A L A W

T N

T M T E ( P C I I E O M O E O R A R N B N N O L

O A

C W J E L L I I C I C T C H T 95

ePosters ISTH 2012 11.6.2012 14:50 Page 96 ISTH 201211.6.201214:50Page97 Leukemia -Anaemia/ESAsHepatitis Haemochromatosis Clinical Haematology-MPD, Venesection, Web Browser Ser basedBenchmarking VTE Assessment New Oral Anticoagulants Come andseeournew modulesfor managing: patient safety. increased productivity, improved qualityofcareand patients andrealize thebenefitsofsoftware with care organizationsmanagingmany thousandsof Many ofourclientsarelargehealth- 500,000 patients. gulation managementsoftware withanestimated Over useDAWN 300clientsworldwide AC anticoa- 4 Milnthorpe Square, The stasis researchandmedical diagnostics inthrombosisandhaemo- products usedworldwide manufacturer of isaprimary Affinity Biologicals, Inc. Dr. Sandhill 1395 Cumbria LA7 7QJ LA7 Cumbria Ancaster United Kingdom United [email protected] www.4s-dawn.com L4G 3Z9 L4G Canada [email protected] www.affinitybiologicals.com www.affinitybiologicals.com Sponsor andExhibitorProfiles A 4 A 4 S S F F

F F D D I I N A N A W W I I T T , Ontar , N N Y Y

B B C C I I l l O O i i n n io io L L i i c c O O a a , MGUSandStable Chronic G G l l

S S I I C C o o A A f f t t L L w w S S a a , , r r I I e e n n c c . . BOOTH N BOOTH N vice Products . °20 °17 protein pur include Services ControlPlasmas. &Abnormal Normal products, VisuCal meeting. and treatment,pleasevisittheAlexion standatthe presenting signsandsymptoms, differential diagnosis, information onrelevantFor further diseaseareas, r These diseasesmay bechronic, progressive, degene- with severe, oftenlife-threatening, ultra-rare diseases. commitment tomeetingtheneedsofpatientsliving combines groundbreaking sciencewithasteadfast Alexion company that isaglobalbiopharmaceutical Village Business Horizon 14 Unit production. lopment, customlyophilization andcustomplasma Brooklands Road, Weybridge 1 Weybridge Road, Brooklands Surrey KT13 0TJ 0TJ KT13 and afulllineofimm analytes, the VisuLize antibody pairsfor immunoassay ofhuman andanimal include anextensive lineofantibodies, conjugates, United Kingdom United [email protected] ative A A L L E E , anddifficulttodiagnosetreat. X X I I O O N N ification, antibodyproduction,assay deve- ™ Calibrator Plasma and VisuCon ™ uno-depleated humanplasma line ofcompleteELISAkits, BOOTH N °26 97 ™

Sponsor & Exhibitor Profiles ISTH 2012 11.6.2012 14:50 Page 98

Sponsor and Exhibitor Profiles

AMGEN BOOTH N°19 trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter 240 Cambridge Science Park applies a unique combination of expertise in medical Milton Road devices, pharmaceuticals and biotechnology to create Cambridge CB4 0WD products that advance patient care worldwide. United Kingdom BAYER HEALTHCARE AG SPONSOR Amgen discovers, develops, manufactures, and deli- vers innovative human therapeutics. A biotechnology Bayer Healthcare Pharmaceuticals pioneer since 1980, Amgen was one of the first com- 13353 Berlin panies to realise the new science’s promise by Germany bringing safe, effective medicines from the lab to www.bayer.com manufacturing plant to patient. Amgen therapeutics have changed the practice of About Bayer HealthCare medicine, helping millions of people around the world The Bayer Group is a global enterprise with core in the fight against cancer, kidney disease, bone competencies in the fields of health care, nutrition and disease, and other serious illnesses. With a deep and high-tech materials. Bayer HealthCare, a subgroup of broad pipeline of potential new medicines, Amgen Bayer AG with annual sales of EUR 16.913 billion remains committed to advancing science to help (2010), is one of the world’s leading, innovative improve people’s lives. companies in the healthcare and medical products For more information about Amgen, our pioneering industry and is based in Leverkusen, Germany. The science and our vital medicines, visit: company combines the global activities of the Animal www.amgen.co.uk Health, Consumer Care, Medical Care and Pharma- ceuticals divisions. Bayer HealthCare’s aim is to BAXTER HEALTHCARE, Inc. BOOTH N°1 discover and manufacture products that will improve One Baxter Parkway human and animal health worldwide. Bayer Health- Deerfield, IL 60015 Care has a global workforce of 55,700 employees United States (Dec 31, 2010) and is represented in more than 100 countries. www.baxter.com

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease,

98 ISTH 201211.6.201214:50Page99 br companya leadingintegrated biopharmaceutical Idec disco Through cutting-edgescienceandmedicine, Biogen 133 Boston Post Rd Post Boston 133 0laigpamcuia opne.Headquartered companies. 20 leadingpharmaceutical Ingelheimgroup isoneoftheworld’sThe Boehringer Av Ellesfield Please visitalso-www.sobi.com developing thenext generation hemophiliatherapies. withBiogenIdec, we are in asuccessfulpartnership continue thesearchfor improved treatment,andnow inhemophiliawe Basedonourlonghistory families. the lives of patientswithrare diseases andtheir company, pleasevisitwww.biogenidec.com For additionalinformation aboutthe immune disorders. neurodegenerative diseases, hemophiliaandauto- innovativeworldwide therapies for thetreatmentof Weston, MA 02493 MA Weston, Bracknell Berkshire Bracknell United States United RG12 8YS RG12 United Kingdom United www.BiogenIdecHemophilia.com www.boehringer-ingelheim.co.uk S B S B Sponsor andExhibitorProfiles B B B B w w i i inging innovative toimprove therapies andservices o o O O I I e e O O g g E E d d e e G G H H i i n n s s E E R R

h h I I N N d d I I

N N O O

e e I I vers, develops anddelivers topatients G G D D c c r r enue p p E E E E h h R R C C a a

I I n n & & N N

G G B B S S i i E E W W o o L L v v E E H H i i t t D D E E r r u u I I I I S S M M m m H H

L L

( ( O O I I S S M M R R o o I I T T b b P P E E i i H H ) ) D D A A N N BOOTH N

B B SPONSOR I I O O V V I I T T R R U U ° 18 M M mark diseases,serious thecompany manufacturers and improving thequality oflife for peoplewith rare and www.boehringer-ingelheim.co.uk For moreinformation pleasevisit: Ingelheim’sof Boehringer endeavors. factorsprotection andsustainabilityareintrinsic inall cooperation and respect,aswell asenvironmental Mutual the foundation oftheglobaloperations. forproviding allemployees equalopportunities form projects, for caring employees andtheirfamilies, and Involvement insocial to besociallyresponsible. Ingelheim’sA central element ofBoehringer cultureis therapeutic value for medicine. humanandveterinary facturing andmarketing novel productsofhigh been committedtoresearching,developing, manu- was founded in1885,thefamily-owned company has Sinceit affiliates andmorethan44,000employees. in Ingelheim,Germany, itoperates globallywith145 ies.Thecompany’s productsarealsousedin disease. pr including hemophiliaandvon Willebrand disease, indicated for thetreatmentofcoagulationdisorders therapies are CSLBehring therapies worldwide. peutics industr isaleaderintheplasmaproteinthera- CSL Behring 1230 Box P.O. 35002 Marburg Marburg 35002 Germany [email protected] www.cslbehring.com C C imary immune deficiencies and inherited respiratory immune deficienciesandinherited imary S S L L ets arange ofplasma-der

B B E E H H R R I I N N G G y. Committed tosaving lives and iv ed andrecombinant BOO TH N °2 99

Sponsor & Exhibitor Profiles ISTH 2012 11.6.2012 14:50 Page 100

Sponsor and Exhibitor Profiles

cardiac surgery, organ transplantation, burn treatment Daiichi Sankyo Europe has affiliates in 12 European and to prevent hemolytic diseases in newborns. CSL countries in addition to a global manufacturing site Behring operates one of the world’s largest plasma located in Pfaffenhofen, Germany. collection networks, CSL Plasma. CSL Behring is a For more information, please visit: subsidiary of CSL Limited (ASX: CSL), a biophar- www.daiichisankyo.com or www.daiichi-sankyo.eu maceutical company headquartered in Melbourne, Australia. ENZYME RESEARCH/ R2 DIAGNOSTICS For more information, visit www.cslbehring.com BOOTH N°24 1801 Commerce Drive DAIICHI SANKYO EUROPE GmbH BOOTH N°14 South Bend, IN 46628 Zielstattstrasse 48 United States 81379, Munich [email protected] Germany [email protected] [email protected] www.enzymeresearch.com www.daiichi-sankyo.eu www.r2diagnostics.com

The Daiichi Sankyo Group is dedicated to the creation Enzyme Research Laboratories provides coagulation and supply of innovative pharmaceutical pro¬ducts to and fibrinolytic proteins from human plasma, other address the diversified, unmet medical needs of source plasmas and platelets. We also offer mono- patients in both mature and emerging markets. The clonal and polyclonal antibodies, immunodepleted company was created in 2005 through the merger of plasmas and ELISA reagents. Custom purifications two traditional Japanese enterprises, Daiichi and and contract services are also available. r2 Diagnos- Sankyo. With net sales of more than ?8.5 billion, tics strives to provide high quality, innovative and Daiichi Sankyo is one of the world’s 20 leading phar- economical products for the hemostasis market. We maceutical companies. While maintaining its portfolio place major emphasis on the production of optimized of marketed pharmaceuticals for hypertension, hyper- and versatile products for the detection of throm- lipidemia, and bacterial infections, the Group is enga- bophilia. We offer clot-based kits for quantitation of PC, ged in the development of treatments for thrombotic PS, and Lupus Anticoagulants. disorders and focused on the discovery of novel oncology and cardiovas¬cular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a “Hybrid Business Model”, which will respond to market and customer diversity and optimize growth opportuni- ties across the value chain.

100 ISTH 201211.6.201214:50Page101 geted therapies. in prevention, suppor a new generation ofpatient-focused cancertreatments GSKisde with morethan160cancercenters. wide researchinthissectorincludescollabor Ourworld- lines intheoncology/haematologysector. developed, resultinginoneofthemostrobust pipe- transforming theway treatmentsarediscovered and approachwe are revolutionary “bench tobedside” ThroughGSK’s difference tothelives ofpatients. haematological malignanciesthatwillmake profound GSK isdedicatedtoproducinginnovations in 1-3 Road Ironbridge oglto n irnlss Ourproductlineofhighly coagulation andfibrinolysis. plasma proteinsinvolved intheregulationofblood facturer ofresearch reagents, specializing inthe Technologies Haematologic 57 Road River Stockley Park West, West, Park Stockley Esse Middlesex UB11 1BT UB11 Middlesex Vermont 05452 Vermont United Kingdom United United States United [email protected] [email protected] www.gsk.com www.haemtech.com Sponsor andExhibitorProfiles H G H G A A L L A A E E x Junction x X X M M O O A A S S T T O O M M L L I I T T O O H H G G K K I I C C L L I I

N N T T tiv E E E E C C e care, chemotherapy andtar- H H N N O O n.(HTI)isamanu- , Inc. L L O O G G I I E E S S , , BOOTH N I I n n BOO c c . . TH N veloping ations °5a °6 clonal antibodies. tors, andinhibitorsaswell asmonoclonalandpoly- proteinsincludeszymogens,purified enzymes, cofac- experience extends years, over driven thirty by acom- Helena Biosciences'unparalleled clinicaldiagnostics South Queensway www.haemonetics.com T transfusion services. ponent collection,thesurgicalsuite, andhospital blood andplasmacom- medicalmarkets: important Ourtechnologiesaddress patients aroundtheworld. of healthcarefor blood collectors, hospitals, and tomers improve clinicaloutcomesandreducethecost deliv consumables, ITproducts, andconsultingservices Together,solutions for ourdevices ourcustomers. and cated toproviding innovative blood management Haemonetics isaglobalhealthcarecompany dedi- 400 Team Valley Trading Estate Trading Valley Team 02184 MA, Braintree, Gateshead - Tyne and Wear and Tyne - Gateshead States United NE11 0SD NE11 www.haemonetics.com United Kingdom Kingdom United [email protected] [email protected] www.helena-biosciences.com www.helena-biosciences.com o learn moreaboutHaemoneticsvisitourweb siteat o learn H H H H E A E A Wood Road Wood er asuiteofbusiness solutionstohelp ourcus- E E L L E E M M N N O O A A N N

B B E E I I T T O O I I C C S S S S C C

I I C C E E O O N N C C R R E E P P S S O O

R R E E A A U U T T R R I I O O O O N N P P E E BOO BOOTH N TH N °10 °15 101

Sponsor & Exhibitor Profiles ISTH 2012 11.6.2012 14:50 Page 102

Sponsor and Exhibitor Profiles

mitment to excellence, value and the best customer HERMANSKY-PUDLAK SYNDROME NETWORK UK service. Specialising in Clinical Electrophoresis and (HPS NETWORK UK) BOOTH N°13 Haemostasis, Helena Biosciences manufacture and market the most innovative diagnostic products, Howards Drive, Hemel Hempstead 49 providing clinicians worldwide with a comprehensive Herts, HP1 3NW portfolio of blue-chip instrumentation, software and United Kingdom assays. [email protected] Helena Biosciences Europe delivers integrated www.hpsnetwork.co.uk capillary and agarose gel electrophoresis systems - in addition to a range of haemostasis instrumentation The HPS Network UK was established in 2010. We and reagents. are affiliated to the US based HPS Network Inc. We are a not-for-profit group working for the benefit of HEMACORE LLC BOOTH N°7 individuals and families affected by Hermansky-Pudlak 34th street of 8 March Syndrome - and those who seek diagnostic testing. 125319, Moscow We aim to work with health professionals to develop: Russia A) quicker consistent routes to reliable testing, B) standards of care and referral for those affected by [email protected] HPS. We encourage affected individuals and families www.hemacore.com to adopt a proactive role in their healthcare by pro- www.thrombodynamics.com viding information and support. HPS involves: a plate- let bleeding disorder, albinism, visual impairment with HemaCore LLC - biotech company, develops medical photophobia and nystagmus, life limiting pulmonary devices and methods for hematology. Main product is fibrosis, a granulomatous ‘Crohns-like’ colitis, immu- Thrombodynamics assay - a new global for nodeficiency and HLH (HPS-2 only). monitoring and prognosis of clotting disorders: bleeding and thrombosis. Thrombodynamics assay is highly sensitive both to pro- and anticoagulant changes in hemostatic balance. Thrombodynamics analyzer and disposables sales in Russia will start in November 2012. Planned launch date in Europe is April 2013.

102 ISTH 201211.6.201214:50Page103 with amissiontoimpro Inspiration was founded by families withhemophilia, to thehemostasislab-including theA ACL Theadvanced range ofhemostasistestingneeds. delivering themostinnovative solutionstoaddress a (IL)ispassionateabout Laboratory Instrumentation 180 Road Hartwell and arecombinantporcinef arecombinantfactor IX products inclinicalstudies: We have two late-stage tomarket. biopharmaceuticals gement teamwithextensive experience bringing Inspiration isledby amana- recombinant therapies. drive innovation andexpand globalaccessto We withthecommunity are working to hemophilia. company focusedbiopharmaceutical exclusively on We aretheonly hemophilia aroundtheworld. East 1400 Building Square, Kendall One Bedford, MA 01730 MA Bedford, 02139 MA Cambridge, O 0 T;and,theACL AcuStar TOP 300CTS; of Hemostasis Testing Systems, featuring thenew ACL United States States United States United www.ilww.com www.inspirationbio.com I I Sponsor andExhibitorProfiles n n I I I I N N s N s N p p S S S S ™ i i T T P P r r a a R R I I R family completeautomation ofsystems brings R t t U U i i o o A A M M n n T T E E

I I B B O O N N i i N N T T o o A A p p

B B T T h h I I I I a a O O O O r r P P m m N N H H

a a L L A A c c A A R R e e ve thelives ofpeoplewith B B u u M M O O t t actor VIII i i A A R R c c C C a a A A l l E E T T s s O O U U R R T T I I Y Y C C CL T ® BOOTH N A A , thefirstfully L L SPONSOR S S OP , , I I n n ® c c Family . . °27 prtradptetI’.TheCoagLite operator andpatientID’s. professional INRtesterwiththefunctiontoupload uses af MEMS (MicroElectroMechanicalSystem)sensor to andintheUS for shortly saleundertheCEmark itisexpectedclinical trials thatthesewillbeavailable Currentlyintheprocessoffinal systems. monitoring specialty testing. automated, chemiluminescentanalyzer for hemostasis for thehemostasislab. assays, ILoffers completediseasestatemanagement reagents, acomprehensive paneloffullyautomated CoagMax Firsttomarket arethe products. microviscometry Microvisk Technologies isaUKbaseddeveloper of House Innovation 4 Unit Ffordd Richard Davies Richard Ffordd point ofcareINRmarket for thefirsttime. thesimplicityofbloodbrings glucosetestingtothe to beassimplepossible for theself-testerand St Asaph Business Park Business Asaph St calcified plasma. theformation ofaclotinbothwholeblood and chart St Asaph, LL170LJ Asaph, St United Kingdom United [email protected] www.microvisk.com www.microvisk.com M M ad h n fteya.Thehighlypatented wards theendof year. I I C C R R O O or V V ® m ofmechanicalclotdetectiontoaccur I I S S and CoagLite K K

T T E E C C Combined withtheHemosILlineof H H CoagMax N N O O L L O O ® G G point ofcarecoagulation I I ® E E S S is designedfor the BOOTH N ® is designed °22 ately 103

Sponsor & Exhibitor Profiles ISTH 2012 11.6.2012 14:50 Page 104

Sponsor and Exhibitor Profiles

MITSUBISHI PHARMA BOOTH N°5b predictivity for stent thrombosis after PCI and allows for superior stratification of major bleeding risk and Dashwood House transfusion requirements in cardiac surgery. Old Broad Street 69 Multiplate® enables the rapid verification or exclusion London, EC2M 1QS of drug induced or disease related platelet disorders. United Kingdom The clinical predictivity of the perioperative use of [email protected] Multiplate® has been validated in several clinical http://www.mitsubishi-pharma.eu studies.

Mitsubishi Pharma Europe is the European Head- NOVO NORDISK SPONSOR quarters of one of Japan’s largest pharmaceutical Novo Nordisk A/S companies, Mitsubishi Tanabe Pharma Corporation. Novo Allé, 2880 Bagsvaerd Based in London, Mitsubishi Pharma Europe is Denmark engaged in the clinical development of new drugs for the European markets. Mitsubishi Pharma Europe is www.novonordisk.com conducting trials in Europe in the following therapy areas; cardiovascular, diabetes, CNS and renal Novo Nordisk is a global healthcare company with 89 conditions. The staff include regulatory, QA, clinical, years of innovation and leadership in diabetes care. biostatistics, medical information, pharmacovigilance, The company also has leading positions within pharmaceutical technology and marketing. haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in MULTIPLATE - VERUM DIAGNOSTICA GmbH Denmark, Novo Nordisk employs approximately BOOTH N°8 32,700 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk’s B Reichenbachstrasse 27 shares are listed on NASDAQ OMX Copenhagen 80469 Munich (Novo-B). Its ADRs are listed on the New York Stock Germany Exchange (NVO). For more information, visit novo- [email protected] nordisk.com. www.multiplate.net

With more than 900 installations Multiplate® is the most widely applied platelet aggregometer in Europe for the monitoring of antiplatelet therapy and the detection of platelet disorders. The POC and labo- ratory use of Multiplate® delivers superior clinical

104 ISTH 201211.6.201214:50Page105 state-of-the-art humanPCC. state-of-the-art octanate ne gency medicine. ders plasma derivatives for treatmentincoagulationdisor- Sweden, France, andMexico, Germany isfocused on produced inourfive manufacturing facilities inAustria, productportfolio, TheOctapharma plasma derivatives. development, productionandsaleofhighquality Since28years, itscorebusiness isthe the world. gest privately owned plasmafractionation specialist in AG,Octapharma aSwiss-basedcompany, isthelar- 2 Seidenstrasse VI-niios octanineF FVIII-Inhibitors. 8853 Lachen 8853 and nano-filteredFactor IXconcentr Switzerland [email protected] www.octapharma.com www.octapharma.com u oglto rdc otoi ossso:wilate consistsof: Our coagulationproductportfolio Sponsor andExhibitorProfiles O O w generation treatmentfor v C C , immunotherapy andintensive careandemer- T T A A P P ® H H , VWF-stabilized FVIIItoprevent andcure A A R R M M A A

A A G G ® high purity SD-treated high purity on Willebr on ts octaplex ates. BOOTH N and patients. °29 ® ® , , products andservice. its customersandinproviding thehighestquality Pathway Diagnosticsishighlyfocused ontheneedsof With many years ofe distributor, Ltd LanganBach Services Ireland throughitsDublin based Ireland andNorthern UK. nationally throughlocaldistributors ordirectlyfromthe Activator haemostasis tests, includingassays for Prekallikrein Pathway Diagnosticsmarkets itsown range of clients research andindustry reagents,toclinical, fibrinolysis andinstrumentation Technoclone GmbHandmarkets theircoagulationand intheUKandIrelandforsive distribution partner Thecompany istheexclu- in thefieldofhaemostasis. distribution andmanufacturing company specialising Pathway DiagnosticsLtdwas established in1999asa Road Curtis House, Eclipse Dorking, Surrey RH4 1EJ RH4 Surrey Dorking, United Kingdom United [email protected] www.pathwaydiagnostics.com www.pathwaydiagnostics.com P P A A T T The company's productranges areav H H W W , and those of Unicorn DiagnosticsLtdinter- , andthoseofUnicorn A A Y Y

D D I I A A G G N N O O S S xper T T I I C C S S ience intheIVDindustry,

L L t t d d BOOTH N ailab °23 le in 105

Sponsor & Exhibitor Profiles ISTH 2012 11.6.2012 14:50 Page 106

Sponsor and Exhibitor Profiles

PENTAPHARM / DSM BOOTH N°16 strive to set the standard for quality, safety and value in the discovery, development and manufacturing of Postfach medicines for people and animals. Our diversified CH-4002 Basel global health care portfolio includes human and animal Switzerland biologic and small molecule medicines and vaccines, [email protected] as well as nutritional products and many of the world’s www.pentapharm.com best-known consumer products. Every day, Pfizer colleagues work to advance wellness, prevention, The Branch Pentapharm, since 2007 part of DSM, is a treatments and cures that challenge the most feared manufacturer of haemeostasis diagnostics: diseases of our time. Test kits e.g. Pefakit® APC-R , PiCT® (for UFH, LMWH and/or anti-FIIa and FXa drug moni- PRECISION BIOLOGIC BOOTH N°12 toring), , in-TDT® (for thrombin gene- Eileen Stubs Avenue 140 ration), or OEM products. Dartmouth Reagents (from research to bulk quantities) including NS, B3B 0A9 customer manufacturing n: synthetic chromogenic, Canada fluorogenic and amperogenic substrates, protease inhibitors and snake venom enzymes. [email protected] Active pharmaceutical ingredients: aprotinin, peptides www.precisionbiologic.com and snake venom derived enzymes (Batroxobin, Haemocoagulase) and synthesis of peptides and small Precision BioLogic develops, manufactures and mar- organic molecules. kets diagnostic products used for testing in routine and special coagulation laboratories around the globe. Our PFIZER BOOTH N°25 unique approach to doing business is built on our superior products, commitment to customer service Pfizer Limited and attention to detail. Over the past 20 years, our IPC 4-1, Walton Oaks, cryocheck™ frozen controls, calibrators and reagents Dorking Road, Walton-on-the-Hill, have become synonymous with quality. Today, we are Tadworth, Surrey growing our product base to help meet customers’ KT20 7NS needs by adding more in vitro diagnostics, including United Kingdom our line of clot-based diagnostic kits. Learn more at www.Pfizer.co.uk www.precisionbiologic.com.

Pfizer: Working Together for a Healthier World™ At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We

106 ISTH 201211.6.201214:50Page107 For moreinf - 2011netsales: - Morethan110,000employees in100countries Sanofi: ges andoppor external adapttofuturechallen- growth opportunities, sing innovation inResearch&Development, seizing increa- order todeliver sustainable growth: long-term strategy isbasedonthreekey in principles Sanofi’ footprint inbiotechnologyandrare diseases. the acquisitionofGenzyme, Sanofihasreinforced its Through betes, innovative productsandanimalhealth. markets, humanvaccines, consumerhealthcare, dia- emerging field ofhealthcarewithgrowth platforms: needsSanofihascorestrengthsinthe on patients’ Sanofi adiversified globalhealthcareleader, focused 54 Boetie la de Rue 75008 Paris 75008 France [email protected] http://en.sanofi.com/home.asp Sponsor andExhibitorProfiles S S A A N N O O F F I I rain http://en.sanofi.com/home.asp ormation: tunities. ?33.4 billion SPONSOR k diagnostic. develop andimprove theaccuracy ofthemedical Stago dedicatesitsresearchandinnovative skillsto Headquarters efficiency, improved patientcare. andsupport designed tostreamlineworkflow, enhanceoperational urinalysis hematology, hemostasis, microbiology, diabetes, solutions -chemistry, immunoassay, automation, Ourdiagnostic ofpatients. ment, andmonitoring information they needfor accurate diagnosis, treat- We provide clinicianswiththevital of-care testing. labs, reference labs, physician officelabs, andpoint- solutions for theinvitrodiagnosticneeds ofhospital unmatched testmenu, andinformation technology hensive ofperformance-drivensystems, portfolio Siemens HealthcareDiagnosticsoffers a compre- 76 Emil-von-Behring-Straße Rue des Frères Chausson 9 Chausson Frères des Rue Marburg 35041 92600 Asnières sur Seine sur Asnières 92600 Germany Fr [email protected] www.stago.com www.stago.com www.siemens.com/healthcare www.siemens.com/healthcare ets w S S P S S P ance T R T R I I E E A A O O M M G G D D orldwide E E O O U U N N , blood gas, andmoleculartesting-are C C S S The firm f The firm T T

H H S S E E

G G , abroadrange ofreagents(routine& A A m m L L T T B B H H H H orm C C A A ulates manufactures andmar- R R E E

D D I I A A G G N N O O S S T T BOO I I BOOTH N C C S S

TH N °28 107 °3

Sponsor & Exhibitor Profiles ISTH 2012 11.6.2012 14:50 Page 108

Sponsor and Exhibitor Profiles

research) and fully automated systems for haemo- TECHNOCLONE BOOTH N°23 stasis & thrombosis. Thanks to its haemostasis expertise, Stago is recogni- Brunner Strasse 67 zed and is in position to cooperate with the scientific 1230 Vienna community worldwide. Austria Affiliates in USA, Canada, China, Australia/NZ, UK, [email protected] France (Headquarters), Germany, Italy, Spain, Portu- www.technoclone.com gal, Austria, Switzerland, the Netherlands, Belgium - wide network of distributors (> 100 countries) BioCytex Technoclone is a world leading producer of global and and Thrombinoscope are Stago Group companies: special coagulation tests, calibration and control - Biocytex develops advanced research tools in field plasmas and Ceveron machines. Ceveron® alpha of cellular biology. TGA is not only a fully automated coagulation analyzer - Thrombinoscope develops systems and reagents in for clotting, photometric and immunological, latex field of Thrombin Generation (TGT). based coagulation tests but also offers the unique feature of fully automated thrombin generation SYSMEX UK Ltd BOOTH N°3 measurement in the routine: CV <5% and assay times Sysmex House, Garamonde Drive, <20min Peak Thrombin. Wymbush, Milton Keynes, MK88DF Another innovation is the Ceveron® MFU 500, a micro United Kingdom particle filtration unit which can identify micro parti- cles thombogenicity in conjunction with the assay [email protected] Technothrombin® MP. Furthermore Technoclone www.sysmex.co.uk provides a complete range of ADAMTS13 ELISAs and Sysmex supply automated in-vitro diagnostic haema- FXIII assays, as well a complete portfolio for the new tology and coagulation analysers, reagents and infor- anticoagulants such as for Xa inhibitors and direct mation systems for laboratories and healthcare thrombin inhibitors. facilities in the UK and Ireland. We work closely with our customers to provide a range of technologies and support services designed specifically to meet your needs, either in a laboratory or in a point of care envi- ronment. The new additions to the Product Portfolio include the revolutionary XN-Series of Haematology Analysers and the ground-breaking CS-5100 Coagu- lation Analyser; all are designed to provide maximum efficiency and optimum workload management.

108 ISTH 2012 11.6.2012 14:50 Page 109 ISTH 2012 11.6.2012 14:50 Page 110

Exhibition Floor Plan

Exhibitors List correct as at 22 May 2012 Booth Number Company Name 20 4S DAWN Clinical Software 17 Affinity Biologicals Inc. 26 Alexion 19 Amgen 1 Baxter Healthcare Inc. 18 Boehringer Ingelheim Limited 2 CSL Behring 14 Daiichi Sankyo Europe GmbH 24 Enzyme Research / r2 Diagnostics 5a GlasxoSmithKline 6 Haematologic Technologies, Inc. 15 Haemonetics Corporation 10 Helena Biosciences Europe 7 Hemacore LLC 13 HPS Network UK 27 Instrumentation Laboratory 22 Microvisk Technologies 5b Mitsubishi Pharma 8 Multiplate - Verum Diagnostica GmbH 29 Octapharma AG 16 Pentapharm / DSM 25 Pfizer 12 Precision BioLogic 3 Siemens - Healthcare Diagnostics Products GmbH / Sysmex UK Ltd. 28 Stago 23 Technoclone / Pathway Diagnostics Ltd.

110 ISTH 201211.6.201214:50Page111 Congress CentreFloorPlan Cityside Riverside Entrance Entrance Cityside Riverside 111

Floor Plans ISTH 2012 11.6.2012 14:50 Page 112